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ABSTRACT 
 
Precisely how Hephaestin (Heph) facilitate iron release from cells is poorly understood. The 
work in this thesis tried to establish the role of different iron metabolic proteins, Mitoferrin 
(Mfrn), IRPs and Heph in iron homeostasis. Analysis of 18 tagSNPs in the Mfrn gene was 
carried out in an Asian-Caucasian population to establish any correlation between the Mfrn 
tagSNPs, haemoglobin levels and birth weight in the presence of covariates such as sex of 
the fetus, gestational age and mother's booking weight. Two-way ANCOVA analysis was 
carried out to check if the covariates have any influence on the dependent variable in the 
presence of fixed factors. From the ANCOVA analysis of Mfrn tagSNPs it can be concluded 
that neither the haemoglobin levels nor the birth weight are dependent on the genotype, fetal 
sex, nor on their interaction.  
Owing to the significance in identifying the interacting partners of IRPs and Heph to 
understand more about their role in iron metabolism, protein-protein interaction studies were 
also carried out. IRPs and Heph genes were successfully cloned with One-Strep tag. Full 
length clones were sequence confirmed for any variation after PCR. Before carrying out 
immunoprecipitation to identify the interacting partners, transfection efficiency, viability and 
the role of magnetic particles on K562 cells was performed by using IRPs and Heph cloned 
with One-Strep tag. Lipofectamine-LTX plus transfection had more viable cells and higher 
efficiency compared with magnetic-assisted transfection. Also, this study confirms that 
magnetic nanoparticles do not have any adverse or significant effect on IRPs during the 
transfection. An unsuccessful attempt was made to identify the interacting partners of IRPs 
and Heph by immunoprecipitation. The current thesis work also involved identification of a 
potential ferroxidase. Ceruloplasmin (Cp) was used as a postive control. Non-denaturing gel 
eletrophoresis of the K562, MDA-MB-231 and PNT2-C2 cell fractions confirmed the 
presence of the extra band establishing the ubiquitous nature of the band. Mass 
spectrometry analysis identified the excised band as Calreticulin (CALR). This is the first 
report of calreticulin having ferroxidase activity. 
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CHAPTER 1 
 
INTRODUCTION 
All living organisms require iron for metabolic functions. The ability of iron to react with 
oxygen to form hydroxyl radicals may cause oxidative damage to proteins and nucleic acids 
that will lead to cell death. Thus maintaining iron homeostasis is necessary to achieve an 
optimal balance of iron import and export in the body. This ensures release of the required 
amounts of iron to maintain all the biochemical activities while preventing the harmful effects 
of low or high iron uptake. Iron homeostasis is maintained in the cells through the co-
ordinated regulation of uptake, storage and secretion. These processes in the cells are 
regulated by the proteins that respond to changes in iron availability by transcriptional and 
post-transcriptional mechanisms. 
Iron is an essential nutrient. Iron is required in all living organisms, from the most primitive 
to the most complex living organisms for metabolic functions (Testa, 2002). Different 
organisms adopted different mechanisms to control iron metabolism as they evolved. 
Mammals have developed an intricate iron withholding defence mechanism against 
microbial infections. Biochemical steps in the metabolism virtually left no free iron in the cells. 
The situation is more complex in advanced species like Homo sapiens who require more 
genes to accomplish iron metabolism from absorption to transport. 
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1.01 Significance of Iron 
Iron is essential for many biological processes like oxygen transport and storage, DNA 
synthesis, mitochondrial electron transfer, enzymatic and redox reactions (Andrews, 2000). 
Iron forms the central atom in the haem moeity of haemoglobin, that provides the capacity 
to bind and carry oxygen. Binding of iron to oxygen depends on oxygen tension, in that 
oxygen is bound by haemoglobin at high oxygen levels and is delivered to tissues that have 
low oxygen levels. Iron forms a part of ribonucleotide reductase, the enzyme that is involved 
in the synthesis of deoxy-ribonucleotides from ribonucleotides. Iron also plays an important 
role in the activity of the cytochromes of the respiratory chain in its capacity to accept and 
loose electrons. 
1.02 Availability of Iron 
Though iron is more readily absorbed in the ferrous state (Fe2+) the majority of dietary iron 
exists in the ferric state (Fe3+). The ferric form (Fe3+) is completely insoluble in water at 
neutral pH. The redox reaction ability of iron is due to the unfilled atomic orbitals and 
therefore is able to undergo changes in oxidative state (Fe2+ and Fe3+) involving one electron. 
As a transition metal, iron readily engages in one-step oxidation-reduction reactions 
between its Fe3+ and Fe2+ states. The redox property of iron in excess can be toxic as free 
iron can participate in ‘Fenton chemistry’, in which donating electrons to hydrogen peroxide 
(H2O2) or lipid peroxides generates highly reactive hydroxyl and lipid radicals OH. or LO. or 
LOO. respectively. The resulting oxygen metabolites can readily react and damage proteins, 
lipids and DNA. During the evolutionary process to allow absorption and metabolism of iron 
all living organisms developed complex iron oxidative-reductive and transport mechanisms. 
The acidic gastric secretions in the stomach play an important role in iron absorption in that 
they facilitate the solubilisation of non-haem iron from the food. 
The approximate total iron content of the body is about 4.5 grams in healthy adult males 
(Andrews, 1999). In men the loss of iron from the gastro-intestinal tract, skin and urinary 
tract is estimated to be about 1mg/day and 2mg/day in a menstruating female (Green et al., 
1968). Iron losses in post-menopausal women are assumed to be similar to those observed 
in men. National survey data shows that in Britain, on an average, adult men consume 13.2 
mg iron/day and women 10.0 mg/day from food sources (Henderson et al., 2003). Due to 
the absence of an active excretion pathway for absorbed iron, under most conditions, 
absorption of dietary iron is the critical determinant of iron status. Loss of iron in the human 
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body is unregulated and the total body iron stores depend on the changes in the rate of 
intestinal iron absorption. 
 
Figure 1: Availability of Iron in humans.  A high percentage of body iron is incorporated 
in haemoglobin of circulating erythrocytes (60-7 0%). Approximately 20-30% of iron in the 
body is in the form of ferritin and hemosiderin in hepatocytes and reticulo-endothelial system 
(RES) macrophages as an excess iron. The amount of iron bound to transferrin is about 3-
4 mg but the plasma transferrin compartment functions as a transit compartment through 
which approximately 20 mg of iron flows each day. Under circumstances of iron overload 
non-transferrin bound iron (NTBI) can appear in the plasma. The bone marrow is the main 
consumer of circulating iron. 18-20 mg of iron, mostly recycled, is used for haemoglobin 
synthesis in 200 billion new erythrocytes every day. Healthy people absorb 1-2 mg of iron 
per day, which compensates for a corresponding iron loss. Figure taken from Pantopoulos 
et al., 2012. 
1.03 Body Iron Requirements 
Approximately 30-40 mg of iron is required daily for internal utilisation by the body, largely 
to re-synthesise the haemoglobin destroyed along with old red blood cells (RBCs). A normal 
adult man has 40 – 50 mg/kg body weight of total body iron (Andrews 1999, Wessling-
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Resnick 2000). Of the total body iron, approximately 60 – 65% is present in the circulating 
erythrocytes in the form of haemoglobin, 10% is present in the skeletal muscle as myoglobin 
and about 30 – 35% is present in the liver, spleen and bone marrow as storage iron in the 
form of ferritin and hemosiderin. Approximately between 80 – 85% of the absorbed iron is 
transported to the developing RBCs by transferrin in the bone marrow for incorporation into 
haemoglobin and the remainder is transported to liver or muscle via transferrin for either 
storage or utilisation for haem synthesis (Tavill and Bacon 1986, Conrad and Barton 1981, 
Conrad et al., 1999). Iron is not excreted from the body in the urine or through the intestines, 
but is lost only with cells from the exteriors or interior surfaces of the body through the 
exfoliation of gastro-intestinal mucosal cells, dead cells from the skin or urinary tract. Adult 
women experience an additional loss of iron due to menstruation. Menstrual loss of iron 
varies among women but losses for an individual woman usually remain constant from 
menarche and throughout her fertile life (Hallberg et al., 1966). To ensure that the required 
amounts of iron are absorbed from an average western type diet without any reduction in 
iron supply to the tissues, the diet must contain about 19mg of dietary iron (estimating that 
at most 15% of the available iron can be expected to be absorbed from this type of diet) 
(Hallberg and Rossander-Hulten., 1991). 
During pregnancy, the requirement of iron increases as additional iron is needed to replace 
basal losses to allow for expression of maternal red cell mass and to serve as a nutrient for 
the needs of the fetus and placenta (International Nutritional Anaemia Consultive Group, 
1981). It has been suggested that the iron requirements are 1mg/day in the first trimester, 
4mg/day in the second trimester and 6mg/day in the third trimester (Bothwell et al., 1989). 
A series of studies using different techniques to measure iron absorption have provided 
clear evidence that iron absorption increases during pregnancy (Hahn et al., 1951, Svenberg, 
1975, Whittaker et al., 1991). After four months of infancy, 0.9mg of iron is required daily of 
which 0.7mg is required to sustain body growth and 0.2mg is required to replace iron losses 
(Dollman, 1980). 
 
1.04 Bioavailability of iron 
Since dietary iron does not exist in a readily usable form (Fe2+) available iron is bound to 
other components that must be digested before iron can be absorbed. Thus, the process of 
iron absorption can be sub-divided into three phases (Carpenter & Mahoney, 1992): iron 
digestion, iron intestinal absorption and iron utilisation.  
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1.04.001 Non-haem iron 
Dietary iron is present in two different forms and they are non-haem iron and haem iron. 
Non-haem iron is not present in readily soluble form and hence the digestion process first 
releases the non-haem iron in a soluble form that can be absorbed by the small intestine. 
The low pH present in the gastric juice facilitates iron solubility as suggested by the stricking 
correlation observed between the gastric juice pH and dietary iron absorption (Bezwoda et 
al., 1978). Due to the gastric digestion process, non-haem iron is solubilised from its ordinary 
dietary forms into a common pool that reaches equilibrium with all dietary constituents to 
which iron can bind. The existence of a common pool for all dietary non-haem iron was 
validated by a large number of studies (Hallberg, 1981, Charlton & Bothwell, 1983). It was 
also shown that non-haem iron remaining outside of this pool is not available for iron 
absorption (Hallberg, 1981, Charlton and Bothwell, 1983). Gastric and duodenal mucin binds 
to iron at acidic pH and keeps the iron soluble at neutral pH (Conrad et al., 1991). Some 
studies suggest that an iron-binding component present in gastric juice called gastroferrin, 
may act as an inhibitor of iron absorption (Davis et al., 1967, Multani et al., 1970). This 
observation was made due to the low levels of gastroferrin in gastric juices of patients with 
haemochromatosis and could be to some extent responsible for the increased iron 
absorption observed in this condition (Davis et al., 1966). However, this hypothesis was 
repudiated in several studies showing that gastroferrin was present in the gastric secretions 
of haemochromatosis (Winter et al., 1968). 
1.04.002 Haem iron 
Haem iron is derived from haemoglobin, myoglobin and other haem proteins. During the 
process of digestion, haem iron forms an important pool in the gastro-intestinal tract. Before 
its absorption, haem must be detached from globin and then be absorbed as free haem. 
Exposure to the acidic pH and proteases of the gastric juice induces the release of haem 
from globin and haem is then converted to hemin through oxidation of iron contained in 
haem (Hazell et al., 1978). The release of haem from globin continues in the duodenum as 
a consequence of the activity of proteolytic duodenal enzymes such as trypsin (Wheby et 
al., 1970). 
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1.05 Intestinal Iron absorption 
Movement of iron from the intestinal lumen to the circulation through epithelial cells of the 
digestive tract, known as iron absorption occurs largely from the proximal small intestine. 
Iron absorption in the intestine is dependent on the intraluminal factors such as the quantity 
of iron ingested, pH of the gut, chemical form of the available iron and also on the mucosal 
factors such as the absorptive surface of the microvilli (Conrad and Umbreit, 2002). 
Mammals absorb dietary iron through the duodenal epithelium of the small intestine (Gitlin 
and Cruchaud, 1962) which is organised in villus structures to maximise its absorption 
surface area (Donovan et al., 2006). Iron that accumulates within the mature enterocytes is 
lost from the body when they become old and are shed into the gut lumen. Absorption of 
iron involves two steps, uptake of iron from the intestinal lumen into the mucosa and the 
transfer across the mucosal cells and serosal membrane into the circulation 
The majority of iron entering the mucosal cells is not transferred to the plasma but remains 
trapped within the cells and is excreted into the lumen when cells are shed. Iron absorption 
depends on the amount of the body iron content. When the iron content in the body 
decreases a high proportion of the available iron is absorbed and as the body iron content 
raises the rate of iron absorption falls. However, when compared to the iron absorption 
during iron homeostasis, the relative enhancement of absorption during iron deficiency is 
greater than the inhibition observed during iron overload. Uptake of iron is also controlled 
by the rate at which red blood cells are produced (erythropoiesis). Iron absorption increases 
when there is an increased rate of erythropoiesis as extra iron is required to sustain new 
haemoglobin synthesis. Changes in iron absorption levels are received from the body via 
the intestinal crypt cells. 
Studies carried out in rats showed that absorption of iron was uniform throughout the length 
of the small intestine, while it showed a steep decrease from the duodenum to the ileum 
(Johnson et al., 1983). Iron in physiological amounts is absorbed by an active transport 
mechanism consisting of an initial mucosal uptake followed by intracellular transfer to the 
basolateral membrane and finally entering into the portal venous blood (Manis et al., 1962). 
A study carried out in Caco-2 cells showed that iron must first be reduced by reductases 
present in the brush border membrane before being absorbed (Han et al., 1995). The 
kinetics of iron absorption was carefully investigated in human upper small intestine 
microvillus membrane vesicles (Teichmann and Stremmel, 1990). The initial phase of iron 
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absorption was reported to be fast and begin within seconds after iron reaches the mucosal 
surface.  
1.05.001 Intestinal iron absorption 
In the past decade much progress has been made to understand the cell biology of iron 
absorption. Most of the non-haem iron in the diet is present as the Fe3+ form. Non-haem iron 
is first reduced by Dyct b (cytochrome b-like ferrireductase) an iron regulated di-haem 
protein, and then it is transported into the enterocyte via a transmembrane DMT-1 (Syed et 
al., 2006). Dyct b is a 6-transmembrane domain, ferric reductase protein. Dyct b which has 
approximately 45% sequence similarity with the sheep cytochrome b 561 reductase, which 
increases the availability of Fe2+ from the dietary iron pool. B-type cytochromes are the di-
haem proteins involved in the transfer of electrons across membranes. Dyct b is expressed 
on the brush border membrane of enterocytes along the villi. Iron-deficient mice showed 
high levels of Dyct b. Evidence supporting the function of Dyct b as a ferric reductase comes 
from Xenopus Ooocytes and cultured cells, where expression of exogenous Dyct b resulted 
in induction of ferric reductase activity, which was partially blocked with antibodies directed 
against Dyct b (Chen et al., 2003, Philpott 2002, Mckie et al., 2001).  
The major transporter involved in cellular non-haem iron uptake (import) is divalent metal 
transporter 1 (DMT1; also known as Nramp2, DCT1 and SLC11A2) (Gruenheid et al., 1995, 
Fleming et al., 1997, Gunshin et al., 1997), which is a principal mammalian proton-coupled 
metal iron transporter. DMT1 is a member of the NRAMP family and has 65% homology 
with the phagocyte specific homolog Nramp1 and is highly conserved in prokaryotes and 
eukaryotes. The pattern of expression of Dyct b and DMT1 is very similar; the expression 
decreases from duodenum to ileum. The region of high Dyct b expression correlates with 
that of high ferrireductase activity (Raja et al., 1992). In iron-deficient mice, mRNA is 
predominantly found in the upper villus of mature enterocytes and is absent in the crypts 
(McKie et al., 2001, Latunde-Dada et al., 2002). In the iron deficient mice it was also shown 
that the region of high Dyct b expression overlaps with the major site of iron absorption, 
where the DMT1-mediated Fe2+ transport occurs. Experiments on knock-out (KO) mice, 
Dmt1int/int generated by Gunshin et al, have demonstrated that Dmt1 is essential for intestinal 
inorganic iron absorption, where anaemia was noted after depletion of parenteral iron stores 
(Gunshin et al., 2005). Studies have shown that unlike in the intestine and bone marrow, 
Dmt1 is dispensable in placenta and liver (Gunshin et al., 2005).  
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Besides Fe2+, DMT1 has a wide range of substrate specificity, including Zn2+, Mn2+, Co2+, 
Cd2+, Cu2+, Ni2+ (Gunshin et al., 1997). DMT1 was first discovered from the cDNA library of 
iron-deficient rat intestine as a 4409 bp DMT1 mRNA, which stimulated iron uptake (Gunshin 
et al., 1997). DMT1 is a 561 amino acid protein with 12 putative transmembrane domains, 
which accounts for its high hydrophobicity (Cellier et al., 1996). DMT1 is synthesised from 
its 60 kDa precursor via extensive N-linked glycosylation, and the glycosylation sites have 
been predicted in the fourth extracellular loop where a consensus metal transport motif is 
located (Gruenheid et al., 1995). The presence of glycosylation sites may help DMT1 to 
localise at the apical membrane rather than in the endosomes (Tabuchi, 2002). The apical 
transporter/iron importer at the apical membrane was identified simultaneously by two 
different laboratories using two different approaches. Gunshin et al (1997) undertook 
expression cloning of the iron transporter by injecting messenger RNA (mRNA) into 
Xenopus Oocytes and looked for stimulation of iron accumulation. mRNA, encoded by 
Nramp2 gene was abundant in iron-deficient rat intestine and it significantly stimulated iron 
uptake (Gunshin et al., 1997).  
Nramp2 was reported in a microcytic anemic mouse through a positional cloning/candidate 
gene approach (Fleming et al., 1997). DMT1 is active in a low-pH environment, as found in 
the duodenum, because it requires proton cotransport (Gunshin et al., 1997). DMT1, 
expressed in the brush border of duodenal enterocytes, appears to be responsible for the 
transport of ferrous iron from the duodenal lumen into the enterocytes (Syed et al., 2006; 
Chen et al., 2004). Free iron from both haem and non-haem sources ends up in the same 
iron pool inside the enterocyte (Chen et al., 2003).  It was reported that disruption of the 
murine duodenal cytochrome b (Dcytb) gene did not significantly impair intestinal iron 
absorption under normal conditions (Gunshin et al., 2005), suggesting that other intestinal 
reductases may substitute or that mice have an efficient mechanism for non-enzymatic iron 
reduction (Donovan et al., 2006). The enterocyte haem importer protein, haem carrier 
protein (HCP1) was found (Shayeghi et al., 2005; McKie et al., 2006; Qiu et al., 2006) to 
mediate dietary haem along with folate across the apical membrane. Once dietary haem 
enters the intestinal epithelial cells, it is likely to be cleaved by intracellular haem oxygenase 
1 to release iron (Raffin et al., 1974). From figure 2 it can be seen that two independent 
transmembrane iron transporters are necessary to bring dietary iron into the cells and to 
transfer the iron within the cell into the plasma. 
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Figure 2: An individual cell showing the role of molecules involved in intestinal iron 
import and export. Readily available iron is picked by transferrin (Tf) and binds to the 
transferrin receptor (TfR), which is expressed on the surface of the cell. Some of the iron 
that enters the cells is transferred to the early endosome, where it is exported into the 
cytoplasm, probably through DMT1. In the intestinal lumen, ferric iron (Fe3+) is reduced to 
ferrous iron (Fe2+) by the cytochrome-b-like reductase DCYTB. DMT1 then facilitates the 
absorption of Fe3+ from the lumen into the cytoplasm. In the cytoplasm, excess iron is stored 
in the form of ferritin. In macrophages, haem-bound iron in the form of haemoglobin or 
haptoglobin is taken up by the cell through the haemoglobin scavenger receptor (CD163). 
Iron is exported from the enterocyte by a permease known as ferroportin IREG-1/FPN-1). 
For circulation in the body, Fe2+ is oxidized to Fe3+ by either the intestinal membrane-
associated oxidase, hephaestin, or the plasma-located oxidase, caeruloplasmin the role of 
which in iron efflux still needs to be established. In the cell, the synthesis of haem and Fe–
S clusters takes place in the mitochondria. Figure taken from Ulrich and Stefan, 2004. 
1.05.002 Export of iron into plasma 
Intracellular iron can either be stored in ferritin (Torti and Torti, 2002) or transported across 
the basolateral membrane of the enterocyte and subsequently into the circulation (Figure 2). 
Degradation of ferritin and iron release helps to mobilise iron for cellular utilisation (Hentze 
et al., 2004). The iron regulatory proteins (IRPs – IRP1 and IRP2) are the key proteins in 
24 
 
this complex interaction, as they represent the sensors of cytoplasmic iron and the 
controllers of ferritin and the transferrin receptor (TfR) expression. Ferroportin (also known 
as IREG1, MTP1 or SLC40A1) was identified as a candidate for the basolateral iron exporter 
(Abboud and Halie DJ 2000; Donovan et al., 2000, McKie et al., 2001). Localisation studies 
in polarised epithelial cell lines confirmed the expression on the basolateral membrane and 
iron efflux was demonstrated in Xenopus Oocytes. Apart from the duodenum, tissue-
screening studies indicated expression of IREG1 in the kidney, liver (Kupffer cells), testis 
and the placenta (McKie et al., 2000). Selective inactivation of the murine IREG1 gene in 
intestinal cells established that IREG1 is the major intestinal iron exporter (Donovan A et al., 
2005). Binding of IRP to a conserved 5’ UTR Iron Responsive Element (IRE) was 
demonstrated in vitro suggesting genetic iron regulation (Hentze et al., 1987; McKie et al., 
2000). In vitro functionality of the 5’ IRE by means of a reporter assay as well as further 
tissue distribution and iron regulation of IREG1 in vivo were demonstrated by Abboud and 
colleagues (Abboud and Haile, 2000). It was also shown that mutations in IREG1 in humans, 
leads to iron retention in the macrophages and liver abnormalities (Pietrangelo, 2007).  
 
 
 
Figure 3: Iron regulation in enterocytes, macrophages and hepatocytes. Enterocytes, 
macrophages and hepatocytes acquire iron to maintain iron homeostasis and deliver the 
excess iron to the rest of the body through the iron exporter IREG-1, which needs copper-
ferroxidases (either Cp or Heph the role of which still need to be established) to release iron 
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to the plasma transferrin (Tf). Heph is expressed predominantly in enterocytes rather than 
in macrophages or hepatocytes. Figure taken from Mariani et al., 2009. 
Iron transported by IREG1 is ferrous as there appears to be a close relationship between 
IREG1 and multicopper oxidases: membrane bound hephaestin (HEPH) expressed on the 
basolateral membrane of the enterocytes, and plasma soluble homologue ceruloplasmin 
(CP) (Chen et al., 2006; McKie et al., 2001). A positional cloning/candidate gene approach 
was also used to gain the insights into basolateral iron transport. Mice with sex-linked 
anaemia (sla mice) were identified after radiation mutagenesis (Grewal., 1962). Sla mice 
have a partial defect in intestinal iron absorption that was shown to be associated with a 
problem in basolateral iron transfer (Edwards & Bannerman., 1970). Vulpe et al., found that 
sla is associated with a deletion mutation in a gene encoding a membrane-bound homolog 
of the multicopper ferroxidase, ceruloplasmin (Cp) (Vulpe et al., 1999). Since Cp was 
previously thought to play a role in cellular iron export they postulated that this new protein, 
designated as Hephaestin (Heph) was the sla gene product. The link with the iron efflux had 
been demonstrated as early as 1968 when Cartwright and colleagues showed impaired iron 
export in copper-deficient pigs (Leet et al., 1968).  
 
Iron deficiency increases the expression of IREG1 in the duodenum and decreases in the 
liver. Harris et al, created a Cp-/- mouse as a model for aceruloplasmianaemia, which 
presented with iron overload in macrophages and hepatocytes as a result of impaired iron 
efflux through IREG1 (Harris et al., 1999) which have normal copper metabolism (Meyer et 
al., 2001). Studies have demonstrated the requirement of glycosylphosphatidylinositol (GPI) 
anchored CP for the stability of cell surface IREG1 in brain and macrophages (De Domenico 
et al., 2007a). As in copper deficient animals, serum iron concentrations of Cp-/- mice do 
not change significantly after the administration of damaged red cells, but do increase after 
the administration of Cp and not aceruloplasmin (Harris et al., 1999). The current model 
shows that Heph expresses in the basolateral membrane of placental transport cells and 
duodenal enterocytes. Heph like Cp is categorised as a ferroxidase which helps in changing 
the oxidative state of iron released by IREG1, facilitating the incorporation into transferrin, 
the major serum iron carrier protein (Donovan et al., 2006). The anaemia of sla mice 
resolves after the neonatal period, suggesting that Heph is primarily needed for iron transfer 
during the accumulation of initial stores and that serum Cp may substitute later (Donovan et 
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al., 2006). Though it is widely hypothesised that Heph may play its role in basolateral iron 
transfer its exact function needs to be established.  
The released iron is sequestered by the apo form of transferrin (Tf). It is currently unclear 
whether the iron is passed to Tf directly or indirectly (Syed et al., 2006). Once bound to Tf, 
Fe3+ is transported to tissues where it is taken up by receptor mediated endocytosis of the 
transferrin receptor (TfR). TfRs are present on the basolateral surface of the intestinal 
epithelium and undergo recycling as in other cells (Buys et al., 1991; Anderson et al., 1990; 
Hughson and Hopkins 1990). TfR assists iron uptake into the mammalian cells through a 
cycle of endocytosis and exocytosis of the iron transport protein Tf (Richardson and Ponka, 
1997).  Iron release in the endosomes may also be facilitated by membrane-bound 
oxidoreducatses (Nunez et al., 1990). Fe3+ is transferred from the endosomal compartments 
to the cytoplasm and other cellular organelles, through a process mediated by DMT1 
(Fleming et al., 1998). The cellular iron trafficking, following its release from the endosome, 
has still not been well characterised, except that in non-erythrocytes excess iron is taken up 
and stored in ferritin. It is hypothesised that a number of proteins must be involved in cellular 
iron trafficking.  The reduced transport of iron from the mucosal cell to the circulation in sla 
mice provides the evidence that Heph plays a role in iron transport. On the basis of its 
homology with Cp, it has been proposed that Heph is a ferroxidase necessary for iron 
release from the intestinal epithelial cells (Vulpe et al., 1999). 
1.05.003 Iron transport to Mitochondria 
Mitochondria are mostly appreciated for their role in energy transduction and other metabolic 
pathways (Richardson et al., 2010). Reversible oxidation states of iron enables the 
mitochondrion to catalyse the electron transport via haem- and iron-sulfur cluster (ISC)-
containing proteins used in the process of energy transduction. However, it is less well 
known that mitochondrion can be considered a focal point when it comes to the metabolism 
of the most common transition metal in cells, namely iron (Napier et al., 2005). Iron in 
mitochondrion may be stored as mitochondrial ferritin (Richardson et al., 2010). 
Mitochondria are the sole site of haem synthesis and a major generator of ISCs both which 
are present in mitochondria and cytosol (Lill and Muhlenhoff, 2008). Haem is exported from 
the mitochondrion for use in the cytosol (Napier et al., 2005). Haem synthesis begins and 
ends in the mitochondria, with several intermediate steps taking place in the cytoplasm, 
which requires transport of biochemical precursors across the mitochondrial membrane 
(Andrews, 2009).  
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Iron is taken up by mitochondria by one or more mechanisms including direct uptake of iron 
(II) from the cytosol, driven by mitochondrial membrane potential (Lange et al., 1999), uptake 
of a chelator-inaccessible low-Mr iron pool from the cytosol (Shvartsman et al., 2007) and 
by a kiss-and-run mechanism, at least in haemoglobin-synthesising cells such as 
reticulocytes, in which Tf-laden endosomes make brief contact with the outer mitochondrial 
membrane (Sheftal et al., 2007, Richardson et al., 2010). Once iron is transported out of 
endosomes via DMT1, it enters the labile iron pool. The only strong evidence that a 
mitochondrial iron pool exists comes from studies with chelators that mobilise iron from cells 
(Ponka et al., 1979, Richardson et al., 1997). Since Tf-bound iron is efficiently used for haem 
synthesis (Richardson et al., 1996, Ponka et al., 1997) an intimate direct transfer of iron from 
Tf to the mitochondrion was proposed to occur (Ponka et al., 1976, Isobe et al., 1997). The 
idea of a direct transfer of iron to mitochondrion has developed and led to the kiss and run 
hypothesis (Ponka 1997). The kiss and run model suggests that a direct transfer of iron from 
the Tf-containing endosome to the mitochondrion occurs, bypassing the cytosol (Richardson 
et al., 1996, Ponka 1997, Richardson et al., 1997, Zhang et al., 2005). The precise molecular 
details and a possible contact between the endosome and the mitochondrion remain 
unknown. 
The labile iron pool (LIP) serves as a bridge for metal transit between cell components and 
between the cell and the medium (Breuer and Cabantchik, 2000). LIP also mediates 
oxidative damage in iron overload conditions leading to iron-dependent tissue damage and 
in hereditary and transfusional haemochromatosis, neurodegenerative disorders and 
anaemia of the reticuloendothelial system. In such diseases, a better understanding of how 
precisely iron homeostasis is disrupted and how LIP is regulated will benefit for therapeutic 
interventions. Fluorescent metal sensors are used as tools to trace LIP in disease models, 
which share iron de-compartmentalisation as a common causative factor (hereditary 
haemochromatosis, genetic ataxias, sideroblastic anaemia and neurodegeneration) 
(Espósito et al., 2002). To find different therapeutic approaches for iron-dependent diseases 
it is important to understand the regulatory mechanisms that enable LIP to reconstitute iron-
requiring enzymes without exposing cells to the damaging effects of metal-triggered 
formation of reactive free radicals. The targeted delivery of probes to organelles such as 
mitochondria and lysosomes may open different avenues to explore the relationship 
between the cytosolic LIP and organellar iron loops, which are the key components of iron 
homeostasis in the cells. In order to design probes targeting mitochondria, designing cellular 
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models of gene expression and assessing the molecular and cellular functions of the 
expressed genes, along with developing analytical tools that define the iron status in the 
same cells, and its movement across distinct organelles will help understand the role of 
Mitoferrin (Mfrn1) in iron metabolism. Also assessing and correlating the cell’s ability to 
adjust to different LIP levels in response to varying amounts of iron with the known regulatory 
activities of IRPs and ferritin may also help in understanding the role of LIP in iron 
homeostasis. Using novel oral iron chelators as therapeutic agents for conditions of iron 
overload (Thalasaemia and haemochromatosis) to understand the mechanisms whereby 
LIP permeates into cardiac cells and raises labile cell iron pools (LCIP) in different cell 
organelles of the heart were studied (Glickstein et. 2005; Cabantchik et al. 2004). 
 
Figure 4: Iron trafficking within the mitochondria. A schematic representation of iron 
trafficking within the mitochondria. (A) Iron uptake and utilisation. (B) The kiss and run 
hypothesis suggests that a direct transfer of iron from the Tf-containing endosome to the 
mitochondrion occurs, by-passing the cytosol. Figure taken from Richardson et al., 2010. 
Foury and Roganti suggested a role for the eukaryotic mitochondrial solute carriers, Mrs3 
and Mrs4, in mediating mitochondrial iron metabolism in yeast (Foury and Roganti, 2002). 
Although the precise biochemistry of Mitoferrin1 (Mfrn1 also known as SLC25A37) and 
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Mitoferrin2 (SLC25A28), which are homologous to Mrs3 and Mrs4 in yeast-mediated iron 
import by mitochondrion, is an unknown gene mutation in anaemic frascati zebrafish showed 
that Mfrn1 transports iron across the mitochondrial membrane (Shaw et al., 2006). Mfrn1 
stabilisation is accomplished through interaction with Abc10 (also known as Abc-me) which 
is restricted to erythroid mitochondria (Chen et al., 2009). An interaction between Mfrn1, 
Abc10 and ferrochelatase was discovered by Chen’s group in 2010. The interaction between 
Mfrn1 and Abc10 probably promotes efficient haem synthesis by funnelling iron directly to 
ferrochelatase, the enzyme that inserts iron into protoporphyrin IX to form haem (Lawen and 
Lane, 2013).  It is still unknown how iron is transported across the outer mitochondrial 
membrane and clearly other transporters may yet be identified. 
 
Figure 5: Figure showing the interaction between Mfrn1 and Abc10 in erythroid cells. 
(A) In the absence of Abcd10, Mrfn1 is relatively unstable in erythroid progenitor cells limiting 
mitochondrial iron transfer.  (B) During erythroid differentiation, Mfrn1 is stabilized by Abcd10 
in the inner mitochondrial membrane to increase iron transfer.  (C) After haem production is 
complete, haem acts to decrease Abcd10 protein levels, leading to turnover of Mfrn1. Figure 
taken from Andrews, 2009. 
1.05.004 Mitochondrial iron storage and export 
Some mammalian tissues express a mitochondrial-specific ferritin (FTMT/MTF) that has a 
high level of sequence identity with a typical H-ferritin. Similar to cytosolic H-ferritin, FTMT 
also shows ferroxidase activity and binds iron (Levi et al., 2001). FTMT expression levels 
appear to be in correlation with the number of mitochondria rather than cellular iron content 
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(Drysdale et al., 2002).FTMT has been found be highly expressed in testes and the 
erythroblasts of sideroblastic anaemia patients (Cazzola et al., 2003, Santambrogio et al., 
2007). FTMT has also been detected in the heart, brain, spinal cord, kidney and pancreas 
(Santambrogio et al., 2007). However, in contrary to H-ferritin, FTMT does not express in 
liver and spleen, suggesting a distinct role of FTMT. FTMT is encoded by an intron-less 
gene and hence fTMT expression is not post-transcriptionally regulated by intracellular iron 
levels (Drysdale et al., 2002). The role of FTMT in iron metabolism was examined in a stably-
transfected cell line that over-expressed FTMT (Nie et al., 2005). FTMT over-expression 
leads to partitioning of iron between haem and ISC synthesis in the mitochondrion (Nie et 
al., 2005). This effect not only alters mitochondrial iron metabolism, but also intracellular iron 
metabolism (Nie et al., 2005). 
Excess iron in the mitochondrion needs to be transported out into the cytosol. A candidate 
iron exporter mammalian mitochondrial ABC protein 3 (MTABC3; also known as ABCB6) 
was identified (Mitsuhashi et al., 2000). MTABC3 had been shown to rescue mitochondrial 
iron loading, respiratory dysfunction and mitochondrial DNA damage in atm1 (human 
ortholog of ABCB7) deficient yeast cells (Mitsuhashi et al., 2000). It is still unclear how haem 
is exported from the mitochondrion. Given the low solubility and highly toxic nature of haem, 
haem-binding protein 1 has been identified as a haem carrier candidate (Taketani et al., 
1998). Although haem-binding protein 1 could be a candidate for haem transport, direct 
evidence for the carrier nature has been lacking. 
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Figure 6: Molecules involved in mitochondrial iron transport. Iron is taken up by most 
body cells as Tf-bound iron, which binds to TfR1 on the cell surface. The iron can also enter 
the mitochondria via the transporter mitoferrin (MFRN) after which it is be incorporated into 
haem or iron-sulfer clusters for use in protein synthesis. Although the role of Frataxin is 
unknown it is also involved in iron-sulfur cluster formation. The ABC transporters are thought 
to play a role in the export of haem and iron-sulfur clusters from mitochondria, although the 
precise molecules involved are still unclear. Excess mitochondrial iron is stored in 
mitochondrial ferritin (MtF). Figure taken from Reid et al., 2009. 
1.06 Cellular iron regulation 
Regulation of cellular iron update, storage and absorption must be controlled at a cellular 
level. Intestinal iron absorption is partially regulated in response to a signal that 
communicates information about the amount of iron in ‘’the stores’’ (Hentze et al., 2004; 
Finch 1994). Erythroid cells consume most of the available dietary iron. Iron regulation is 
achieved at transcription, mRNA processing and decay, initiation of translation and post-
translational levels. The adaptation of the body to iron deficiency or iron overload depends 
on the extent of iron absorption by the intestinal mucosa. Regulation of iron absorption is 
important to maintain iron balance within the body. Since both apical iron uptake and 
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basolateral iron transfer are required in iron absorption, regulation of iron absorption can 
involve the expression or function of proteins on either surfaces of the enterocyte. The two 
factors that play an important role in regulating the rate of intestinal iron absorption are the 
level of iron stores in the body and the level of erythroid cell production in bone marrow. 
1.06.001 Regulation of iron in stores 
The cellular and molecular mechanisms through which the above factors determine the 
control of intestinal absorption are poorly defined. Regulation of iron absorption may be 
achieved by changes in the ‘number of mucosal cells’ adapted to absorb iron or changes in 
the individual mucosal cells ability to absorb iron or both. Several theories were proposed to 
explain the biochemical mechanisms undergoing the control of iron absorption by mucosal 
intestinal cells (Cook, 1990; Flanagham, 1989). According to the Mucosal Block Theory 
(MBT) proposed by Hahn (Hahn, 1941) the number of iron acceptor molecules present in 
the intestinal mucosa is limited. As a consequence, if these acceptors are blocked either by 
exogenous or endogenous iron a block of dietary iron absorption takes place. Granick 
(Granick, 1954) revised the mucosal block theory and suggested that the ferritin-
apotransferrin system in mucosal intestinal cells directly controls the amount of iron 
absorbed. 
 
Figure 7: Cellular iron metabolism. Most cells acquire plasma iron via TfR1-mediated 
endocytosis of Tf-bound iron. Iron uptake systems feed the so-called labile iron pool (LIP). 
The LIP is utilized for direct incorporation into iron proteins or iron transport to mitochondria 
via Mfrn, where the metal is inserted into haem and Fe/S cluster prosthetic groups. The 
fraction of the LIP that is not utilized for metalation reactions can be exported via IREG1, 
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which works together with ferroxidases for iron loading onto Tf, or stored in a nontoxic form 
in ferritin shells. Ferritin can be released into the extracellular milieu by unknown 
mechanisms and interact with specific receptors on the cell surface. Some cells also express 
a mitochondrial form of ferritin to protect the organelle against iron-induced toxicity. The size 
of the LIP is determined by the rate of iron uptake, utilization, storage, and export and these 
processes should be efficiently regulated to avoid any iron excess or deficiency. Figure 
taken out from Hentze et al., 2010. 
Granick’s theory lost the support since no apoferritin or ferritin was observed on brush border 
intestinal membranes. In contrast to the MBT, several studies have shown that iron 
continues to be absorbed even when tissues are loaded with iron. The observation that iron 
is localised in the epithelial cells of intestinal mucosa was made from the dietary and body 
iron stores (Conrad et al., 1964, Chisari et al., 1966) led to the hypothesis that the quantity 
within the absorptive cells regulates iron absorption in the intestinal mucosa. Experiments 
using isolated duodenal epithelial mucosal cells challenged this hypothesis (Balcerzak and 
Greenberger, 1968). 
 
The existence of an iron-dependent control mechanism of intestinal iron uptake was 
demonstrated by Goddard et al in 1997 in human enterocytes. The metal cation transporter 
DMT1 may play a relevant role in the intestinal iron absorption (Goddard et al., 1997). 
Another theory suggests that iron absorption is regulated by a balance mechanism. This 
theory is based on the probability of exchanges that may occur between the plasma and 
various cellular iron pools (Cavill, 1975). Ultra-structural methods using Prussian blue 
staining proved that low levels of stainable iron within the small intestinal mucosal cells of 
iron-deficient animals is found in comparison with specimens from normal fasting rats 
(Parmeley et al., 1979). Observations made by Parmeley et al in 1979 showed that the 
quantity of iron within small intestinal mucosal cells varies directly with the degree of iron 
repletion and suggests that this phenomenon may play a role in the regulation of iron 
absorption. With free ionic iron being a toxic oxidant it is difficult to accept that the ionic iron 
directly inhibited iron uptake by the intestinal mucosal cells. Hence it was postulated (Conrad 
et al., 1987) that this iron might make iron-binding receptors of some molecules within the 
mucosal cells act as regulators of iron absorption. The transcriptional mechanisms of iron 
regulation involving Hepcidin (HAMP) has been well characterised as most of the iron 
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sensing is thought to be mediated posttranscriptionally (IRP-IRE loop) or through HAMP on 
a systemic level. Direct effects of levels of iron, hypoxia or localised inflammation are difficult 
to distinguish from liver HAMP mediated effects as HAMP responds to all the conditions. 
Iron homeostasis is also altered in response to hypoxia, through a proposed humoral 
‘’hypoxia regulator’’ (Hentze et al., 2004). Liver-specific stabilization of the hypoxia-inducible 
factor 1 (HIF1) and HIF2 decreases HAMP expression and chemical HIF stabilizers can 
suppress HAMP mRNA expression in hepatoma cells (Peyssonnaux et al., 2007). From 
these findings it can be hypothesised that iron-dependent prolyl hydroxylases involved in 
HIF degradation may act as hepatic iron sensors but their interaction with HAMP promoter 
is currently controversial. 
 
Figure 8: Systemic iron regulation in iron overload and deficient conditions. Figure 
depicts the systemic iron regulation in both iron overload and iron deficiency conditions are 
shown. Iron-loaded (diferric) transferrin (Tf-Fe2), indicated by red dots, supplies iron to all 
cells by binding to the TfR1 and subsequent endocytosis. TfR1 is highly expressed on 
haemoglobin-synthesizing erythroblasts. Hepatocytes sense Tf saturation/iron stores and 
release HAMP accordingly. Red cell iron is recycled by macrophages via IREG1 and the 
ferroxidase Cp. In iron overload (left), high HAMP levels inhibit IREG1-mediated iron export 
by triggering internalization and degradation of the complex to reduce Tf saturation. HAMP 
expression is also high. In iron deficiency (right), iron is released by IREG1 into the 
circulation. Haemoglobin-derived haem is catabolized in macrophages by haemoxygenase-
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1 (HOX1). Hepcidin expression is low in case of iron deficiency. Figure taken from Hentze 
et al., 2010. 
1.06.001.1 Molecules involved in the regulation of cellular iron 
Communication between the sites of uptake, utilisation and storage in an organism controls 
the cellular iron balance. The trafficking of iron into plasma is largely controlled by the iron 
regulatory hormone hepcidin (HAMP). HAMP, is a 25 residue peptide which was purified 
from serum with antimicrobial activity LEAP1 (liver expressed antimicrobial peptide) (Krause 
et al., 2000; Pantopoulos et al., 2012). Later HAMP was isolated from human urine, by Park 
and colleagues, in which additional peptides of 20 and 22 residues were detected in which 
HAMP was truncated at the N terminus (Park et al., 2001). The authors ishowed the 
homology with small cystine rich peptides – β defensins, reported to be involved in innate 
immunity and with broad spectrum antimicrobial activity (Park et al., 2001). The mature, 
active form of HAMP is the 25 amino acid peptide. The 25 amino acid form is rich in β sheets 
and contains four disulphide bonds integrated within the conserved cysteines. Hepcidin is a 
circulating peptide secreted by hepatocytes (Krause et al., 2000, Park et al., 2001, Pigeon 
et al., 2001) that binds to ferroportin at the cell surface to initiate ferroportin internalisation 
and degradation (Nemeth et al., 2004) thus reducing the dietary iron absorption. Ferroportin 
is the only exporter of inorganic iron in mammalian cells (Pantopoulos et al., 2012). 
Therefore, inactivation of ferroportin causes intracellular iron retention (Weiss 2009, Brasse-
Lagnel et al., 2011). Hepcidin has also been shown to promote proteasomal degradation of 
DMT1 (Brasse-Lagnel et al., 2011). Loss of hepcidin protein results in severe iron overload 
in mice (Nicolas et al., 2001) and human patients (Roetto et al., 2003, Papanikolaou et al., 
2004), confirming the role of HAMP in regulating iron balance in the body. Expression of 
HAMP, which is known as a negative regulator of iron absorption, decreases in response to 
anaemia and hypoxia (Nicolas et al., 2002). The negative regulatory effect of hepcidin turns 
out to be advantageous as it makes more iron available for erythropoiesis. However, 
expression of HAMP increased during inflammation (Nemeth et al., 2004) and non-genetic 
iron overload (Pigeon et al., 2001). Increased expression of HAMP during inflammation and 
non-genetic iron overload minimises the availability of iron, inhibiting the growth of 
pathogens and limiting iron availability (Donovan et al., 2006).  
Genetic experiments have suggested that HAMP helps iron release from enterocytes and 
macrophages. It was reported that injection of synthetic HAMP into mice inhibited iron 
uptake in isolated duodenal segments (Laftah et al., 2004). IREG1 has shown to be the 
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HAMP receptor (Nemeth et al., 2004). HAMP causes the internalisation and degradation of 
IREG1 and in doing so switches off the iron export (Robson and Drakesmith, 2005). Studies 
confirmed that the iron exporting tissues and cells have no significant alternative to the 
IREG1 efflux pathway and provide further support for the fundamental role of the HAMP-
IREG1 interaction in systemic iron homeostasis (Donovan et al., 2005). 
 
Figure 9: Schematic representation of normal iron regulation. Figure taken from 
Donovan et al., 2006. 
Though the discovery of HAMP and the conditions that regulate HAMP expression is known, 
the question of how HAMP expression is altered in response to body iron requirements is 
not well known. Membrane proteins like transferrin receptors (TfR1 and Tfr2), hemojuvelin 
(HJV/HFE2) and HFE (major histocompatability complex MHC-1 class protein) have been 
associated with modulating hepcidin expression in vivo (Anderson and Frazer, 2006) and 
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iron-dependent induction. Mice and humans deficient in HFE have been reported to have 
reduced hepcidin expression despite iron overload (Ahmad et al., 2002, Muckenthaler et al., 
2003, Bridle et al., 2003). The fact that HFE forms a protein complex with the transferrin 
receptor (TfR) has led to a hypothesis that a soluble factor such as diferric Tf (which 
competes with HFE for TfR binding) might modulate HFE activity and regulate a potential 
pathway signalling to the hepcidin promoter. HFE is strongly expressed in hepatocytes, like 
HAMP, suggesting that it is in hepatocytes that HFE is exerting its effect on HAMP 
expression (Zhang et al., 2004). Evidence suggests that hepatic iron and circulating iron 
induce HAMP expression by distinct pathways (Corradini et al., 2011, Ramos et al., 2011). 
 
Figure 10: Regulation of HAMP expression. Figure shows the negative and positive 
regulators in HAMP regulation. Figure taken from Donovan  et al., 2006. 
HJV is expressed in different tissues like liver, heart, skeletal muscle and also found in 
plasma in a soluble form. Cell-associated HJV is required for normal HAMP expression in 
hepatocytes and soluble HJV negatively regulates HAMP expression in hepatocytes (Lin et 
al., 2005). Disruption of HAMP regulation is associated with disturbances of iron metabolism 
by at least two independent mechanisms which both converge their effects on to the bone 
morphogenic proteins (BMP) signalling pathway. The membrane-associated protease, 
TMPRSS6 physically interacts with HJV and cleaves HJV when both proteins are expressed 
on the cell surface, suggesting that HJV is the major TMPRSS6 target for iron regulation 
(Silvestri et al., 2008a). Genetically, the deficiency of both HJV and TMPRSS6 causes iron 
overload, suggesting that TMPRSS6 acts upstream of HJV (Truksa et al., 2009, Finberg et 
al., 2010). Increased HJV surface expression has however yet to be confirmed in 
TMPRSS6-deficient mice or IRIDA patients. However, it needs to be investigated, how 
38 
 
TMPRSS6 expression and activity are regulated, and the relative contributions of TMPRSS6 
to the regulation of HJV and systemic iron homeostasis. 
 
High HJV expression in skeletal muscle leads to speculation that, soluble HJV (SHJV) is 
released as a muscle signal in iron deficiency. The release of SHJV mainly from the muscle 
into the blood can act to antogonise BMP signalling because of the competition for the 
hepatocyte BMP receptors. Release of sHJV not only depends on the amount of serum 
holotransferrin but also on the iron status of the muscle. Relase of sHJV from the muscles 
is mediated by furin cleavage which is regulated by iron (Silvestri et al., 2007). In the iron-
depleted condition sHJV downregulates HAMP by interfering with BMP signalling and this 
negatively regulates HAMP expression. Whereas increased levels of serum holotransferrin 
reduces the release of sHJV thus augmenting BMP signalling and increased HAMP 
expression. 
Membrane proteins like HFE, TfR1 and TfR2 have also been implicated in hepatocyte HAMP 
regulation by iron (Schmidt et al., 2008; Robb and Wessling-Resnick, 2004). Like HFE, 
deficiency of TfR2 attenuates HAMP expression in mice (Kawabata et al., 2005) and 
humans (Nemeth et al., 2005) and results in moderate iron overload. TFR2 is expressed in 
both hepatocytes and erythroblasts. Since no erythropoeitic abnormalities have been 
reported in mice or humans, it suggests that TfR2 requirement for HAMP regulation is 
intrinsic to hepatocytes and not the result of feedback through the anaemia/hypoxia 
regulatory pathway. HJV-deficiency in mice (Huang et al., 2004, Papanikolaou et al 2004) 
and in humans (Huang et al., 2005, Niederkofler et al., 2005) has been shown to reduce the 
HAMP levels further than HFE and TfR2, resulting in severe iron over-loading. TfR1 when 
bound to HFE keeps it in an inactive state and the competition between holotransferrin and 
HFE for TfR1 forms the key component of iron sensing. An increase in serum holotransferrin 
will result in relase of HFE from TfR1 thus allowing it to bind to TfR2 which in return begins 
the signal for HAMP induction. An in vivo study in mice has suggested that BMP stimulation 
may be independent of HFE, TfR2 and IL-6 (Truksa et al., 2006). Hence, through an 
unknown pathway the HFE/TfR2 complex could directly regulate HAMP transcription.  
1.06.001.2 Regulation by Inflammatory and Stress Signals 
The inflammatory cytokines IL1 and IL6 are both potent inducers of hepcidin expression. IL6 
activates the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) 
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signalling pathway, which activates the hepcidin promoter via a STAT-binding motif close to 
the transcription start site (Fleming 2007). The BMP signalling pathway also contributes to 
the inflammatory response via SMAD4 (Casanovas et al., 2009; Wang et al., 2005). 
Hepcidin transcription was severely impaired in mice with targeted deletion of IL-6 in the 
liver (Pietrangelo et al., 2007). Mice injected with lipopolysaccharide (LPS) increases the 
hepcidin transcription even in the context of iron overload. LPS counteracts the diminished 
hepcidin expression in response to iron deficiency, suggesting that the two signals are 
integrated at the hepcidin promoter and that inflammatory and iron store regulators operate 
independently rather than following a strict hierarchy (Huang, et al., 2009a).  Stress in the 
endoplasmic reticulum (ER) also increases HAMP expression. This stress response can be 
controlled by the transcription factor cyclic AMP response element-binding protein H 
(CREBH) (Vecchi et al., 2009) or by the stress-inducible transcription factors CHOP and 
C/EBPalpha (Oliveira et al., 2009). It has also been suggested that increased hepcidin 
transcription and iron deprivation may represent defense mechanisms against excessive 
cell proliferation and cancer, possibly by binding of the p53 tumor suppressor protein to a 
response element in the hepcidin promoter (Weizer-Stern et al., 2007). 
 
 
 
 
 
40 
 
 
Figure 11: HAMP regulation by inflammatory stimuli. Figure depicts Hepcidin regulation 
by inflammatory stimuli. Interleukin 6 (IL6) activates the Janus kinase (JAK)/ signal 
transducer and activator of transcription (STAT) signaling pathway and stimulates the 
hepcidin promoter via a STAT binding motif close to the transcription start site. The BMP 
signalling pathway also contributes to the inflammatory response via SMAD4. Figure taken 
from Hentze et al., 2010. 
 
1.06.001.3 Regulation of iron absorption by erythropoiesis 
The effect of erythropoietic rate on iron absorption can be dependent on the basis of its 
effect on plasma iron turn over. The theory proposed by Carpenter and Mahoney (1992) is 
based on the idea that iron absorption is controlled through mechanisms similar to those 
responsible for iron-dependent control of the synthesis of ferritin, transferrin and transferrin 
receptor. It must be pointed out that a close parallel exists between iron absorption and rate 
of erythropoiesis (Finch, 1982). HAMP expression in hepatocytes is regulated by multiple 
paths, mainly by systemic iron availability (such as diferric transferrin, Tf-Fe2), iron stores in 
hepatocytes, erythropoietic activity, hypoxia, and inflammatory/infectious states. 
Erythropoiesis requires considerable quantities of iron, and the inhibition of HAMP 
expression by erythropoietic signals. HAMP suppression in response to phlebotomy or 
hemolysis depends on intact erythropoietic activity in mouse models: irradiation and 
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cytotoxic inhibition of erythropoiesis prevent HAMP suppression (Pak et al., 2006). GDF15 
and TWSG1 are both released by erythroid precursors. High doses of GDF15 are detectable 
in the serum of patients with ineffective erythropoiesis such as β-thalassemia (Tanno et al., 
2007). Lower GDF15 concentrations fail to suppress hepcidin in cellular models and are 
apparently ineffective in patients with sickle cell anaemia, myelodysplastic syndrome, and 
ACD. In cellular models, the BMP-binding protein TWSG1 inhibits BMP-dependent 
activation of Smad-mediated signal transduction that leads to hepcidin activation (Tanno et 
al., 2009). However, the molecular mechanisms and factors responsible for erythropoiesis 
are still poorly understood. 
 
Figure 12: Iron regulation by HAMP using erythropoietic signals. Growth differentiation 
factor 15 (GDF15) and twisted gastrulation BMP signalling modulator 1 (TWSG 1) are 
released by erythroid precursors to inhibit BMP/SMAD activation of HAMP in iron-loading 
anaemia. Figure taken from Hentze et al., 2010. 
1.07 Current study 
Although the molecular mechanisms regulating iron absorption remain to be determined it 
is clear that the entire process of iron absorption, storage and transport is a highly regulated 
process. Though the mechanism and regulation of iron absorption has been well 
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documented, establishing the role of few candidate proteins would advocate possible roles 
for all of them in iron metabolism. Though Heph is known to be expressed on the basolateral 
membrane of the cell, its role in efflux of excess iron along with Cp has not been established 
yet. Since protein:protein interaction studies reflect on the interacting partners of protein of 
interest, the current study seeks to establish any interactions between Heph, Cp and other 
molecules expressed on the basolateral membrane of the cells to confirm the role of Heph 
in iron efflux. By carrying out a protein:protein interaction approach the current study was 
also focussed on establishing the role of IRPs (IRP1 and IRP2) in the regulation of systemic 
iron metabolism. Along with Heph and IRPs in this study tagSNP analysis of Mfrn gene was 
also carried out to establish any correlation between the tagSNPs of the Mfrn gene and DNA 
samples of Asian and Caucasian DNA samples for which different covariates, like 
gestational age, mother’s booking weight and birth weight were considered. 
1.07.001.1 Mitoferrin, a solute carrier in SLC25 super family 
SLC25A37 belongs to the SLC25 family of nuclear-encoded transporters embedded in the 
inner mitochondrial membrane and in a few cases other organelle membranes. The 
members of SLC25 family are widespread in eukaryotes. SLC25 mitochondrial carriers can 
be easily recognized by their striking sequence features, i.e., a tripartite structure, six 
transmembrane α-helices and a 3-fold repeated signature motifs. Although the molecular 
mechanism of substrate translocation may be basically the same among the SLC25 
members, they vary greatly in the nature (most of the transported substrates are negatively 
charged, but some are positively charged or zwitterions at physiological pH values) and size 
of their transported substrates and modes of transport (i.e., uniport, symport or antiport). 
Based on substrate specificity, 24 subfamilies have been functionally characterized mainly 
by transport assays upon heterologous gene expression, purification and reconstitution into 
liposomes. Fe2+ acts as a major susbtrate for SLC25A37. Mutations in the SLC25 genes 
have been shown to be responsible for 11 diseases, highlighting the important role of SLC25 
in metabolism. Mitochondria and cytosol share and participate mutually in a large number 
of metabolic cellular processes. Due to the enzyme compartmentalization, a continuous and 
highly diversified flux of solutes into and out of mitochondria takes place across the inner 
membrane. Mitochondrial carriers (MCs) are involved in many important metabolic pathways, 
such as oxidative phosphorylation, the citric acid cycle, fatty acid (FA) oxidation, amino acid 
degradation, gluconeogenesis, lipogenesis, transfer of reducing equivalents, synthesis and 
breakdown of mtDNA, mtRNA and mitochondrial proteins, urea synthesis, haem 
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biosynthesis, ketone body production and utilization, modulation of the nucleotide and 
deoxynucleotide pools in the mitochondrial matrix, heat production, Ca2+ cell signaling, and 
necrotic and apoptotic cell death. 
 
 
Figure 13: Metabolic roles of different mitochondrial carriers (MCs). The schematic 
representation of the above figure shows 16 functionally identified MCs catalyzing 
metabolite, nucleotide or coenzyme transport through the inner mitochondrial membrane. 
These carriers are involved, with partial overlap, in: oxidative phosphorylation (AAC, PiC, 
UCP); oxidation/reduction pathways (AGC, OGC, DIC, CIC, CAC); synthesis and 
breakdown of mitochondrial DNA and RNA (PNC); homeostasis of the intramitochondrial 
adenine nucleotide pool (APC); methylation of mtDNA, mtRNA and some intramitochondrial 
proteins (SAMC); import of thiamine pyrophosphate (ThPP) required for pyruvate- and 
oxoglutarate-dehydrogenase complex activities (TPC); import of coenzyme A (CoA) 
required for fatty acid (FA) b-oxidation, Krebs cycle, biosynthesis of haem, branched-chain 
amino acid catabolism, urea cycle and mitochondrial type II FA synthase (CoA carrier); and 
amino acid metabolism (AGC, ORC, GC, ODC). Figure taken from Palmieri, 2013. 
44 
 
1.07.001.2 Phylogenetic analysis of SLC25 carriers 
A phylogenetic tree of all human MCs is revealed in figure 13. Based on sequence similarity, 
human MCs cluster into many different clades suggesting a large variety of specialized 
functions. Given that the MCs of H. sapiens, S. cerevisiae and A. thaliana cluster into the 
same clades, with very few exceptions, one can deduce that a common ancestor for all 
eukaryotes had already possessed many MC functions that have been retained in fungi, 
plants and animals (Palmieri et al., 2011). Low-grade sequence similarity detected in the 
two helices of each repeat, has aided in hypothesising that the primordial repeat may itself 
have evolved by the duplication of a DNA sequence encoding a single transmembrane 
segment (Fiermonte et al., 1999). 
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Figure 14: Phylogenetic tree of human mitochondrial carriers. Phylogenetic tree of 
human MCs was result of ClustalW multiple-sequence alignments by using the neighbor-
joining method implemented in MEGA5. All 53 human mitochondrial carriers are shown. 
Bootstrap values for 1000 replicates are reported on each node (Palmeieri, 2013). Based on 
the substrate specificity, MCs can be divided into carriers for carboxylates, keto acids, amino 
acids, nucleotides, dinucleotides and other substrates. The carriers categorised under 
uncoupling proteins (UCP) and carriers transporting nucleotides, carboxylates and amino 
acids are boxed. Figure taken from Palmieri, 2013. 
1.07.001.3 SLC25 solute carrier structure 
All mitochondrial carrier family members, including SLC25A37 have a tripartite structure, i.e., 
consist of three tandemly repeated homologous domains of about 100 amino acids in length; 
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each repeat contains two hydrophobic stretches, that span the membrane as α-helices, and 
a signature sequence motif PX[D/E]XX[K/R]X[K/R] (20–30 residues) 
[D/E]GXXXX[W/Y/F][K/R]G, which may not be completely conserved (Palmieri, 2013). 
Based on their hydropathy profile and accessibility to impermeable reagents, proteolytic 
enzymes and peptide-specific antibodies, MCs possess six helices traversing the membrane, 
N- and C-termini on the cytosolic side of the membrane, three repeats linked by two loops 
on the cytosolic side and the two transmembrane α-helices in each repeat connected by 
three loops on the matrix side (figure 14). The 3D crystallographic structure of the ADP/ATP 
carrier in complex with its inhibitor, carboxyatractyloside, was solved to 2.2 Å (Pebay-
Peyroula et al., 2003). The structure of uncoupling protein 2 (UCP2), in complex with GDP 
was determined by nuclear magnetic resonance (Berardi et al., 2011). The atomic structure 
of MCs consists of a six-transmembrane α-helix bundle (H1–H6) and three short α-helices 
(h12, h34, h56) parallel to the membrane plane on the matrix side. 
 
Figure 15: SLC25 carrier protein structure. In the figure above the SLC25 carrier protein 
sequence was divided into three similar domains, each with two transmembrane α-helices. 
Within each domain the two helices are connected by long matrix loops, whereas the 
domains are connected by shorter cytosolic loops. Figure taken from Palmieri, 2013. 
MCs have only one binding site which is alternately exposed on the two opposite sides of 
the membrane, namely, the cytosol in the c-conformation or towards the mitochondrial 
matrix in the m-conformation. When the substrate enters the carrier from the cytosolic side 
(in the c-state) or from the matrix side (in the m-state) the protein rearranges until the 
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transition state is reached. The substrate-induced conformational changes occurring during 
the transition from the c- to the m-state, and vice-versa, are largely due to ‘‘flexible hinged 
helix movements’’ of the even and odd transmembrane α-helices, which consist of a tilt of 
the helical segments and a kink/swivel of their termini at the level of the conservative prolines 
and glycines (Palmieri et al., 2011). In brief, viewing the carrier from the cytosol, the even 
and odd helices would be seen rotating clockwise during the c- to m-state transition, counter-
clockwise during the m- to c-state transition, and vice-versa, viewing the carrier from the 
matrix side (Palmieri, 2013). 
1.07.001.4 SLC25A37 and its physiological role 
SLC25A37 shares 40–41% identical amino acids with yeast MRS3 and MRS4, which have 
been proposed to transport Fe into mitochondria. SLC25A37, as well as zebrafish slc25a37, 
has been shown to efficiently complement the growth defect of MRS3–4D yeast mutant in 
iron-depleted conditions (Shaw et al., 2006), indicating that slc25a37 is also a mitochondrial 
iron transporter. A zebrafish null mutant for slc25a37 manifests hypochromic anaemia and 
erythroid maturation arrest (Shaw et al., 2006). This phenotype was rescued by 
microinjecting mouse SLC25A37 cDNA into defective embryos. Studies on mitochondrial 
DNA showed that European haplogroups with presumed functional differences were 
associated with AIDS progression (Hendrickson et al., 2008). During tumor progression 
healthy cells acquire an altered metabolism to become cancer cells, either as a cause or as 
a consequence of an increased need of energy and nutrients. Carbohydrates, proteins, lipids 
and nucleic acids, the four major classes of macromolecules are affected during the 
transformation of a normal cell to a cancer cell. As a result, solute carriers (SLCs) which are 
the major transporters of these molecules are differently expressed thus making them 
important targets in the treatment of cancer. It has been suggested that SLC2A13 (HMIT) 
might be a potential CSC marker in oral squamous cell carcinoma based on microarray 
studies (Lee et al., 2011). Microarray data revealed that members of the SLC25 
(mitochondrial carrier family) and SLC39 (metal ion transporter family) families were more 
common in noncancer stem cells (CSCs) (El-Gebali et al., 2013). 
 
A 
B 
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Figure 16: Blast output of human SLC25A37. Figure B shows the sequence identity of 
human Mfrn and yeast MRS3 and MRS4 genes. 
 
1.07.001.5 tagSNPs in Mitoferrin 
Mitoferrin (Mfrn/SLC25A37) is located on chromosome 8. The human genome encodes the 
blueprint of life, but the function of the vast majority of its nearly three billion bases is 
unknown (The ENCODE Project Consortium, 2012). Despite intensive study, especially in 
identifying protein coding genes, our understanding of the genome is far from complete, 
particularly with regard to noncoding RNAs, alternatively spliced transcripts, and regulatory 
sequences (The ENCODE Project Consortium, 2012). There are about three million single 
nucleotide polymorphisms (SNPs) in the human genome, two thirds of which are in non-
coding DNA (Fairweather et al., 2007). Mutations in the proteins involved in iron metabolism 
may have an impact on iron metabolism and subsequently on human health. Rare genetic 
mutations and knock-out animal models have been invaluable tools in understanding the 
molecular events controlling iron metabolism (Donovan and Andrews, 2004). 
Most SNPs do not occur in the coding region of genes or even in genes (Venter et al., 2001). 
Few SNPs that are present in the coding region, changes an amino acid (which are termed 
as non-synonymous SNPs) within a protein (Cargill et al., 1999). Based on the presumption 
that amino acid change will lead to a change in protein function, non-synonymous SNPs 
generally become the primary targets for SNP analysis. However, non-synonymous SNPs, 
though obvious suspects in causing a proportion of human disease, do not account for all 
SNPs that can cause disease or susceptibility to disease. SNPs implicated in human disease 
or susceptibility to disease include SNPs in the promoter region (Klerkx et al., 2003), introns 
(Tokuhiro et al., 2003), splice sites (Betticher et al., 1995) and intragenic regions (Helms et 
al., 2003). Even synonymous SNPs (which do not cause change of amino acid when there 
is a change of base in coding sequence) have been reported as having a functional 
implication via unknown mechanisms (Duan et al., 2003). 
SNPs constitute 90% of the variation in the population (Kruglyak and Nickerson, 2001). 
Since a mutation is a very rare event, each new allele is associated with aother allele that 
happened to be present on the same chromosome. The specific set of alleles observed on 
a single choromosome, or part of a chromosome, is called a haplotype. The coinheritance 
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of SNP allele on these haplotypes leads to associations between these alleles in the 
population (known as linkage disquilibrium, LD) (HapMap consortium 2003). The further the 
SNPs are from each other the less are the chances of association and coinheritance. 
Previous studies (Reich et al., 2001, Sklar et al., 2002) have shown that highly significant 
levels of LD, and often strong associations occur between nearby SNPs. These strong 
associations between the nearby SNPs results only in a few haplotypes, and these 
associations account for most of the variation among people in those specific chromosomal 
regions (Gabriel et al., 2002). SNPs with a strong association in a chromosomal region have 
a practical advantage. Genotyping only a few chosen SNPs in the region will provide enough 
information to predict much of the information about the remainder of the common SNPs in 
that region (The International HapMap Consortium 2003). By which, only a few of these 'tag' 
SNPs (also known as htSNPs) are required to identify each of the common haplotypes in a 
region (Johnson et al., 2001). 
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Figure 17: Schematic representation of SNPs and tagSNPs. Figure taken from The 
International HapMap Consortium, 2003. 
Using the knowledge of common haplotypes and reduced sets of SNP markers that 
uniquely identify, or tag them has the potential to greatly reduce the scale and cost of 
genotyping. 
1.07.001.6 Mfrn as a candidate 
Iron deficiency anaemia in pregnancy is a risk factor for subsequent low birth weight (Baker 
et al., 1969). Prominent manifestation of iron deficiency is anaemia as most of the body’s 
iron is used to produce red blood cell haemoglobin. At the time anaemia is detected 
population averages for red blood cell volume and red cell haemoglobin content are 
significantly lower than normal. Interestingly, genetic defects more commonly lead to iron 
overload. A SNP association study approach could be used in translating the role of genetic 
variants in iron metabolism and birth weight. Defects in iron homeostasis results in either 
iron deficiency or iron overload. Precise regulation of iron transport in mitochondria is 
essential for haem biosynthesis and haemoglobin production. Mfrn (SLC25A37) functions 
as the principal mitochondrial iron importer essential for haem biosynthesis in vertebrate 
erythroblasts (Shaw G C et al., 2006). Based on the function of Mfrn in erythroid iron 
assimilation proposed by Shaw et al my study considered it as a candidate gene for tagSNP 
analysis. 
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Along with understanding the role of Mfrn tagSNPs in iron metabolism, realising how protein-
protein interactions play a major role in cellular processes, the current study also tried to 
elucidate the role of Iron regulatory proteins (IRPs) and Heph in iron metabolism. It is now 
becoming clear that protein-protein interactions determine the outcome of most cellular 
processes (Giot et al., 2003). 
1.08 Protein-Protein Interactions (PPIs) 
Vital processes of life in an organism, such as adaptation to a given environment, 
reproduction and differentiation are dependent on an efficient communication between cells 
and cell compartments. Virtually every cellular function requires physical protein-protein 
interactions (PPIs) between cellular proteins (Westermarck et al., 2013). Commonly PPIs 
are understood as physical contacts with molecular docking between proteins that occur in 
a cell or in a living organism in vivo (Rivas and Fontanillo, 2010). Cellular signals (e.g. 
hormones) or environmental conditions (e.g. extracellular matrix composition) are 
recognised by a variety of specific cell surface receptors which in turn are transmitted to the 
nucleus via signalling cascades that eventually activate specific subsets of genes in the 
nucleus. In order for the cell to integrate different but connected signals into one 
expressional output, many signalling pathways cross talk with each other resulting in a 
complex signalling network. Further, these signalling processes are controlled by PPIs, 
which are further regulated by protein modifications. Identifying different interaction partners 
of a given gene product thus facilitates the identification of the function of the gene of interest 
in the organism. 
Protein-protein interactions can be classified into different types depending on their strength 
(permanent and transient), specificity (specific or non-specific), the location of interacting 
partners within one or on two polypeptide chains, and the similarity between the interacting 
sub-units (homo and hetero oligomers) (Shoemaker and Panchenko, 2007). The issue of 
whether two proteins share a functional contact is quite distinct from the question of whether 
the same two proteins interact directly with each other (De Las Rivas and Fontanillo, 2010). 
Identification of PPIs is at the heart of functional genomics (Keskin et al., 2008). 
PPIs can be analysed by approaches which have been categorised into biochemical (in 
which interactions between proteins are detected or analysed in vitro, for example cross-
linking and co-purification), genetic (which the classical yeast two- hybrid is the most popular 
method to detect protein–protein interactions in vivo) and physical [X-Ray crystallography, 
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fluorescence resonance energy transfer (FRET)] (Shoemaker and Panchenko, 2007). 
Previously PPI studies were carried out in in-vitro models such as Yeast two Hybrid Systems 
(Y2H) and pull-down assays which were integrated with more physiological approaches to 
assess the complexity of PPIs in living cells. A generic procedure to co-purify proteins 
expressed at their natural level with a Tandem Affinity Purity (TAP) tagged bait protein under 
native conditions using TAP purification (Rigaut et al., 1999) was developed. However, 
extended washing and time consuming cleavage steps made TAP tagging process prone to 
artefacts and unable to detect PPIs with transient interacting partners (Glockner et al., 2007). 
Since it is also important to understand the PPIs with short half-lives which could be lost 
during the extended washing steps during the pull down Junttila et al., in 2005 proposed a 
3kDa sized One-Strep tag to enable a rapid one-step pull down of the protein complex that 
can be analysed for interactions without losing weak interacting partners. 
In the current study, to understand the role of IRPs and Heph in iron metabolism, we carried 
out biochemical approach by co-purification. The discovery of many molecules involved in 
iron uptake, storage and transport enhances the possibility to understand the roles of 
different proteins in iron metabolism in different cell types. Thus understanding the roles of 
IRPs and ferroxidases may enhance the understanding of their respective role in iron 
metabolism. As is well known, proteins in the cells do not act in isolation. A critical aspect in 
understanding and comprehending the role of an individual protein is by evaluating and 
elucidating the activity and function of each protein in the cell. The role of an individual 
protein is controlled and modified through its interactions with neighbouring polypeptides 
and with other molecular components of cells such as nucleic acids, phospholipids, 
carbohydrates and secondary messenger molecules. To understand the complexity of 
cellular functions, studying localised protein interactions is not only necessary but also 
knowledge of the connections between different protein complexes is also necessary. Hence 
protein-protein Interactions (PPIs) play an important role for every process in a living cell.  
The half-life of some PPIs may be long enough to form stable protein complexes or may be 
very brief which is enough to modify the interacting partners thus changing the PPI. 
1.08.001.1 Iron Regulatory Proteins (IRPs) 
Mammalian cells must manage the import, export and sequestration of iron to achieve the 
cytosolic concentrations needed to support the synthesis of iron binding proteins and 
prevent unfavourable iron dependent oxidation events (Rouault, 2009).  Iron regulatory 
protein’s (IRPs) recognise the iron response elements (IREs) in a sequence and structure- 
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specific manner (Leibold et al., 1987, Rouault et al., 1988). IREs are short conserved hair 
pin loops bound by iron response proteins. IREs are found in the untranslated regions (UTRs) 
of various mRNAs whose products, the proteins, play an important role in iron metabolism. 
Mutagenesis studies of the 3’-untranslated regulatory region of the transferrin receptor 
mRNA revealed two types of mutations. Key to iron homeostasis are the IRPs, which 
respond to the cytosolic iron pool by binding to target mRNA and regulating the synthesis of 
iron metabolic proteins (Rouault, 2006). Some mutations abrogated iron-dependent 
regulation of the transferrin receptor while other mutations produced an increased and 
unregulated expression of transferrin receptor mRNA (Casey et al., 1988, Mullner et al., 
1989, Owen et al., 1987). Other studies led to the purification and preliminary 
characterisation of the iron regulatory protein (IRP) (Haile et al., 1989, Barton et al., 1990).  
IRPs are the key cytosolic sensors in mammalian cells and they are present as free cytosolic 
proteins or RNA-bound protein inside the cells. Sequence analysis of a cDNA clone 
encoding human IRP showed that IRP resembles mitochondrial aconitase, an enzyme 
containing a 4Fe-4S cluster (Rouault et al., 1990, Hentze et al., 1991). Two IRPs (IRP1 and 
IRP2) are present in mammalian cells. Transfection experiments of IRE mutants specific for 
either IRP1 or IRP2 showed that IREs maintain their IRP specificity in-vivo and are able to 
mediate translational control (Menotti et al., 1998). Though IRP1 and IRP2 share 64% amino 
acid sequence similarity, different mechanisms are thought to control the regulation of their 
RNA binding activity.  
1.08.001.2 The IRP-IRE system 
By interacting with the IREs found in the mRNAs of many genes both IRP1 and IRP2 are 
involved in iron sensing. According to the requirements of a cell, the IRE/IRP system 
responds to changes in cellular iron status and through the interaction of IRPs with IREs 
regulates the amount of iron taken up and/or stored by a particular cell. The IRP-IRE system 
is the best characterised regulatory mechanism for maintaining iron homeostasis within a 
single cell. The IRE canonical stem loop structure – CUGTGA – and a cytosine bulge on the 
stem at the 5th residue position are found to be conserved and essential for the IRP binding 
(Casey et al., 1988; Addess et al., 1997). Stems can be of variable lengths. The IREs are 
found to be situated either at the 5’ or 3’ UTR elements of a transcript in number of different 
iron genes. Binding of an IRP to the 5’ UTR of an IRE may repress the translation. Both H 
and L ferritins along with IREG1 transcripts contain a single IRE in their 5’ UTR (Henze et 
al., 1987; McKie et al., 2000). In cellular iron deficiency, where IRP binding to IRE is 
54 
 
promoted, further translation of ferritin and IREG1 is inhibited at an early stage resulting in 
cellular iron utilisation. The opposite can be said in iron repletion condition in which IRP 
binding is decreased and excess iron is either stored or exported. 
On the other hand, IREs located at the 3’ UTR of a gene may increase the mRNA half-life. 
When IREs are located in the 3’ UTR of TfR1 transcripts, iron deficiency promotes 
stabilisation and contributes to increased protein synthesis and cellular iron uptake (Hubert 
and Hentze, 2002; Gunshin et al., 2001). The TfR1 transcript contains five IREs in tandem 
in its 3’ UTR (Erlitzki et al., 2002). IRP binding to these IREs protects the message from 
endonuclease cleavage and degradation. Although a 3’ UTR IRE in DMT1 has also been 
identified, its role and contribution in iron regulation is still not clear (Gunshin et al., 2001). 
Other transcripts such as mitochondrial aconitase (Eisenstein and Ross, 2003) and hypoxia-
inducible factor 2 (HIF-2) (Sanchez et al., 2007) have also been shown to possess IREs. 
The cellular iron pool regulates the binding of IRP1 and IRP2 to the IRE by distinct 
mechanisms. 
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Figure 18: IRP-IRE system. Figure A and B show iron deplete cells in which binding of 
IRP1/2 at the 5´UTR IRE of ferritin and ferroportin mRNA block translation hampering its 
initiation and binding of IRP1/2 at the 3´UTR IRE of TfR mRNA stabilize its transcript, 
respectively. In iron replete cells representing C in the figure, IRP1 act as aconitase and 
IRP2 is degradated by proteases so translation of 5´UTR IRE mRNA of ferritin and IREG1 
is carried out undisturbed and in the presence of sufficient iron there is no binding of IRP1/2 
and stabilization of 3´UTR IRE transcript of TfR (D). Figure taken from Tandara and 
Salamunic, 2012. 
1.08.001.3 Iron regulatory protein 1 (IRP1) and IRP2 
IRP1 and IRP2 which are capable of binding to an IRE, though at different binding sites are 
also conserved across the species at 90% sequence identity (Henderson et al., 1993; 
Samaniego et al., 1994; Guo et al 1995; Butt et al 1996). 
The IRP1 gene on 9q13-22 encodes an IRP1 (98kDa) protein which is identical in sequence 
to cytosolic aconitase that catalyses the conversion of citrate to isocitrate via the 
intermediate cis-aconitate in the Krebs cycle (Rouault et al 1991; Hentze and Argos 1991). 
Based on the crystal structure of the homologous mitochondrial aconitase it is thought that 
IRP1 is a 4 domain protein, with domain 4 linked by a hinge region to the other 3 domains, 
and a cleft forming between domains 1-3 and domain 4 (Dupuy et al 2005, 2006). IRP1 in 
complex with the ferritin IRE (Selezneva et al 2006) supports the importance of the cleft 
region in IRP1’s mutually exclusive functions (Figure 1.4C). Increased iron levels in a cell 
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promotes the formation of the iron-sulphur cluster (4Fe-4S), which can occupy the cleft and 
determine the function of the protein, which acts either as an active cytosolic aconitase 
(holoprotein) or as an RNA binding protein (apoprotein) when the protein lacks this cluster 
(Constable et al 1992, Haile et al 1992) (Figure 1.5A). IRP1 is a dual function protein that 
performs two mutually exclusive activities depending on cellular iron status. Reduced 
cellular iron levels increases IRP1’s affinity to bind to IRE and vice-versa. In the iron replete 
form, IRP1 is the cytosolic isoform of aconitase (Haile et al., 1992, Rouault et al., 1991) and 
promotes the disassembly of the 4Fe-4S cluster and the cleft widens enough to 
accommodate an RNA molecule, which is critical for the IRE/IRP interaction. In cells that 
are rich in iron, IRP1 ligates an iron-sulfur cluster and IRP1 functions as an aconitase that 
interconverts citrate to isocitrate through a cis-aconitate intermediate in the cytosol and has 
30% aa sequence identity with mitochondrial matrix aconitase, which catalyses the same 
reaction in the mitochondrial matrix (Beinert and Kennedy, 1993).  Kocking out IRP1 has 
little effect on iron regulation, suggesting that its primary role may be in maintaining cytosolic 
aconitase rather than to control iron metabolism (Rabie et al., 1995). Other than levels of 
iron in a cell, nitric oxide has also proved to be the first factor able to regulate the RNA 
binding activity of IRP1 to IREs (Drapier et al., 1993) and others like phosphorylation 
(Eisenstein et al 1993) and oxidative stress (Pantopoulos and Hentze 1995) emerged to 
influence the IRP1-IRE interaction. 
A second IRE binding protein, called IRP2, has been identified and characterised in murine 
cells. Human IRP2 (105kDa) shares 61% sequence identity and 79% amino acid sequence 
similarity to human IRP1 (Samaniego et al 1994). IRP2 is always active in binding to IREs 
and unlike IRP1, IRP2 appears neither to be enzymatically active nor post-translationally 
reversibly convertible between active and inactive RNA binding forms. IRP2 is regulated via 
de novo synthesis and proteasome-mediated degradation (Guo et al 1995; Iwai et al 1995). 
Both IRPs have been found to be regulated by protein degradation in the presence of iron 
or haem (Goessling et al 1998, Clarke et al 2006), but this mechanism is more pronounced 
for IRP2. IRP2 (gene location on chromosome 15) (962 amino acids) contains a 73 amino 
acid region encoded by a single exon, which is not present in IRP1 (889 amino acids) targets 
IRP2 for iron dependent degradation. The unique “iron- dependent degradation domain” in 
IRP2 can bind free iron resulting in a localised oxidation site that forms or acts as the 
recognition signal for ubiquitination and the subsequent degradation of the protein (Iwai et 
al 1998). In iron-rich cells the oxidation of IRP2 has been proposed to be induced by haem, 
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as well as oxygen (Yamanaka et al 2003, Bourdon et al 2003). Unique degradation domain 
is dispensable for both iron and oxygen mediated degradation (Hanson et al 2003), while 
additional stimuli may be involved in creating recognition signals within and outside the 
boundaries of the degradation domain (Wang et al 2004). Unlike IRP1, protein levels which 
do not change following iron loading IRP2 protein levels decreases to the detectable levels 
in cells loaded with iron (Guo et al., 1994). Also IRP2 does not have aconitase activity like 
IRP1. The IRE-binding activity of IRPs differentially controls the translation of different 
mRNA involved in iron homeostasis. For example, when cells are low in iron, IRPs inhibits 
the translation of mRNA encoding the cytosolic iron-binding protein, ferritin. The inhibitor 
effects of IRPs on mRNA of ferritin results in reduction of iron storage, thus making it 
available for cellular iron processes. IRP binding also protects mRNA encoding the TfR1 
(which transports iron into the cells) from degradation, and consequently boosts TfR1 
expression when the concentration of cytosolic iron is low (Rouault, 2009). Vashisht et al 
and Salahudeen et al in 2009 reported that human cells gauge cellular iron and 
concomitantly alter the activity of IRPs through a mechanism that depends on the F-box and 
leucine-rich repeat protein 5 (FBXL5).  
The human genome includes more than 20 proteins that contain both an F-box (Skaar et al., 
2009) and a domain of leucine-rich repeats that provides the platform for protein-protein 
interaction studies (Bella et al., 2008). The C-terminal region of FBXL5 contains leucine rich 
repeats that help the binding to IRPs (Vashisht et al., 2009 and Salahudeen et al., 2009). 
Since, iron and oxygen stabilises FBXL5, targeting of IRPs for degradation occurs in cells 
that are replete in iron. As expected (Rouault, 2009) changes in FBXL5 activity affected the 
amounts of ferritin (Vashisht et al., 2009) and TfR1 mRNA levels in cells (Salahudeen et al., 
2009). Thus, the activity of the IRE-IRP regulatory system is controlled by FBXL5, which 
directly reflects cellular iron status through the iron binding of its conserved haemerythrin 
domain [(haemerythrin is a conserved domain recognised as oxygen-carrying proteins in 
invertebrates and as a potential oxygen sensor in bacteria, and are absent in higer 
organisms (Stenkamp, 1994)] (Feig and Lippard, 1994). In the slow but never ending 
evolutionary process, haemrythrin was surpassed by haem as the oxygen carrier of choice 
(Kurtz, 1999). However, it seems that in higher organisms, the haemrythrin domain was 
successfully repurposed as an iron sensor to function in cellular iron homeostasis. Both 
Vashisht et al and Salahudeen et al (2009) reported that the binding of iron and oxygen to 
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the haemrythrin domain stabilises FBXL5, where as a lack of iron (or lack of oxygen in the 
presence of sufficient iron) results in FBXL5 degradation. 
 
Figure 19: IRP1 and IRP2 in iron replete and deficient cells. In iron-deficient cells (right 
panel in the figure), IRP1 or IRP2 bind to cis-regulatory hairpin structures called iron-
responsive elements (IREs). The binding of IRPs to single IREs in the 5′ UTRs of target 
mRNAs inhibits their translation, whereas the interaction of the IRP with multiple 3′ UTR 
IREs in the TfR1 transcript increases its stability. As a consequence, TfR1-mediated iron 
uptake increases whereas iron storage in ferritin and export via IREG1 decreases, thereby 
increasing the LIP (labile iron pool). In the iron-replete cells (left panel in the figure), the 
FBXL5 iron-sensing F-box protein interacts with IRP1 and IRP2 and recruits the SKP1-CUL1 
E3 ligase complex that promotes IRP ubiquitination and degradation by the proteasome. 
IRP1 is primarily subjected to regulation via the assembly of a Fe/S cluster that triggers a 
conformational switch precluding IRE-binding and conferring aconitase activity to the 
holoprotein. IRPs also modulate the translation of the mRNAs encoding the erythroid-
specific ALAS2, the mitochondrial aconitase (ACO2) and the HIF2α hypoxia-inducible 
transcription factor. Single 3′ UTR IRE motifs are present in the DMT1 and CDC14A 
mRNAs, but their role and mechanism of function are not yet fully defined. Figure taken 
from Hentze et al., 2010. 
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Based on the fact that IRP1 is more abundant than IRP2, IRP1 would be expected to be the 
predominant regulator but the necessity and presence of two IRPs is still not clearly 
understood (Hentze and Kuhn, 1996). Mis-regulation of iron homeostasis in Ireb2-/- mice 
and lack of the mouse gene encoding IRP2 exemplifies the importance of IRP2 in iron 
homeostasis and suggests that IRP1 alone cannot regulate iron metabolism appropriately 
(LaVaute et al., 2001). Irp1-/- mice show only compromised normal iron metabolism in 
tissues in which the levels of IRP1 exceed those of IRP2, suggesting that unlike IRP1, IRP2 
can compensate for loss of IRP1 activity by increasing IRP2 levels (Meyron-Holtz et al., 
2004a). Animals lacking both IRPs are unable to survive through gestation (Smith et al, 2006) 
and it is likely that IRP1 and IRP2 operate in a continuum in which the partial pressure of 
oxygen determines relative activity (Meyron-Holtz et al., 2004b). Though the role of IRPs in 
iron homeostasis is well established, understanding of the significance of multicopper 
ferroxidase protein, Hephaestin (Heph) is not conclusive in iron metabolism. The sex-linked 
anaemia (sla) mice develop moderate to severe microcytic hypochromic anaemia due to 
impaired intestinal iron absorption (Pinkerton, 1968; Bannerman, 1976). Iron uptake across 
the brush border membrane in sla mice is normal indicating there is a defect in an ‘exit’ step 
of iron absorption. Thus, Heph could possibly be the factor limiting iron transfer across the 
basolateral membrane of the enterocyte. It is thought Heph plays a significant role in the 
basolateral membrane as an iron exporter. In the current study we tried to confirm the 
previously established protein interactors of Heph and also tried to examine for any new 
interacting partners with whom Heph may be cross talking that sheds some light on iron 
transport at the basolateral membrane. 
1.09 Hephaestin (Heph) 
 
1.09.001 Heph and Blast analysis 
Hephaestin (Heph) is a putative multi-copper oxidase that was identified through the study 
of the sex-linked anaemia (sla) mouse (Vulpe et al., 1999). Between humans, mouse and 
rat, Heph shows more than 85% homology both at protein and nucleotide levels. Heph is 
present on the X chromosome with 21 exons, spanning a little over 106 kb. 21 exons of 
Heph encode a polypeptide of 1158 amino acids (130 kDa protein) with a putative N-terminal 
signal peptide. Due to N-glycosylation and possibly because of post-translational 
modification (Nittis and Gitlin, 2004) the theoretical calculated molecular mass of the mature 
Heph is 150-160 kDa. Heph, in contrast to its soluble serum homologue, contains an 
additional 86 amino acids at the C-terminus, which includes a single predicted 
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transmembrane domain and a short cytosolic tail, attributing its nature to be a membrane 
protein with a large Cp like ectodomain (Petrak and Vyoral, 2005).  
 
 
Figure 20: Blast output of human, mouse and rat Heph. Above parts of figure, A and B 
represents the blast results obtained after carrying out Protein blast with multiple alignment 
among human (Q9BQS7), mouse (Q9Z0Z4) and rat (Q920H8) Heph using data from 
UniProt database. Part A of the figure shows the alignment of mouse and rat protein 
sequence against human Heph. Part B of the figure shows the percentage of identity 
between human, mouse and rat Heph protein sequences. 
1.09.002 Heph and sla mice 
It was observed that in the sla mice the mucosal uptake of dietary iron although is normal 
they are unable to release it from the duodenal enterocytes into the bloodstream (Anderson 
et al., 1998). Although sla mice take up iron from the intestinal lumen into mature epithelial 
cells normally (Manis, 1970) the subsequent exit of iron into the circulation is diminished 
(Bannerman, 1976). As a result, iron accumulates in enterocytes and is lost during turnover 
of the intestinal epithelium (Edwards, et al., 1977). An in-frame mutation of Heph, which is 
responsible for the sla phenotype in mice, results in a truncated protein and possibly due to 
mislocalization of Heph, Heph was not detected on the basolateral membrane of the small 
intestine in sla mice (Chen et al., 2004; Kuo et al., 2004). Structural modelling shows that 
the mutation causes a substantial deformation of the secondary structure, partial loss of 
copper binding sites, reduces protein stability and implicates partial loss of ferroxidase 
activity of Heph in sla mice (Syed et al., 2002; Petrak and Vyoral,  2005). 
1.09.003 Heph and Cp 
Heph is homologous to Cp and is a member of the ‘blue’ copper oxidase family. The 
biochemical activity of Heph has yet to be defined. The extensive similarity between the 
ecto-domains of Heph and Cp (approximately 50%) suggests that they share the same fold 
A 
B 
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and further implies that Heph may function as a ferroxidase (Vulpe et al., 1999). 
Comparative structural modelling based on the known crystal structure of Cp revealed 
several important facts of the Heph’s ectodomain (representing more than 92% of its 
sequence). Heph and Cp share a similar β fold and the key structural features critical for 
folding and function of Cp are conserved in Heph. Along with the copper-binding sites, all 
the cysteine residues essential for the formation of disulphide bridges are also conserved in 
the putative structure of Heph. The putative iron-binding site with a negatively charged 
aspartate-rich tract in its vicinity is also conserved in Heph (Syed et al., 2002; Petrak and 
Vyoral, 2005). 
At the basolateral membrane, Fe2+ is exported into the extracellular environment via the 
transmembrane permease ferroportin (Mackenzie and Garrick, 2005) and is oxidised into 
Fe3+ by a ferroxidase. Outside the cell, the available Fe3+ loads onto serum transferrin (Tf), 
the iron carrier in blood. Tf specifically binds Fe3+, but not Fe2+, very tightly with an 
approximate KD of 10-24 M at physiological pH (Richardson and Ponka, 1997). Iron-loaded 
Tf (holo-Tf) then travels throughout the circulation and delivers Fe3+ to all tissues via a 
binding interaction with the TfR. Because of the insoluble nature of free Fe3+ under 
physiological conditions and the potential of Fe2+ and Fe3+ to generate harmful hydroxyl-free 
radicals, the regulation of iron is fundamental to the prevention of cell toxicity (Aisen et al., 
2001). It has been suggested that as a means of preventing the release of unbound Fe3+, a 
direct protein– protein interaction may occur between Tf and Heph during intestinal iron 
export (Syed et al., 2002; Griffiths et al., 2005). This hypothesis is supported by a study that 
reported the formation of a stable complex between a multicopper ferroxidase and Tf in 
algae (Paz et al., 2007). Furthermore, the identification of an interaction between Cp and 
lactoferrin (a Tf analog) under physiological conditions provides additional support (Pulina 
et al., 2002; Sokolov et al., 2006). However, it was concluded that the human ferroxidases 
and Tf do not interact directly and suggest alternative mechanisms for iron-loading Tf during 
intestinal iron export (Hudson et al., 2008). It was established that the ferroxidases, Heph 
and Cp do not form a stable complex or directly interact with Tf by gel analysis and SPR in 
solution (Hudson et al., 2008). The localization of Heph to both the intracellular and 
extracellular environments presents some uncertainty concerning its function, as it is not 
clear how an intracellular ferroxidase would function in iron transport. However, it has been 
implicated that an intracellular Cp as well as Heph to play significant roles in iron absorption 
(Cherukuri et al., 2005). The processing of absorbed iron by Heph or Cp inside the cell could 
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also explain the absence of a direct interaction with Tf. It can also be explained that the lack 
of interaction between the ferroxidase and Tf is based on their physical locations. After being 
oxidised Fe3+ would be released into the mucosa, while Tf is typically found circulating 
throughout the vasculature. In such condition, an unknown iron-carrying intermediate, such 
as citrate, could transport iron through the interstitial fluid to the portal blood; thereby 
bypassing the need for a direct ferroxidase–Tf interaction. On the other hand, with Tf serum 
concentrations as high as 50 mM (Richardson and Ponka, 1997), Tf may act as an efficient 
scavenger for released Fe3+ without the need for intermediates or direct protein–protein 
interactions. Ferroportin (IREG-1/FPN-1) has been shown to export iron both in the 
presence of Tf but in the absence of a ferroxidase (Donovan et al., 2000) and in the presence 
of ferroxidase but in the absence of Tf (McKie et al., 2000). 
1.09.004 Heph and IREG1 
Molecular genetic studies in yeast cells (DeSilva et al., 1995; Stearman et al., 1996; Singh 
et al., 2006) showed that Ferroportin1 (IREG1/FPN-1) and Heph may be located on the 
basolateral membrane of enterocytes, and they may interact in the processes of iron export 
across the basolateral membrane of intestinal absorptive cells, but it remains to be explored.  
The transporter responsible for the export of iron across membranes was identified in three 
different laboratories and is variously referred to as FPN-1 (Donovan et al., 2000), Ireg1 
(McKie et al., 2000), and MPT1 (Abboud and Haile, 2000). It is not clear where these 
proteins are exactly located, and how they are involved in the process of iron exit in intestinal 
enterocytes. The previous study showed that Heph protein was located on the basolateral 
membrane of small intestine in mice (Kuo et al., 2004). IREG-1 and Heph proteins are 
primarily located on the basolateral membrane of intestinal cells, which support their 
proposed roles in iron exit across the basolateral membrane of enterocyte. Furthermore, 
confocal microscopy data demonstrate that Heph is colocalized with IREG-1-GFP on the 
basolateral membrane in human intestinal absorptive cells. These observations support the 
possibility that FPN-1 and Heph may interact in the processes of iron exit across the 
basolateral membrane of intestinal absorptive enterocytes, as shown previously in 
astrocytes (Jeong and David, 2003) and yeast cells (De Silva et al., 1995; Stearman et al., 
1996; Singh et al., 2006). Once ferrous ion is exported across the cell membrane, oxidation 
of Fe2+ to Fe3+ by Cp is required for the release of iron from the tissues into the circulation 
(Osaki et al., 1971). However, aceruloplasminemia in mice led to iron accumulation in many 
tissues but not in the intestine (Harris et al., 1999) suggesting that intestinal epithelium 
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utilizes another ferroxidase to convert Fe2+ to Fe3+. Colocalisation of Heph and IREG-1 
proteins on the basolateral membrane of intestinal cells suggests the possible interactions 
of IREG-1 with Heph in the processes of iron export across the basolateral membrane of 
enterocytes. Molecular genetic studies in yeast cells have shown that iron transport across 
cell surface requires both iron transporter (Ftr1) and an associated multi-copper oxidase 
(Fet3) (De Silva et al., 1995; Stearman et al., 1996; Singh et al., 2006). Ftr1 is needed for 
Fet3 biosynthesis and localization to the plasma membrane (Stearman et al., 1996). In yeast, 
the requirement that both Ftr1 and Fet3 proteins must be simultaneously synthesized for 
proper processing suggests that these proteins might function as a complex on the cell 
surface. A Cu oxidase in cultured placental cells is mainly in an intracellular membrane 
compartment, but not on the expected basolateral membrane (Gambling et al., 2001). In 
addition, whether the Cu oxidase expressed in placenta is Heph or Cp or another homologue 
has not been confirmed. The current evidence suggests that the expression of Heph may 
be regulated by Cu, Fe and Zn (Reeves et al., 2005; Kelleher et al., 2006; McArdle et al., 
2008). However, there is no IRE structure in Heph mRNA, so its expression regulated by Fe 
may not depend on the IRE/IRP system. Iron export in mammalian cells requires the iron 
transporter IREG-1, and recent studies have revealed a direct association between FPN-1 
and the glycosylphosphatidylinositol (GPI)-anchored multi-copper oxidase Cp during iron 
movement from mouse astrocytes (Jeong and David, 2003) suggesting a possibility that 
IREG-1 and Heph are required for the exit of iron across the intestinal basolateral membrane 
and express as an associated complex. 
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Figure 21: Efflux of iron across the basolateral membrane. Efflux of iron across the 
basolateral border is mediated by Ireg-1, in conjunction with the ferroxidase, hephaestin. 
Figure taken from Griffiths and Cox, 2000. 
The role of Heph was suggested for iron egress from intestinal enterocytes into circulation 
and that acts as an important link between copper and iron metabolism in mammals (Vulpe 
et al., 1999). Contrary to the behaviour of most proteins involved in iron homeostasis, Heph 
expression is not regulated via iron-responsive elements and IRE-binding proteins. Known 
factors influencing expression levels of Heph in the intestine include iron and copper levels 
(Vyoral and Petrak 2004). The absence of Heph in the basolateral membrane seems to be 
critical and could explain the iron deposition in enterocytes of sla mice (Kuo et al., 2004). 
Direct evidence of Heph ferroxidase activity comes from experiments in yeast (Li et al., 2003). 
In vitro enzymatic assays confirmed Heph ferroxidase activity and showed that a residual 
Heph ferroxidase function is retained even in the severely truncated Heph in the sla-mice 
(Chen et al., 2004). Heph could be in direct contact with a membrane-bound iron exporter 
(possibly Ireg1) transporting ferrous iron through the membrane, and Heph may oxidise the 
ferrous ion to enable its subsequent binding by transferrin (Vyoral and Petrak 2004). It has 
been shown that Glycophosphatidylinositol (GPI)-anchored Cp physically associates with 
Ireg1 in astrocytes (Jeong and David, 2003). Localisation studies have suggested that Heph 
65 
 
co-localises with Ireg1 to the basolateral membrane in association with transferrin receptor 
(TfR) (Han and Kim, 2007) in differentiated Caco2 cells. It is an absolute requirement for 
membrane-bound Heph and basolateral localisation for proper IREG1 expression and 
localisation to achieve the mode of iron exit from intestinal cells (Chen et al., 2009) which is 
similar to that of brain (De Domenico et al., 2007b). Heph was shown to be translocated to 
the basolateral membrane when rats were fed an iron-replete diet (Yeh et al., 2009). In 
addition, the basolateral targeting of Heph results in an interaction with Ireg1 (Yeh et al., 
2009) which has been reported to be reduced upon iron feeding (Yeh et al., 2011). The 
principle involved in the process of placental iron transport is similar to that in duodenum. 
IREG-1 and Heph have been identified as the important molecules involved in duodenal iron 
export. However, the molecular mechanism of iron efflux is still not clear. 
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Aims and Objectives of the research study 
 
Aim of this study was to carry out tagSNP analysis of Mitoferrin (Mfrn) SNP using an Asian 
and Caucasian cohort. The current research study is also aimed to establish the interacting 
partners of IRPs (IRP1 & IRP2) and Heph in iron metabolism using protein-protein 
interaction analysis in K562 cells 
• To establish any correlation between Mfrn tagSNPs, birth weight and haemoglobin 
levels in Asian and Caucasian DNA samples. 
• Identification of interacting partners of IRPs (IRP1 and IRP2) and Heph 
 
Objectives to achieve the above mentioned aims in the current research include 
• Selecting tagSNPs in Mfrn gene using HapMap and haploview 
• Statistical analyses of the tagSNPs genotyping data using SPSS 
• To perform relative gene expression analysis of iron metabolic genes (Heph and IRPs) 
in K562 cell lines using TaqMan Gene expression probes 
• Molecular cloning of the Heph, IRP1 and IRP2 cDNA using One-Strep tag approach 
• Pull down analysis of the Heph, IRP1 or IRP2 protein complex using Mass 
Spectrometry to identify the protein protein interactions 
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CHAPTER 2 
 
 
 
2.01 UK/Irish and South Asian Cohort for Mfrn tagSNP analyses 
In this study, a total of 1811 DNA samples were included for the Mfrn tagSNP analyses, of 
which 896 were UK/Irish and 915 were of South Asian descent. The samples were collected 
from women while they were attending 18-week antenatal scans at Northwick Park Hospital 
(Northwest London Hospitals) between 1997 and 1999 for genetic analysis. Data from all 
the women recruits was maintained to ascertain details about family origin along with 
different family diseases including asthma, stroke and heart diseases. Information such as 
birth weight, sex and gestational age of the child was also taken during the sample collection. 
DNA samples of both Asian and Caucasian samples were used to find if any correlation 
exists between birth weight, levels of haemoglobin and Mfrn tagSNPs. Since no data for the 
blood serum ferritin or transferrin (percentage saturation and total iron binding concentration 
or TIBC) was available for the cohort used in Mfrn atgSNP analysis, Hb levels were used as 
a proxy for body iron levels. To carry out the correlation analysis, both the population data 
and the samples were kindly provided by Dr. Una Fairbrother. 
2.01.001 Mfrn tagSNP selection 
Considering the significance of Mfrn in haem biosynthesis and as an essential iron importer 
for the synthesis of mitochondrial haem and iron-sulfur clusters, this study chose tagSNPs 
in Mfrn using Haploview (Barrett et al., 2005) between the regions 23437 and 23490 on 
chromosome 8 to find any correlation between levels of haemoglobin, birth weight and Mfrn 
tagSNPs in Asian and Caucasian DNA samples. From the 74 SNPs that were found, the 
settings on Haploview were changed so that the Hardy-Weinberg equilibirum (HWE) cut off 
was p<0.05, minimum genotyping (genotype success rate) was 80% and minor allele 
frequency (MAF) was also 0.05 (5%), cutting the number of SNPs from 74 to 68. The Tagger 
application in Haploview was then run from SNPs 4 to 74, and identified 24 SNPs capturing 
65 of the 74. Two synonymous SNPs were added that did not appear in Haploview but may 
be of interest (rs34146184 and rs34968988) in the context of genotyping and testing the 
SNPs for correlation study. Considering the significant role of hepcidin in iron metabolism, 
region 40466 - 40469 on chromosome 19 was also analysed for potential tagSNPs in 
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Haploview. Haploview returned a list of 6 SNPs which were tagged to 3. Only rs10421768 
was considered as it captured the SNPs that appear in the 5'UTR region. 
 
Figure 22: Haplotype block of Mfrn tagSNPs. Haploview 4.2 (Barrett et al., 2005) output 
for Mfrn tagSNPs in the region of 23437 to 23490 on chromosome 8 showing haplotype 
blocks. 
2.01.002 Primer design for Mfrn tagSNP genotyping 
MassARRAY software was used to design the primers for the SNPs, to accommodate the 
maximum number of reactions in one assay without any interference of the primer products 
or a reduction in performance in any of the SNPs when the Matrix-Assisted Laser 
Desorption/Ionisation Time-Of-Flight (MALDI-TOF) was carried out. The Ensembl database 
was used to obtain the 5ˈ and 3ˈ end sequences surrounding each SNP for uploading into 
the MassARRAY software. The SNP information along with the flanking 5ˈ and 3ˈ sequences 
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was copied and pasted. SNP itself was put in a square bracket with a forward slash 
separating the two alleles. Three sets of primers were designed for the multiplex PCR 
amplification with a third primer (extension primer) for the iPLEX extension reaction.  The 
forward and reverse primers were ordered at 25 nmoles and the extension primers at 200 
nmoles respectively. The extension primer anneals adjacent to the SNP, which is then 
extended by a single terminal base. The resulting product varies in mass depending on the 
base added and is easily differentiated using MALDI-TOF mass spectrometry. Maximum 
multiplex level was set to forty. SNP capture details were set to an amplicon length ranging 
between 80bp – 160bp, with the optimum being 100bp. To ensure, that the MS multiplexing 
remains the same, the extended primer was set so that the length of the extended primer 
was between 15bp and 30 bp. The lower and the upper limit mass of the extension primer 
was set between 4500Da and 8500Da respectively. The minimum distance between the two 
MassEXTEND primers was adjusted to ten and the minimum distance between the expected 
mass peak of the two assay analytes was kept at fifty. Once the settings were saved, the 
final results were displayed indicating how many assays the SNPs can be incorporated into, 
the full report, which was saved as an excel file. The saved file included the information 
regarding the assay and the primers.  
2.01.003 Initial PCR reaction 
The primers were made up to a final concentration of 100pmoles/µl and the extension 
primers were made up to a final concentration of 500pmoles/ µl using deionised water. 2 µl 
aliquots of the South Asian DNA samples were added into each well of a 384-well plate, with 
water placed randomly as a blank.  The PCR mix was made for a total of 500 reactions to 
provide sufficient quantities for all the wells of a 384-well plate. Final concentration of 25mM 
MgCl2, 25mM dNTP, 500nM primer mix and 5 Units/µl of Hot Start Taq were mixed in the 
final PCR reaction. 3 µl of the PCR mix was added to the wells containing 2 µl of DNA. PCR 
was carried out on a Peltier thermal cycler. 
After the completion of the PCR, the obtained product was treated with shrimp alkaline 
phosphatase (SAP), to clean up the PCR product and also to degrade any remaining primers 
to prevent any non-specific carry over into the subsequent reactions. SAP was deactivated 
at 80°C. Once the initial PCR and clean-up step was finished, the Sequenom iPLEX 
extension reaction was carried out. The resulting mixture of products was run on the 
Sequenom MassARRAY system.  
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2.01.004 Single base extension reaction 
The volume of the extension primer is directly proportional to the mass of the primer. A 
primer with a high mass was added at a higher concentration and a primer with a lower mass 
at a lower concentration, as the higher mass primers were hard to ionise compared with the 
lower mass primers.  The concentration of the extension primer was determined using the 
regression method as recommended by Sequenom. The single base extension reaction was 
carried out in a thermal cycler. 
2.01.005 MALDI-TOF Mass Spectrometry 
Products obtained after the Sequenom single base extention reaction were treated with an 
anion exchange resin to remove adduct-forming ions, which can hamper the efficiency of 
the MALDI-TOF mass spectrum. A MassExtend clean resin treated 384-well plate is left to 
air dry for thirty minutes after which the adhesive film was removed. 16 µl of dH2O was 
added into each well.  Adhesive lids were placed on the plate and the plate was constantly 
rotated for ten minutes which resulted in the resin being suspended within the solution. 15-
25nl of the extended primer products were robotically (MassARRAY NanoDispenser) 
dispensed onto the SecrtroCHIP array which contained matrix spots (3-hydroxylpicolinic 
acid) in a 384-well format. Calibrant, which contains three standard oligonucleotides of know 
mass 5100, 8500 and 10,000 mass units, was also spotted and used as a standard.  
Gentyping was carried out in Imperial College, UK. The design (other than choosing the 
candidate gene, Mfrn) involving selection of the Mfrn tagSNPs, primers, extension primers 
and the experimental procedure was carried out by Dr.Laura Towns. Once the genotyping 
data was given, I carried out the statistical analysis was carried out using SPSS (v.20) 
software. 
2.02 Cell culture 
Human carcinoma cells MCF7, chronic myelogenous leukemic cells K562 and placental 
choriocarcinoma BeWo cells provided by Health Protection Agency (HPA) were selected 
based on the expression data of IRPs and Heph as provided by the protein atlas database 
(Uhlen et al., 2005). MCF7 and K562 cells were cultured using RPMI1640 growth media. 
BeWo cells are cultured using Ham’s F12 growth media. Complete media was prepared by 
adding 2mM of glutamine and 10% fetal bovine serum (FBS). Culture flasks were sub-
cultured at 70-80% confluency for BeWo cells. Adherent cells, MCF7 and BeWo, were 
harvested using trypsin (Sigma, UK). Cell numbers and viability were determined using a 
haemocytometer and trypan blue staining, respectively. Aseptic conditions were maintained 
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throughout the culturing to avoid any contamination. Owing to the relatively easy handling 
of K562 cells, high levels of expression of both IRPs and Heph, erythroid K562 cells 
represent a functionally different type of cells and also there are not many studies in the 
literature concerning the effect of iron availability on the expression of IRPs and Heph; K562 
cells were selected to carry out gene expression, gene synthesis and protein protein 
interaction analysis of IRPs and Heph. 
2.03 RNA extraction from K562 cells 
Total RNA was extracted from K562 cells using the protocol provided by the E.Z.N.A total 
RNA kit I (Omega Biotek, VWR International Ltd, UK) for further analysis. 1 x 107 cells were 
lysed using the TRK lysis buffer. Lysate was added to the HiBind RNA mini columns to bind 
the RNA. Columns were washed three times using RNA wash buffer I and II provided in the 
kit. RNA was eluted using diethylpyrocarbonate (DEPC) water, so as to inactivate any 
remainings of ribonuclease (RNase) enzymes which when present degrade RNA. 
2.04 Amplification of cDNA (complementary DNA) using RNA extracted 
from K562 cells by Reverse Transcription 
During Reverse transcription, a single stranded DNA was synthesised from RNA using 
Promega’s IMProm-II reverse transcription system. OligodT (0.5µg/reaction) and RNA 
(1µg/reaction) extracted from the K562 cells were used initially to denature the 
oligonucleotides. 
2.04.001 RT reaction mix 
The final reaction mix contained 1x IMProm-II reaction buffer, 2.0-4.0mM MgCl2, 0.5mM 
each dNTP and 1µl of Reverse Transcriptase enzyme in a 20 µl final volume. 
2.04.002 cDNA primers 
Primers were designed using IBA-tagnology’s (IBA, Germany) Primer D’Signer software. All 
primers were 3’ phosphorothioate (PTO)-protected oligonucleotides which are protected 
against the exonuclease activity of proof-reading polymerases. The gene of interest (GOI) 
was extended by PCR with combinatorial sites and the StarCombinase recognition sites, 
introduced by the primers which are important for the oriented insertion of the PCR fragment 
into the entry vector during the molecular cloning. Table below shows the list of primers that 
were designed to synthesise Heph, Hephl1, IRP1 and IRP2 cDNA. 
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Gene Primer 
name 
Sequence 5'  to 3' Scale 
 Length 
Expected 
cDNA 
fragment 
Heph HuHp-F agc ggc tct tca atg gag tca 
ggc cac ctc ctc 
40 
nmol 
33 3.5kb 
 HuHp-R agc ggc tct tct ccc ctg ttt 
gaa aga cag aag ctt g 
40 
nmol 
37  
IRP1 IRP1-F agc ggc tct tca atg agc aac 
cca ttc gca cac c 
40 
nmol 
34 2.6kb 
 IRP-1R agc ggc tct tct ccc ctt ggc 
cat ctt gcg gat c 
40 
nmol 
34  
IRP2 IRP2-F agc ggc tct tca atg gac gcc 
cca aaa gca gga t 
40 
nmol 
34 2.9kb 
 IRP2-R agc ggc tct tct ccc tga gaa 
ttt tcg tgc cac aaa g 
40 
nmol 
37  
Table 01: PCR primers for Heph, IRP1 and IRP2. Above table shows the Heph and IRPs 
primers used to synthesise the respective cDNA along with the expected PCR product size. 
2.05 Polymerase Chain Reaction (PCR) 
cDNA fragments are synthesised using the RT product by the polymerase chain reaction 
(PCR). PCR was performed with the final concentrations of the following reagents in a 25 µl 
reaction mixture containing 10 pmol of each sequence-specific primer, 5 units (U) of Phusion 
taq polymerase, 2-4 mM MgCl2, 10x NH4 reaction buffer (160mM [NH4]2SO4, 670mM Tris-
HCl pH 8.8), and 200 µM dNTPs 
PCR reaction set up involved an initial denaturation step of 30 seconds at 98 °C, followed 
by 35 cycles of denaturation step for 30 seconds at 98 °C, an annealing step for 30 seconds 
at variable temperatures, followed by an extension step for another 2.30mins-3.30mins 
(1min/kb amplicon size) at 72 °C and finally the reaction was concluded with an extension 
of five minutes at 72 °C. To rule out DNA contamination a water blank was included in every 
experiment as a negative control. 
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2.06 Agarose gel electrophoresis 
Depending on the size of the PCR product, DNA samples were resolved on 0.7 – 3 % 1xTBE 
agarose gels with addition of ethidium bromide. 
2.07 Low melting gel electrophoresis 
Since PCR resulted in non-specific amplicons in addition to the bands of the right size, 0.7% 
low melting gel was prepared using 1xTAE buffer to extract the respective band of Heph 
(3.5kb), IRP1 (2.6kb) and IRP2 (2.9kb) PCR product. Gel was placed on the UV illuminator 
to cut the precise band using a scalpel washed with ethanol to eliminate any contamination. 
The respective fragment was gel extracted using QIAquick gel extraction kit as per the 
provider’s protocol.  
2.08 RNA and DNA quantification 
The quality of RNA extracted from the K562 cells and gel-extracted cDNA fragments was 
carried out by measuring the absorbance values at 260 nm and 280 nm using a NanoDrop 
DNA Spectrophotometer (Thermo Scientific, UK). Only samples with 260/280 values ranging 
from 1.8 – 2.0 were used. 
2.09 Real-Time quantitative Polymerase Chain Reaction (qRT-PCR) 
cDNA prepared from the K562 cells was used to analyse the differential expression of Heph, 
IRP1, IRP2 and Mfrn in K562 cells with and without 100 µM FAC. Beta actin (β-actin) was 
used as a normalizing or a house-keeping gene. The TaqMan gene expression assays and 
the master mix were used to carry out the reaction set up. qRT-PCR analyses were carried 
out in triplicates in 96-well opaque plates (Bio-Rad, UK). A DNA Opticon Monitor Engine II 
(MJ Research) was used to carry out the quantitative real time PCR. Thermal cycling 
conditions of 95°C for 10 mins, 95°C for 15 sec and 60°C for 1 min for 40 cycles was used 
to run the samples. qRT-PCR reactions were carried out in a 20 µl volume containing 10 µl 
of master mix, 1 µl of TaqMan gene expression assays with integrated TaqMan probes and 
25-100 ng of cDNA diluted in 9 µl of DEPC water. 
2.09.001 qPCR Data analysis 
Calculation of relative gene expression was carried out by normalizing the target gene data 
to a housekeeping gene (beta actin). The advantage of using a housekeeping gene (such 
as GAPDH, β-actin, etc.) in normalizing the data is that this method overcomes the need for 
accurate quantification and loading of the starting material. The drawback of using relative 
gene quantification normalized to housekeeping gene is that this method requires that the 
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known reference gene (β-actin) has a constant expression in both treated and un-treated 
samples under study. Once the C(T) values [C(T) value or the threshold cycle value is the 
cycle number at which the fluorescence generated during the real time PCR when the 
fluorescence signal crosses the fluorescence threshold] are obtained, different methods like 
Livak method (Livak and Schmittgen, 2001), ΔC(T) method using a reference gene 
(Schmittgen and Livak, 2008) or Pfaffl method (Pfaffl, 2001) can be used to determine the 
expression level of the target gene in the treated sample relative to the un-treated sample. 
Each sample reaction was run in triplicate and expression was quantified as the C(T) of GOI 
minus the C(T) of the β-actin gene [ΔC(T)]. The relative gene expression of the target and 
housekeeping gene in both treated cells to control samples was calculated with the 2-ΔΔC(T) 
method [delta delta C(T)] (Livak and Schmittgen, 2001). The real time PCR statistical 
analysis was performed using the student t-test for two group comparisons on ΔC(T) 
numbers. 
2.1 Molecular Cloning of Heph, IRP1 & IRP2 
 
Step 1: Donor Vector generation 
 
2.1.01 Workflow of Donor Vector Generation 
In the first step, during the cDNA synthesis by Reverse Transcription PCR (RT-PCR), the 
gene of interest (GOI) was extended at both the 5’ and 3’ ends with the combinatorial and 
StarCombinase sites included in the primers. The gel-extracted PCR fragment of GOI was 
then inserted into an Entry Vector by a one-tube reaction. 
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Figure 23: Workflow for donor vector generation. Insertion of GOI into the Entry Vector 
to create the Donor Vector, Figure taken from IBA, manual PR26-0022 version. 
The StarCombinase recognises the recombination sites and simultaneously cleaves and 
ligates the DNA. This helps the PCR product and the Entry Vector to be recombined at the 
combinatorial sites (red and light orange regions in figure 27) leading to the Donor Vector 
generation and loosing the StarCombinase1 recognition areas (dark orange) which results 
in unidirectional recombination reaction. 
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Figure 24: Donor vector generation and StarCombinase Recognition site. Donor Vector 
generation with GOI using StarCombinase Recognition sites. Figure taken from IBA, 
manual PR26-0022 version. 
2.1.01.001 Donor Vector with GOI 
The PCR product of GOI was inserted into the Entry Vector pENTRY-IBA51 to generate the 
Donor vectors of interest, which in this study are Heph, IRP1 & IRP2. Reaction for Donor 
vector generation was explained as follows: 2nM of the gel extracted PCR product was 
added to the 10µl of the entry vector along with the StarSolutions provided by IBA as 
suggested in the manual version PR26-0022.  The reaction tube was mixed gently and 
incubated for 1hr at 30°C.  A vial of competent E.coli cells was thawed on ice.  After 1hr 
incubation 10 µl of the reaction mixture was added to the thawed competent E.coli cells. 
Cells were then incubated on ice for 30mins, followed by incubations at 37°C for 5mins and 
again on ice for 5mins. 900µl of LB medium was added to the cell mixture and the vial was 
incubated at 37°C for 45mins in a shaking incubator. 100µl of the cell mixture was plated on 
to LB agar containing 50 mg/L Kanamycin and 50mg/L X-gal. The remaining cell mixture 
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(900µl) was centrifuged for 30 seconds in a microfuge at 10,000 RPM. The pellet was 
resuspended in 100µl LB medium and the whole amount was plated. Plates were incubated 
overnight at 37°C for colony growth. The Entry Vector carried the LacZα gene and therefore 
produces blue colonies on X-gal containing plates while LacZα was replaced with GOI in the 
Donor Vector and hence will generate white colonies. 
2.1.01.002 Donor Vector Plasmid DNA extraction 
Three white colonies were cultivated in 5ml LB medium containing 50µg/L kanamycin and 
plasmid DNA extraction was carried out. The Donor Vector’s plasmid DNA was extracted 
using QIAprep® Spin Miniprep kit (Qiagen, UK) using the following protocol: an overnight 
bacterial culture of 3ml was centrifuged at 10,000 RPM for 3mins in a table top micro 
centrifuge. The pellet was resuspended thoroughly in 250µl of Buffer P1. To it 250µl of Buffer 
P2 was added and mixed thoroughly by inverting the tube 6-7times. 350µl of Buffer N3 was 
added to the above centrifuge tube and mixed immediately and thoroughly by inverting the 
tube again for 6-7times. Then the tube was centrifuged for 10mins at 10,000 RPM in a table 
top micro-centrifuge. Supernatant was collected into a QIAprep spin column and was 
centrifuged for 1min at 10,000 RPM. The column was then washed with 500µl of Buffer PB 
and was centrifuged for 1min at 10,000 RPM. Again the column was washed with 750µl of 
Buffer PE. Additional centrifugation for 1min at 13,000 RPM was carried out to remove any 
residual wash buffer. 50µl of elution buffer, Buffer EB (10mM Tris·Cl, pH 8.5) was added to 
the centre of the column and the column was left on the table for 2mins. To elute the pDNA 
the column was placed in a micro-centrifuge tube and was centrifuged at 13,000RPM for 
1min. 
2.1.01.003 Donor Vector identification 
XbaI/HindIII restriction enzymes were used to identify the clone with the GOI. A fragment 
having the length of the GOI and another fragment with 40bases long is expected as long 
as no XbaI/HindIII restriction sites are present internally in GOI. The putative clone with GOI 
was then selected and the sequence was confirmed via Donor Vector forward and reverse 
sequencing primers provided by IBA. The regions flanking the GOI should have the 
sequences TCTAGA (XbaI restriction enzyme sequence) and AAGCTT (HindIII restriction 
enzyme sequence).  
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Step 2: Destination Vector generation 
 
2.2 Destination Vector generation 
The resulting Donor Vector after restriction enzyme and sequence confirmation was used 
as the basis or template for the sub-cloning of the GOI into an Acceptor Vector which has 
the tag, the One Strep tag in this study. The resulting Destination Vectors with the GOI are 
then transformed into the respective host cell such as K562 (Human Caucasian chronic 
myelogenous leukaemia) cells for systematic expression and purification screening. 
2.2.01 Destination Vector Generation work flow 
 
 
Figure 25: Work flow of Destination vector generation. Insertion of Donor Vector into the 
Acceptor Vector to create the Destination Vector. Figure taken from IBA’s manual PR26-
0022 version. 
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Acceptor Vectors provide the necessary genetic make up such as tag, promoter and signal 
sequence for the correct orientation of the GOI during the cloning process. The pESG-IBA 
acceptor vector was mixed with the respective Donor Vector with the GOI Heph, IPR1 and 
IRP2 and with StarSolutions A1-A3 to generate the desired Destination Vector after a short 
incubation. 
The reaction mixture was then used to transform the E.coli. The E.coli transformation mix is 
then plated onto the LB agar plates containing ampicillin and X-gal. Desired Destination 
Vectors with GOI (Heph, IRP1 and IRP2) will generate white colonies while non-desired 
Acceptor Vectors will generate blue colonies. 
 
 
 
Figure 26: LB agar plates with X-gal and ampicillin. Selection on the LB-agar plates with 
X-gal and ampicillin. Due to the selection on the ampicillin plates, Donor Vector and the by-
product – which provide a kanamycin resistance gene only will not be enable the E.coli 
growth. However, Acceptor Vector and Destination Vector’s with the GOI growth is enabled 
due to the ampicillin resistance gene. The Acceptor Vector carries the LacZα gene and 
therefore produces blue colonies on X-gal-containing plates. The LacZα gene will be 
replaced by the GOI in the Destination Vector which therefore generates white colonies. 
Figure taken from IBA’s manual PR26-0022 version. 
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2.3 GOI transfer reaction into destination vector 
Respective Donor Vector pDNA (Heph, IRP1 and IRP2) is used as a template while 
generating the Destination Vector during the Destination Vector generation. StarSolutions 
A1, A2, A3 and 2ng/µl Donor Vector were added to the Acceptor Vector. After mixing gently 
the tube was incubated at 30°C for 1hr. During the final minutes of the above incubation, 
competent E.coli cells were thawed on ice. After 1hr incubation of the Acceptor Vector along 
with the above mix, 10µl of the reaction mixture was added to the thawed competent E.coli 
cells. Then mixed gently (by pipetting) and incubated the E.coli cells for 30mins on ice. After 
30mins of incubation the tube was mixed gently again by pipetting and was incubated on 
the hot plate at 37°C for subsequent 5mins. Once the incubation was finished the tube was 
then replaced in the ice box for 2-5mins. Then the reaction mix of 10µl was plated (mixed 
with 90µl LB medium) and 100µl on LB agar plates containing 100mg/L ampicillin and 
50mg/L X-gal. 
2.3.01 Destination Vector Plasmid DNA extraction 
Destination Vector plasmid DNA was extracted by following the similar method used to 
carry out donor vector extraction. 
2.3.02 Destination Vector Identification 
pESGIBA an Acceptor Vector has both XbaI and HindIII restriction sites flanking the 
expression cassette and therefore either enzyme can be used to analyse the Destination 
Vector pDNA that has been extracted. Webcutter 2.0 (Maxwell, 1997) tool was used to carry 
out an exact calculation of the expected fragment lengths after an overnight restriction 
enzyme digestion of the destination vector pDNA. 
2.4 GOI transfection and expression 
The Destination Vector pDNA with the GOI (Heph, IRP1 and IRP2) as confirmed by 
sequencing, was used to transfect the K562 cells. Transfection is a process in which the 
GOI (nucleic acids) is forcibly introduced into the expression system, in this case the 
eukaryotic expression system using K562 cells. The GOI cloned with One-Strep tag is 
introduced into the K562 cells to examine the protein expression and localisation in the cells. 
There are different methods of transfection and part of this study examines the chemical 
based (using Lipofectamine-LTX) and particle based (Magnet assisted) to establish the 
correct, efficient method for Iron metabolic genes (Heph, IRP1 and IRP2). 
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2.4.01 Chemical based Transfection 
Chemical based transfection involves addition of the DNA to Lipofectamine LTX-Plus 
reagent (Invitrogen, UK) and subsequent release of the DNA into the cell. For eukaryotic 
cells, transfection efficiency is better achieved using cationic liposomes (or mixtures), 
because the cells are more sensitive. The Lipofectamine reagent contains the lipid subunit 
which forms liposomes in an aqueous environment, which then envelope the transfection 
material, i.e. plasmid DNA. The DNA-containing liposomes then fuse with the plasma 
membrane of eukaryotic cells and enter the cells, allowing nucleic acids to cross into the 
cytoplasm and organelle to be available to the cell for replication and expression. The 
process of using liposomes during transfection (i.e., Lipofection) generally uses a positively 
charged (cationic) lipid to form an aggregate with the negatively charged (anionic) genetic 
material (Felgner et al., 1987).  A net positive charge has been assumed to increase the 
effectiveness of transfection through the negatively charged phospholipid bilayer (Felgner 
et al., 1987). Lipofectamine LTX-Plus reagent transfection technology performs the same 
tasks as other biochemical procedures utilizing polymers, DEAE dextran, calcium phosphate, 
and electroporation. The advantages of Lipofectamine LTX-Plus reagent are its high 
efficiency, its ability to transfect all types of nucleic acids in a wide range of cell types, its 
ease of use, reproducibility, and low toxicity. 
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Figure 27: Transfection process involving Lipofectamine-LTX plus reagent. 
Transfection flow chart showing different steps involved in the process of transfection using 
Lipofectamine LTX-Plus reagent and pDNA. Figure taken from Life technologies website. 
2.4.01.001 Transfection of K562 cells using Heph, IRP1 and IRP2 by Lipofectamine 
LTX-Plus reagent 
On the day of transfection, K562 cell culture were counted to determine the culture density. 
3 x 105 cells per well were plated in 0.5ml of RPMI-complete growth medium. For each well 
of cells to be transfected, 2.0μg of DNA was diluted in 100μl of Opti-MEM® I Reduced Serum 
Medium (Invitrogen, UK) without serum. PLUS™ Reagent (Invitrogen, UK) was mixed gently 
before use and then the PLUS™ Reagent was added in a 1:1 ratio to the diluted DNA. The 
mix was then incubated for 5-15 minutes at room temperature. For each well of cells, 5μl of 
Lipofectamine™ LTX was diluted into the above diluted DNA solution, mixed gently and the 
mix was incubated for 25 minutes at room temperature to form DNA-Lipofectamine™ LTX 
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complexes. 100μl of the DNA-Lipofectamine™ LTX complexes was added directly to each 
well containing cells and mixed gently by rocking the plate back and forth. 1ml of RPMI-
complete growth medium was added after 24hr incubation. Following the transfection, 
transfection complexes were not removed. Before assaying for transgene expression by 
Flow Cytometry and Western blotting, cells were incubated at 37°C in a CO2 incubator for 
24-48 hours post-transfection. 
2.4.02 Particle based transfection 
Magnet-assisted transfection (MATra) is a transfection method, which uses a magnetic force 
to deliver DNA into the target cells. In this process nucleic acids are first associated with 
magnetic particles. Then, application of magnetic force drives the nucleic acid particle 
complexes towards and into the target cells (Bertram, 2006) leading to efficient transfection. 
To carry out the MATra approach cells must be adherent to the cell culture vessels. 
Therefore the suspended cells like K562 need pre-treatment first by incubating the cells with 
the magnetic reagent MATra-S Immobilizer or by using polylysine plates. 
 
Figure 28: MATra principle. Flow chart showing different steps involved in carrying out 
magnetic-assisted transfection. Figure taken from IBA’s manual version PR09-0015. 
2.4.02.001 Transfection of K562 cells using Heph, IRP1 and IRP2 by MATra 
85 
 
3 x 105 cells were diluted in 1ml of RPMI complete growth medium in the cell culture plate. 
30ul of MATra-S Immobilizer was added to the above cell suspension and was incubated 
for 10mins at room temperature in the culture hood. The plate was then incubated on a 
magnetic plate for 15mins at 37°C. 2µg of pDNA was diluted in 50µl of serum-free RPMI cell 
culture medium. 2µl of MATra-A reagent was added to the above diluted pDNA mix and was 
mixed thoroughly. The mixture was incubated at room temperature for 20mins. After the 
incubation the DNA:bead mixture was added to the cells and was mixed by pipetting 
immediately. After mixing, the plate was placed immediately on the magnatic plate and the 
plate was incubated for 15mins at 37°C. Transfected cells were left in the incubator at 37°C 
for 48hrs prior to carrying out protein expression analysis by flow cytometry, and western 
blotting. 
2.5 Protein expression analyses by Western Blotting 
 
2.5.001 Western blotting solutions and buffers 
 
Lysis buffer- pH 7.4 
100 mM - HEPES-KOH 
2 mM     - CaCl2 
0.2%      - Triton X-100 (v/v) 
10 mM   - Protease inhibitor (AEBSF) 
                Millipore water 
Made up to 50 ml and stored as 1 ml aliquots at -20°C. pH was adjusted with 4 M HCl. 
SDS Sample buffer- pH 6.8 (4X) 
200 mM - Tris-HCl 
40%      - Glycerol 
2%        - SDS (w/v) 
0.2%     - Bromophenol blue (w/v) 
20 mM  - DTT (added fresh on the day) 
               Millipore water 
pH was adjusted using 4 M HCl solution 
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Resolving buffer- pH 8.8 (1.5 M) 
18.17 g - Tris base 
Dissolved in 100 ml deionised water and pH adjusted to 8.8 
Stacking buffer- pH 6.8 (0.5 M) 
6.06 g - Tris base 
Dissolved in 100 ml deionised water and pH adjusted to 6.8 
Resolving gel solution (12%) 
2 ml         - double distilled H2O 
1.25 ml    - 1.5 M Tris-HCl, pH 8.8 
0.050 ml  - 10% SDS (w/v) 
1.66 ml    - Acrylamide/Bis 30% (w/v) 
0.025 ml  - 10% APS (w/v) 
0.0025 ml- TEMED 
Stacking gel solution 
1.53 ml     - double distilled H2O 
0.625 ml   - 0.5 M Tris-HCl, pH 6.8 
0.025 ml   - 10% SDS (w/v) 
0.335 ml   - Acrylamide/Bis 30% (w/v) 
0.0125 ml - 10 % APS (w/v) 
0.0025 ml - TEMED 
10X Electrophoresis running buffer (1L) 
250 mM   - Tris-HCl, pH 8.3 
1925 mM - Glycine 
50 ml       - 20% SDS (w/v) 
950 ml     - double distilled H2O 
 
Coomassie Brilliant Blue G-250 
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0.025% - Coomassie blue (w/v) 
10%      - Acetic acid (v/v) 
90%      - double distilled H2O (v/v) 
Destain solution (500 ml) 
35 ml   - Acetic acid 
25 ml   - Methanol 
440 ml – double distilled H2O 
Transfer buffer (10X) 
250 mM   - Tris base 
1925 mM - Glycine 
500 ml     - double distilled H2O 
Sartoblot buffer (500 ml) 
40 ml   - Transfer buffer (1X) 
100 ml - Methanol 
360 ml – double distilled H2O 
Phosphate Buffered Saline (PBS) solution - 1L 
140 mM - NaCl 
2.7 mM  - KCl 
10 mM   - Na2HPO4 
1.8 mM  - KH2PO4 
                Double distilled H2O 
Phosphate Buffered Saline – Tween 20 (PBS-T) 
1 L   - PBS 
1 ml - Tween 20 
 
 
Blocking buffer 
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6%       - Milk powder (w/v) 
100 ml - PBS-T 
Antibody dilution buffer (WB) 
3%       - Milk powder (w/v) 
100 ml - PBS-T 
2.5.001 Sample preparation for SDS-Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
Transfected and untransfected samples were aliquoted into the 1.5ml eppendorf tubes and 
were washed with ice-cold PBS. PBS was replaced with cell lysis buffer and the samples 
were spun at 16,000g for 20mins at 4°C. Supernatant was removed and was followed by 
incubation at 95°C for 5 min. Before loading the samples onto the gel, a centrifugation step 
was performed (2,000 g, 2 min) to collect all the sample to the bottom of the reaction tube 
and loaded into the gel wells. 
2.5.002 SDS-Polyacrylamide Gel Electrophoresis 
To separate proteins according to molecular mass, the cell lysate was denatured by sodium 
dodecyl sulphate (SDS). SDS polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed as described (Laemmli, 1970) using the Mini PROTEAN III Electrophoresis Unit 
(Bio-Rad). Gels were cast between two glass plates by pouring freshly prepared 8% 
resolving gel solution containing acrylamide/bisacrylamide into the gel cassette fixed in a 
casting frame. Unpolymerized separating gel solution was overlaid with H2O-saturated 
butanol to achieve an even surface. After polymerization, H2O-saturated butanol was poured 
off, the gel washed twice with deionised water, and the excess water was blotted using a 
filter paper (Whatman 3 MM, Whatman AG). Then unpolymerized stacking gel was poured 
into the gel cassette and a plastic comb was inserted from the top, to form the loading wells 
in the stacking gel. 
Gels were used immediately after polymerization. Gel electrophoresis was performed by 
placing the gel into the electrode assembly device inside a clamping frame in the tank of the 
Mini PROTEAN III system. Electrophoresis running buffer was added to the inner and outer 
chambers of the tank and the plastic comb was carefully removed. Wells were washed with 
the running buffer to remove any free unpolymerized acrylamide/bisacrylamide/air bubbles 
so as to allow the to run sample freely. Samples were loaded into the wells of the stacking 
gel. Electrophoretic separation was performed at 150 V (constant voltage) until the 
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bromophenol blue front of the SDS sample buffer reached the end of the resolving gel. Gels 
were either stained with Coomassie Brilliant Blue or transferred onto nitrocellulose 
membrane for Western blotting analysis. 
2.5.003 Analysis of SDS-PAGE 
Proteins separated by SDS-PAGE were transferred onto a Hybond C nitrocellulose 
membrane for further analysis using a semidry transfer device (Bio-Rad Sartoblot system). 
A Hybond C nitrocellulose membrane and two pieces of blotting paper (Whatman 3 MM, 
BioRad) were cut to the size of the gel. Blotting paper, nitrocellulose membrane and the 
sandwich-blotting cassette were equilibrated by soaking in sartoblot buffer. One piece of 
blotting paper was placed on the cathode plate, and the nitrocellulose membrane was placed 
on top of the blotting paper. The gel was removed from between the sandwich-blotting 
cassette which was placed in the sortoblot buffer immediately after taking out from the gel 
tank and placed on top of the membrane. A second blotting paper was also placed on top 
of the gel. Having removed air bubbles by rolling a test tube on the top blotting paper, 
towards the anode plate, also dampened with the sartoblot buffer was used to complete the 
sandwich. Electroblotting was carried at 35V (constant voltage) for 1hr. 
2.5.004 Immunochemical protein detection using the ECL System 
The blotted membrane was incubated in blocking buffer at 4°C, overnight, in the fridge. 
Following blocking, the membrane was rinsed with PBS-T and incubated with the primary 
antibody in the desired dilution for 2 hrs at room temperature on a shaker. Three 10 min 
washing steps with PBS-T were performed and the membrane was incubated with goat-anti-
mouse-IgG antibodies coupled to HRP in a 1:5000 dilution. After six 10 min washes with 
PBS-T on a shaker, protein band detection was performed using the enhanced 
chemiluminescence reagent system (ECL, Amersham Pharmacia). The ECL solutions 
(reagent A and B) were mixed at equal volumes and the membrane was incubated with the 
mixture for 2 mins at room temperature in the dark. Chemiluminescence was detected using 
a UVP ChemiDoc-It system (UVP systems, UK). 
2.6 Protein expression analyses by Flow Cytometry 
K562 cells transfected with Heph, IRP1 and IRP2 tagged with One-Strep tag were used to 
carry out the protein expression analyses by flow cytometry. The Guava flow cytometer can 
be used to analyse various assays, however in the current study only the Guava 
ExpressPlus assay has been used to measure protein expression levels in transfected and 
untransfected samples. 
90 
 
2.6.001 Sample preparation for Flow Cytometry analyses 
Transfected samples along with Untransfected samples (controls) were washed with ice- 
cold PBS in a 1.5ml eppendorf tube. Cells were then centrifuged at 400g for 5 mins and the 
washing was carried out three times. 
2.6.002 Intracellular Antigen Staining for Flow Cytrometry 
To eliminate any potential artifacts due to dead cell contamination, fixable viability dye was 
performed to allow exclusion of dead cells from the analysis. After performing the fixable 
viability dye incubation, cells were fixed by adding 100µl of IC fixation buffer (eBioscience, 
UK) and mixed by vortexing. The tube was incubated for 20mins at room temperature under 
the cell culture hood in the dark. Without washing 1mL of 1x permeabilization buffer 
(eBioscience, UK) was added to each tube and was centrifuged at 400g for 5mins at room 
temperature. The cell pellet was resuspended in 1mL of 1x permeabilization buffer and 
mixed again by pipetting. The tubes were again centrifuged at 400g for 5mins at room 
temperature. After decanting the supernatant, the cell pellet was resuspended in 10µl of 1x 
permeabilization buffer and one in 500 concentration of fluorochrome-labeled antibody was 
added for detection of intracellular antigen and was incubated in the dark at room 
temperature for 20mins. Cells were then resuspended in 1mL of 1x permeabilization buffer 
and were centrifuged at 400g for 5mins at room temperature. Then the cells were washed 
with ice-cold PBS thrice and after the final wash the cells were then resuspended in 200µl 
of 3%PBS-BSA to carry out flow cytometry analyses. 
2.7 Protein-protein interactions 
Protein-protein interactions (PPIs) govern almost all the important cellular processes in living 
organisms. Thus carrying out PPI studies and analyses only helps to establish a rapid and 
accurate function of the protein in question. Figure 32 shows the different steps involved in 
PPI studies. 
2.7.001 One-STrEP tag background 
One-Strep tag (Strep tag) is an eight amino acid peptide (WSHPQFEK) that specifically 
binds to streptavidin. Since Strep-tag binds reversibly, where the natural ligand D-biotin 
forms the complex, it can be applied for the efficient purification of corresponding fusion 
proteins on affinity columns with immobilized streptavidin. The Strep-tag has a neutral amino 
acid composition and hence does not hamper protein folding or secretion and so does not 
interfere with protein function. 
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2.7.002 One-STrEP tag suitability for PPI studies 
Purification of the protein complex depends on the the very low tendency of Strep-Tactin to 
bind with other proteins non-specifically, the highly specifc Strep-tag:Strep-Tactin interaction 
for adsorption and the specific elution with minute amounts of biotin or desthiobiotin in the 
same physiological buffer. Strep tags are also ideal for the isolation of functional protein 
complexes to investigate in vivo PPIs (Rigaut et al., 1993). 
 
Figure 29: Work flow in protein complex purification and analysis. Steps 1-3 in the 
above figure shows the protein complex purification and Step 4 shows protein complex 
analysis. Figure taken from IBA’s manual PR27-0001 manual. 
Figure 29 shows the affinity tag-based protein complex isolations and protein interaction 
work flow. In step 1 the tagged bait (Heph-Strep, IRP1-Strep and IRP2-Strep) was 
expressed in K562 cells. After 24-48 hr incubation cells were lysed. The lysate containing 
the bait with putatively interacting preys was subjected to tag-based chromatography to 
perform a pull down. Isolated protein complexes were then analysed using SDS-PAGE and 
coomassie blue staining and compared to mocked isolates or controls. Potential preys are 
then identified by mass spectrometry, LC-MS-MS. 
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2.7.003 Preparation of cell lysates for PPI studies 
4mL of ice-cold lysis buffer (Buffer L) was used for every 109 K562 cells transfected and 
untransfected cells. Cells were homogenised on ice by using a pestle. Resulting cell mix 
was centrifuged at 750g for 10 mins at 4°C to pellet the cellular debris. 5µl of 5x SDS-PAGE 
sample buffer was added to 20µl of supernatant and the samples were stored at -20°C prior 
to SDS-PAGE analysis. 
2.7.004 Buffers used to perform purification of protein complex 
Lysis Buffer (Buffer L):  
50 mM Tris/HCl, pH 7.4  
7.5 – 10% glycerol 
1% Triton X-100 
150 mM NaCl 
and  2 mM MgCl2 was added to Buffer L 
5x SDS-PAGE sample buffer:  
0.25 M Tris/HCl, pH 8.0,  
25% glycerol 
7.5% SDS 
0.25 mg/ml bromophenol blue 
12.5% v/v mercaptoethanol 
Protease Inhibitors (Roche), 1 mM Na3VO4, 0.5 mM DTT; all added fresh to lysis buffer. 
Buffer W (washing buffer):  
100 mM Tris/HCl 
150 mM NaCl 
1 mM EDTA 
1% Triton X-100 
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1% Glycerol 
2 mM MgCl2, pH 8 
Buffer E (desthiobiotin elution buffer):  
100 mM Tris/HCl 
150 mM NaCl 
1 mM EDTA 
2.5 mM desthiobiotin, pH 8 
Buffer BE (biotin elution buffer):  
100 mM Tris/HCl 
150 mM NaCl  
1 mM EDTA,  
2 mM biotin 
2 mM MgCl2, pH 8 
2.7.004 Purification of One-Strep-tag fusion proteins 
Before proceeding with protein complex purification, the cell extracts were subjected to 
centrifugation for 1 hr at 24,000g and 4°C to prepare the lysate (the IBA protocol suggested 
that the centrifugation is carried out at 100,000g but this was not possible owing to the 
unavailability of the centrifuge that can perform 100,000g). Storage buffer was removed from 
the Stre-Tactin column prior to equilibration with two column bed volumes of washing buffer 
(IBA, Germany). 100nmol of cell extract was added to the column. The column was washed 
5 times with one volume of column wash buffer. One volume of flow through was collected 
in a 1.5ml eppendorf tube. 20µl of sample of each subsequent fraction was analysed by 8% 
SDS-PAGE. 
2.7.005 Protein Identification on Coomassie stained gels 
SDS gels were stained with Coomassie stain to identify positive bands between transfected 
and un-transfected samples. 
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2.8 Ferroxidase assay 
2.8.001 Preparation of K562, MDA-MB-231 and PNT2-C2 cell fractions for 
Ferroxidase assay 
Cells from liquid nitrogen were cultured in RPMI 1640 full medium for 48 hrs or batches of 
cells were only used after passage three. Cells were centrifuged at 160 g, 20 °C for 5mins 
to remove dead cells from the supernatant. Then the cell pellet was washed twice in PBS 
and resuspended to 107 cells / mL in hypotonic lysis buffer (10 mM Tris, 3 mM MgCl2 pH 
7.2). Cells were incubated for 2 hrs on ice. Cell lysis was checked after 45mins and an hour 
and half by Trypan blue exclusion.  The cell lysate was then centrifuged in microfuge tubes 
at 25,000 g for 2 hours at 4 °C (to ensure pelleting of any PMVs that may be released by 
cell lysis). The supernatant was retained as cytosolic fraction. To extract the membrane 
fraction, the resulting cell pellet was washed once with hypotonic lysis buffer and spun 
25,000 g for 5 min.  The cell pellet was incubated on ice for 5mins in 150µl of 1.0% TX-100 
/ PBS. The pellet was spun at 12,000 rpm for 5 min. The supernatant was used as 
membrane extract. All fractions were stored in the freezer (-20 °C) for native gel analysis. 
2.8.002 Non-denaturing gel electrophoresis 
8% non-denaturing gel electrophoresis was carried out as described in 2.5.002, except that 
non-denaturing gels and buffers were prepared without the inclusion of SDS. 
2.8.003 Non-denaturing gel analysis 
Non-denaturing gels after electrophoresis were analysed for ferroxidase activity by 
performing ferroxidase staining. Gels removed from the electrophoresis tank were briefly 
rinsed in 0.1M acetate buffer (pH 5.8). The gel was incubated in 50ml of 5mM (0.08% w/v 
ferrous sulphate or ferrous ammonium sulphate) in 100mM sodium acetate with pH 5.8 for 
2hrs at 37°C. After 2hrs the gel was placed in 1% (w/v) potassium ferrocyanide in 0.1M HCl. 
A prussian blue band was observed and the band was stable for 24hr. To confirm the 
Prussian blue band in ferroxidase stained gel, 8% non-denaturing gel was run for coomassie 
blue staining confirmation.  
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2.8.04 SDS-PAGE electrophoresis to analyse the ferroxidase bands 
2.8.04.001Gel piece of interest excision & preparation 
The M1 band, a potential new ferroxidase from non-denaturing gel was transferred onto 8% 
SDS-PAGE by the following protocol obtained from our collaborator Dr.Rob Edwards, 
Imperial College, London. Gel band (M1) of interest was excised over an illuminated light 
box. Each gel band was placed in a labelled tube (e.g. Eppendorf microcentrifuge tube). The 
stained gel piece was destained in a solution of 0.2 M ammonium bicarbonate/50% 
acetonitrile (0.5 – 1.0 ml/tube) for 0.5 - 1 hour with shaking. The solution was discarded. In 
case of the M1 band the tube was incubated for 3 hrs at room temperature with frequent 
changes of 0.2 M ammonium bicarbonate/50% acetonitrile solution every 30mins to achieve 
complete decoloration. The destained gel piece was washed with 0.5 - 1 mL of water for 1 
min and discarded the solution. Gel piece was dehydrated using 1 ml acetonitrile for 15 
mins. After 15 mins incubation the gel pieces turned into white or dehydration step was 
carried out till the gel piece turned white. Gel piece was left to dry at room temperature. The 
preparation is now quite stable. Gel piece was rehydrated in sample treatment solution for 
SDS-PAGE and placed the gel piece on a standard SDS-PAGE gel to perform the 
electrophoresis.  
2.8.04.002 Preparation of Samples/gel piece of interest 
2.5 µl of the sample buffer, DTT (500 mM) and Iminodiacetic acid (IDA - 250 mM) was added 
to the gel piece. The gel band of interest was incubated at 94°C for 2 min.  Then the gel 
piece of interest was allowed to cool at room temperature. Then, freshly prepared IDA was 
added to a final concentration of 250mM. Before placing the sample on the 8% SDS-PAGE 
well, the eppendorf tube was incubated with the gel piece of interest at room temperature 
for 20 min in the dark. 8% SDS-PAGE electrophoresis was carried out as described in 
2.5.002 to confirm the M1 band transfer from the non-denaturing gel to the SDS gel. The 
size of M1 band was approximately established against the standard protein ladder. M1 
bands on SDS gel were confirmed by coomassie staining. 
2.8.04.003 Analysis of the M1 band by MS 
The M1 band, a potential ferroxidase that appeared on the non-denaturing gel, was 
subjected to MS-MS by Dr.Rob Edwards, Imperial College. Data obtained from the MS-MS 
was analysed and the results were given to identify the potential ferroxidase. 
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CHAPTER 3 
 
Mfrn tagSNP result and discussion 
3.01 tagSNP statistical analysis 
Research into identifying the proteins responsible for the absorption, transport, utilization, 
and storage of iron produces new insights into the pathophysiology of genetic abnormalities 
affecting iron metabolism. Understanding the effects of the underlying mutations or 
variations in a candidate gene which cause disturbances in iron metabolism that leads to 
clinical abnormalities helps establish the cause of the disorder. It is understood that if a 
variant, and hence the haplotype, is relatively common in the general population. It might be 
possible that studying tagSNPs could ascertain their role in disease predisposition. If, 
however, the disease is caused by a rare variant, the tagSNP study approach may fail to 
detect association. 18 tagSNPs (SNPs in the 5ˈUTR and Intron of Mfrn) were analysed using 
the Asian-Caucasian cohort for understanding the role of covariates like sex of the fetus, 
birth weight, haemoglobin levels, gestational age and mother’s booking weight. Table 02 
shows the number of samples analysed for each tagSNP (n), %SNP success before and 
after sorting the data and the Hardy-Weinberg Equilibrium (HWE) p value. After performing 
the initial PCR reaction, clean up and Sequenom single base extension reaction and finally 
MALDI-TOF (as in 2.01.001 – 2.01.005 sections of the thesis), data were pooled together 
and both %SNP success and HWE p value were calculated. To improve the % of SNP 
success and HWE p value data was then sorted by deleting the samples with repeated data 
and samples with no genotype data. SNPs with >80% SNP success and HWE p value 
greater than 0.05 from the below table were used to carry out ANCOVA analysis using IBM 
SPSS statistics 20. 
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Table 02: Percentage SNP success and HWE p values for tagSNP analysis. Percentage SNP success and HWE p value for the SNPs before 
and after data sorting 
SNP id n (number of 
samples 
analysed after 
data sorting)  
Before data 
sorting 
After data sorting Comments 
  % SNP 
success 
HWE p 
value 
% SNP 
success 
HWE p 
value 
 
rs721183 735 NA NA NA NA Only one genotype was read and hence any further analysis 
was carried out. Only 11 samples resulted in AA genotype 
rs10104250 751 58.72% 1E-06 54.72% 0.104 Though HWE p value is significant the % SNP success is 
too low 
rs10421768 743 81.29% 1E-06 87.75% 0.015 The difference between the observed & expected is not 
significant & not consistent with HWE distribution as p value 
is less than 0.05 
rs1009840 740 80.38% 1E-06 85.94% 1E-06 The difference between the observed & expected is not 
significant & not consistent with HWE distribution as p value 
is less than 0.05 
99 
 
rs2928684 743 NA NA NA NA Very few samples had  the genotype of which most of them 
were TT genotype 
rs2978477 740 74.74% 1E-06 76.62% 0.008 The difference between the observed & expected is not 
significant & not consistent with HWE distribution as p value 
is less than 0.05 
rs4872145 739 67.31% 1E-06 69.68% 0.03 The difference between the observed & expected is not 
significant & not consistent with HWE distribution as p value 
is less than 0.05 
rs4872153 744 64.18% 1E-06 60.48% 0.0006 The difference between the observed & expected is not 
significant & not consistent with HWE distribution as p value 
is less than 0.05 
rs6986233 746 81.98% 1E-06 86.59% 0.317 The difference between the observed & expected is 
significant & consistent with HWE distribution as p value is 
greater than 0.05 
 
rs7833754 745 73.73% 1E-06 74.89% 0.609 Though the HWE p value is significant the % SNP success 
is low before and after data sorting 
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rs7834536 740 37.44% 1E-06 16.89% 0.103 Though the HWE p value is significant the % SNP success 
is too low before and after data sorting 
rs11781222 704 85.31% 1E-06 82.95% 0.096 The difference between the observed and expected is 
significant & consistent with HWE distribution as p value is 
less than 0.05 
rs13439692 741 NA NA NA NA After the data sorting only one genotype (CC) was observed 
in all the resulting samples. Hence no further analysis was 
carried out 
rs17089331 745 78.87% 1E-06 82.41% 0.086 The difference between the observed & expected is 
significant & consistent with HWE distribution as p value is 
greater than 0.05 
rs17089358 741 85.05% 1E-06 88.12% 0.127 The difference between the observed & expected is 
significant & consistent with HWE distribution as p value is 
greater than 0.05 
rs17698981 700 75.43% 1E-06 74.28% 0.021 The HWE p value is not significant and the % SNP success 
is also low 
rs34146184 None NA NA NA NA No genotype data was observed from any of the nine data 
sheets 
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rs34968988 746 NA NA NA NA Only 37 samples resulted in a genotype which gave the least 
SNP success and hence did not carry out any further 
analysis 
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3.02 Normalisation of the data 
From the above resulting table, SNPs rs6986233, rs11781222, rs7089331 and rs17089358 
were found to be in HWE with p values greater than 0.05. Before performing the analyses, 
genotype data was combined with phenotype data and the variables of fetal birth weight, 
maternal booking weight and gestational age were individually checked for normal 
distribution using the SPSS (v20) analysis software. Histograms showed maternal booking 
weight to be positively skewed, Gestational age to be negatively skewed and fetal birth 
weight showed a normal distribution. Hence the maternal booking weight and gestational 
age were transformed using logarithm function and reflect and square root function. Subjects 
with gestational age <36 weeks (as they are considered premature births) were excluded 
and only singleton births were considered in the analysis. 
a b  
c d  
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e f  
g h  
Figure 30: Normalisation of the data using SPSS. Above figure shows the distributions 
of mothers booking weight, birth weight, and gestational age before and after transforming 
the data. Figures a and c show positively skewed distribution of mothers booking weight. 
Figures b and d shows normal distribution of mother’s booking weight by transforming the 
data using log 10 function in SPSS. Figures e and f shows the normal distribution of birth 
weight in both males and females considered for tagSNP analysis. Figure g shows 
negatively skewed data distribution of gestational age. Figure h shows normal distribution 
of gestational age after transforming the data using reflect and square root function using 
SPSS. 
3.03 ANCOVA analysis using SPSS software 
Two-way ANCOVA analysis (two independent and two dependent variables) was carried 
out to check if the covariates have any influence on the dependent variable in the presence 
of fixed factors.  Genotype and sex of the fetus are considered as independent 
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variables/fixed factors, birth weight and haemoglobin levels as dependent variables, 
gestational age and mother's booking weight as covariates. The test of between-subjects 
effects, tells whether there is a significant effect for any of the independent variables and 
whether the interaction between the two independent variables is significant or not, for which 
the Sig. value p value should be more than 0.05. However what the p value does not tell is 
the degree of association between two variables. Hence it is important to understand 
whether the difference has any practical or theoretical significance by observing the effect 
size (also known as strength of association). The most commonly used parameter to 
compare groups is partial eta squared effect size which can be obtained from the ANCOVA 
analysis output. Partial eta squared effect size statistic shows the amount of variance of the 
dependent variable that can be explained by the independent variable. Values can range 
from 0 to 1 or by multiplying the partial eta squared value by 100 to express in percentage. 
3.04 Mfrn tagSNPs in correlation with Hb levels and birth weight 
 
3.04.001 ANCOVA results and analysis 
Two-way ANCOVA analysis showed Leven's Test of Equality of Error Variance does not 
violate the assumption of equality of variance as Sig. value is greater than 0.05 for all four 
(SNPs rs6986233, rs11781222, rs7089331 and rs17089358) tagSNPs as shown in the 
below table.  Significant association was considered when the p value was less than 0.05 
(p<0.05) and trend associated when p value was 0.05<p<0.1. From the table 03, when the 
dependent variable was haemoglobin no tagSNP showed any significant p value either in 
association with genotype and fetal sex. Also, from the below table it can be said that the 
effect of haemoglobin levels on either fetal sex or genotype is not statistically significant in 
any four (rs6986233, rs11781222, rs7089331 and rs17089358) tagSNPs as p values are 
greater than 0.05. Likewise when birth weight was considered as a dependent variable, birth 
weight did not show any significant p value in association with genotype and fetal sex in any 
four (rs6986233, rs11781222, rs7089331 and rs17089358) tagSNPs. Since the p value is 
not significant it may be said that effect of independent variable (genotype) is not dependent 
on the level of the other independent variable, fetal sex in the four tagSNPs analysed. Hence 
it can be concluded that the haemoglobin levels or the brith weight are neither dependent 
on genotype nor the fetal sex or in interaction. However, significant p value can be observed 
in rs6986233 (p=0.035) and rs17089331 (p=0.019) between fetal sex and birth weight and 
between birth weight (p=0.026) and the genotype in rs11781222. Hence in this study we 
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can confirm that, in tagSNPs rs17089331 and rs6986233 birth weight is more dependent on 
genotype and fetal sex than on haemoglobin levels. 
Table 03: Leven's test of equality of error variance and p values. Table shows the p 
values for Leven’s test of equality of error variances and p values between the dependent 
and independent variables 
SNP id Dependent 
variable 
Leven’s test 
of equality of 
error 
variance p 
value 
P value for 
genotype and 
fetal sex 
association 
P value for 
    Genotype Fetal 
sex 
rs6986233 Birth weight 0.201 0.355 0.400 0.035 
Haemoglobin 0.195 0.984 0.101 0.618 
rs11781222 Birth weight 0.206 0.228 0.026 0.674 
Haemoglobin 0.630 0.581 0.631 0.146 
rs17089331 Birth weight 0.130 0.638 0.436 0.019 
Haemoglobin 0.253 0.129 0.890 0.723 
rs17089358 Birth weight 0.478 0.445 0.872 0.985 
Haemoglobin 0.770 0.929 0.063 0.616 
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Table 04: Effect size on the independent variable interaction. Table shows the effect 
size on the independent variable interaction in the presence of dependent variables 
SNP id Dependent 
variable 
Partial eta 
squared value 
of genotype 
and fetal sex 
interaction 
Percentage eta 
(% of variance 
explained) 
Effect size 
significance 
level 
rs6986233 Birth weight 0.004 0.4 Negligible 
Haemoglobin 0.000 0 None 
rs11781222 Birth weight 0.006 0.6 Negligible 
Haemoglobin 0.002 0.2 Negligible 
rs17089331 Birth weight 0.002 0.2 Negligible 
Haemoglobin 0.008 0.8 Negligible 
rs17089358 Birth weight 0.003 0.3 Negligible 
Haemoglobin 0.000 0 None 
 
From the ANCOVA analysis it is observed that not haemoglobin levels but birth weight, 
which is also a dependent variable, has a significant association with the covariates, 
gestational age and squared maternal booking weight. The effect size on genotype and fetal 
sex interaction and also individually in the presence of either birth weight or haemoglobin 
levels can be analysed by considering the partial eta squared values from the ANCOVA 
outputs. As shown in table 04, ANCOVA analysis of all four tagSNPs rs6986233, 
rs11781222, rs7089331 and rs17089358 showed the partial eta squared values. Eta 
squared guidelines suggested by Tabachnick and Fidell, (2007) suggests that eta squared 
value with more than 1 % has a small, 6% has medium and anything more than 13.8% has 
a large effect size.  ANCOVA analysis of rs6986233, rs11781222, rs7089331 and 
rs17089358 showed very negligible effect size with values ranging between 0 – 0.8 %. 
Hence it can be concluded that the significant associations in rs6986233 and rs17089331 
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between birth weight and fetal sex, and in rs11781222 between birth weight and genotype 
owing to small effect size are not practically or theoretically significant. 
3.04.002 Mfrn tagSNPs discussion 
Studies with S. cerevisiae and cells from patients have suggested that mutations in the 
ABC7 lead to mitochondrial iron accumulation, responsible for the cellular damage that 
causes the neuronal and erythroid disease and is thought to be involved in haem transport 
from the mitochondria (Allikmets et al., 1998). Mis-sense mutations were found in HFE in 
87% of chromosomes from patients homozygous for hereditary hemochromatosis (Feder et 
al., 1998). Mutations in the causative gene, HFE, are responsible for most cases of 
hereditary hemochromatosis (Feder et al., 1996). Aceruloplasminemia is a newly 
recognized, rare autosomal recessive disorder of iron metabolism that results from 
deficiency of ceruloplasmin ferroxidase activity as a consequence of mutations in the 
ceruloplasmin gene (Harris et al., 1995). Molecular studies have identified multiple point 
mutations in the IRE of the L-ferritin mRNA affecting the highly conserved CAGUGU motif 
that constitutes the IRE loop and mediates the high-affinity interaction with the IRP 
(Beaumont et al., 1995, Girelli et al., 1995). The mutation was found to abolish the binding 
of IRP and result in constitutive, poorly regulated L-ferritin synthesis (Beaumont et al., 1995). 
Finberg et al. identified TMPRSS6 mutations in individuals with iron-refractory iron 
deficiency anaemia (IRIDA) (Finberg et al., 2008).  Normal to low urinary hepcidin levels 
with regards to the levels of iron stores have been found in patients with DMT1 mutations, 
probably accounting for the increased intestinal iron absorption (Iolascon et al., 2008). 
From the above studies, it can be understood that if the correct mutation or variation when 
examined reveals the underlying role of the mutation/variation in causing the disease. 
Choosing a subset of maximally informative SNPs, or "tag" SNPs, to be genotyped in a 
larger sample can be reduced without losing the ability to capture most of the variation. 
Where available, in the case of the candidate gene approach it is preferable to compare the 
HapMap data with the sequence data. This has the advantage of aiding in the discovery and 
coverage of SNPs with frequencies in the range of 1% to 5% which are unlikely to appear in 
the HapMap database (Constantine et al., 2008). The discovery of new genes like DMT1 
and TMPRSS6 implicated in iron metabolic disorders, suggests that the molecular diagnosis 
of the iron metabolic disorders is within reach. However, the difficulty lies in identifying the 
candidate gene for analysis. Mfrn tagSNPs analysed in our study may not have resulted in 
showing any significant association between Hb levels and birth weight. No previous findings 
108 
 
or literature was available on Mfrn tagSNP association studies. However, analysing 
tagSNPs of other genes involved in iron metabolic disorders may reveal the role of tagSNPs 
in iron metabolism. 
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CHAPTER 4 
 
Protein-Protein Interaction results and discussion 
 
4.01 Introduction 
The foundation for the discoveries in the field of iron homeostasis is to identify key modifiers 
along with the identification of mutated genes in well-characterized cohorts of patients with 
inherited haemochromatosis from across the globe (Roy, 2013). Mammalian iron 
homeostasis is maintained through the concerted action of sensory and regulatory networks 
that modulate the expression of proteins of iron metabolism at the transcriptional and/or 
post-transcriptional levels (Eisenstein, 2000). The ferroxidase activity of Heph is thought to 
play an important role during iron export from intestinal enterocytes and the subsequent iron 
loading of the blood protein Tf, which delivers iron to the tissues (Vashchenko and 
MacGillivray, 2012). In the absence of a regulated physiological mechanism for iron 
excretion, iron absorption by the proximal intestine is a critical determinant of body iron 
availability and loading in mammals (Hentze et al., 2010; Knutson, 2010). Owing to the tight 
regulation of intestinal iron absorption, it is known that it increases with body iron 
requirements and decreases when body iron stores enlarge. Key aspects of cellular iron 
metabolism are controlled by both IRP 1 and 2. A recent description of a whole-
transcriptome repertoire of potential novel IRP targets suggests that IRP function extends 
beyond iron metabolism regulation (Sanchez et al., 2011). Research till today has long 
appreciated the importance of identifying protein interactions through different techniques 
such as confocal microscopy for intracellular colocalization of proteins, 
coimmunoprecipitation, surface plasmon resonance (SPR) and spectroscopic studies. The 
partners with which a protein (bait) interacts forms a key component that describes the 
function of any protein. In this study, using K562 cells I carried out experiments to find 
interacting partners of Heph and IRPs by coimmunoprecipitation using affinity-tagged 
proteins to understand their role in iron metabolism. Initially the expression of Heph and 
IRPs were checked in K562 cells by carrying out real time PCR, then the GOIs were cloned 
with One-Strep tag to carry out expression and coimmunoprecipitation analysis of the Heph 
and IRPs complexes. 
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4.02 qRT-PCR data of Heph, IRP1, IRP2 and Mfrn 
qRT-PCR was carried out using Applied Biosystems TaqMan probes for analysing the 
differential gene expressions of Heph (assay id: Hs00953259_m1), IRP1 (assay id: 
Hs00158095_m1)  and IRP2 (assay id: Hs00386293_m1) using β-Actin (assay id: 
Hs99999903_m1) as a housekeeping gene. Prior to synthesising Heph, IRP1 and IRP2 for 
the PPI study, expression of Heph, IRP1 and IRP2 was checked in K562 cells. RNA 
extracted from K562 cells after 100 µM FAC treatment for 72hrs and control cells without 
FAC was used as a template during qRT-PCR.   
 
Figure 31: Gene expression of Heph, IRP1, IRP2 and Beta-actin in K562 cells. Figure 
shows the gene expression pattern of Heph, IRP1, IRP2 and beta-actin in both untreated 
(UT) and treated (72 hrs incubated) K562 cells (K) using the C(T)values. 
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Figure 32: Gene expression of Heph, IRP1 and IRP2 after normalisation. Figure shows 
the Heph, IRP1 and IRP2 expression pattern on X-axis and the difference of Ct values 
between the reference gene and normalised gene on the Y-axis. K = K562 cells, UT = 
untreated or control sample, 72 = cells treated for 72 hrs with 100 µM FAC. 
Green bars in the figure 35 show the expression of control (K562 cells without FAC 
treatment) and red bars show the expression pattern of Heph, IRP1 and IRP2 in treated 
cells. FAC treated K562 cells showed up-regulation of Heph and IRP1 and IRP2 has been 
down-regulated. Statistical analysis of real time PCR data of the untreated and treated K562 
cells for Heph, IRPs and beta-actin was carried out using GraphPad Prism. In all the samples 
n = 3, where three biological and technical replicates were used in every run. In the case of 
K562 cells treated with 100 µM FAC shown more expression than normal K562 cells while 
K562 cells treated with 100 µM FAC showed more down regulation of IRP2 when compared 
with untreated cells. Unpaired t-test was used to carry out the statistical analysis. While 
examining the expression of Heph using the C(T) values in the untreated and 100 µM FAC 
treated K562 cells, a very significant p value of 0.005 was observed along with the Mean 
±SEM (Standard error of the mean) of 1.213 ± 0.217 with the unpaired t test. Likewise when 
the C(T) values were considered and expression analysis was measured between the 
untreated K562 cells and the treated K562 cells for IRP1 and IRP2 expression, no significant 
p value was observed with Mean ± SEM of 1.267 ± 1.037 for IRP1 and -1.093 ± 1.324 for 
IRP2 gene. However, when the ΔC(T) was measured by subtracting the C(T) of the GOI 
with the C(T) of the housekeeping gene there was a significant change in the fold expression 
in all three genes. 
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4.03 Relative gene quantification of Heph, IRP1, IRP2 and Mfrn by the 
Livak method 
The Livak method (Livak and Schmittgen, 2001) was used to measure the fold increase or 
decrease of gene expression after normalizing Heph, IRP1, IRP2 and Mfrn against the 
housekeeping gene (β-actin). Table 05 shows the relative gene expression fold increase or 
decrease of the target gene against the reference gene. 
Reference-Target gene Fold increase or decrease of target 
gene expression 
β-actin – Heph 2.8 fold increase of Heph expression in 
100 µM FAC treated K562 cells 
β-actin-IRP1 2.8 fold increase of IRP1 expression in 
100 µM FAC treated K562 cells 
β-actin – IRP2  0.5 fold decrease of IRP2 expression in 
100 µM FAC treated K562 cells 
β-actin – Mfrn 0.3 fold increase of Mfrn expression in 
100 µM FAC treated K562 cells 
Table 05: Fold increase and decrease of Heph, IRP1 and IRP2 in treated and untreated 
K562 cells. Table 05 shows the fold increase and decrease of Heph, IRP1 and IPR2 against 
the house-keeping gene, β-actin. 
Once the gene expression of Heph, IRP1 and IRP2 was confirmed by real time PCR in K562 
cells, protein expression of Heph, IRP1 and IRP2 was carried out by Western blotting to 
confirm the expression of the Heph, IRP1 and IRP2 proteins in K562 cells. 
4.04 Detection of Heph, IRP1 and IRP2 by western blotting 
Western blotting was carried out to analyse the expression pattern of Heph, IRP1 and IRP2 
using both treated with 100µM FAC and untreated K562 cell lysates to examine the 
expression patterns between the control and sample cell lysates. 
 
 
 
113 
 
 
      
Figure 33: Protein expression analysis of Heph, IRP1 and IRP2 by Western blotting 
and Image J. Part A and B of the figure shows the Western blot membranes with bands of 
Heph, IRP1 and IRP2 in K562 cells treated with 100µM FAC and untreated cells. Part C and 
D of the above figure shows the peaks plotted by using Image J software (Abramoff et al., 
2004). Small peaks in part C of the figure represent the Heph and large peaks represent β-
actin.  Extreme left peaks in part D of the figure represent the IRP1 and IRP2 and big peaks 
at the extreme right represent the β-actin. 
 
 
A B 
C D 
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Protein of interest Area calculated by ImageJ 
Heph – K562 cells control 2600.617 
Heph – K562 cells treated with 100 µM FAC 3308.902 
IRP1 – K562 cells control 3691.598 
IRP1 - K562 cells treated with 100 µM FAC 2203.598 
IRP2 – K562 cells control 3903.598 
IRP2 - K562 cells treated with 100 µM FAC 2593.255 
Table 06: Quantification of Heph, IRP1 and IRP2 in treated and untreated K562 cells 
using ImageJ. Image J software was used to calculate the peak areas of the Heph, IRP1 
and IRP2 in both K562 treated with 100 µM FAC and normal K562 cells. 
The band intensity obtained after western blot staining/detection by chemiluminiscence, in 
figure 36 show that Heph, IRP1 and IRP2 showed increased expression in K562 cells 
treated with 100µM FAC while K562 treated with 100µM FAC showed very little expression 
of IRP2 compared to the untreated K562 cells. Quantitative analysis of the western blots 
using Image J, confirmed a 1.2 and a 1.6-fold increase of Heph and IRP1 in K562 cells 
treated with 100 µM FAC compared with normal K562 cells. K562 cells treated with 100 µM 
FAC showed 1.5 fold less IRP2 expression compared with IRP2 expressed in normal K562 
cells. In the case of Heph and IRP1 the western blotting data is in par with the gene 
expression data as shown previously. However, for IRP2, gene expression was more down 
regulated in FAC treated K562 cells compared to untreated cells, which is in contrast to the 
western blotting analysis. In western blotting, K562 cells treated with 100µM FAC expressed 
more IRP2 than untreated control cells. This indicates that not always gene expression and 
protein expression data are not always correlated owing to the different stability of mRNA 
and protein and different transcription and translation rates in a given cell. qPCR and 
western blotting studies showed that expression of Heph, IRP1 and IRP2 in K562 cells which 
allowed K562 cells to be used as model cells to perform protein protein interaction analysis 
of Heph, IRP1 and IRP2. 
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4.05 Cloning and sequence confirmation of Heph and IRPs from K562 
cells 
 
4.05.001 Cloning of Heph, IRP1 and IRP2 using K562 cells 
The idea behind carrying out cloning of Heph and IRPs using K562 cells is to take advantage 
of the in-vivo affinity fusion-based protein purification by using a genetically fused affinity 
tag, which in this study is One-Strep tag. Heph (3.6kb), IRP1 (2.6kb) and IRP2 (2.9kb) genes 
were PCR amplified using the primers as described in 2.05.002 section. The figure below 
illustrates the potential PCR fragments of IRP1, IRP2 and Heph. 
 
Figure 34: PCR amplicons of Heph, IRP1 and IRP2. Above figure shows an approximate 
fragment of IPR1 (2.6kb), IRP2 (2.9kb) and Heph (3.6kb) compared to the 1kb ladder in lane 
one. The boxed fragment in lane one is a 3kb fragment of the 1kb ladder from NEB (New 
England Biolabs). NEB’s 1kb ladder ranges from 10kb – 0.5kb bands. The sixth band boxed 
in lane 1 is the 3kb band in the marker. 
4.05.002 Sequencing results confirming PCR amplicon identity 
Sequencing of the Heph, IRP1 and IRP2 PCR amplicons was carried out prior to molecular 
cloning to confirm their usage as templates to generate the Donor and Destination Vector’s 
with a Strep tag for PPI studies. Sequencing of the samples was carried out at UCL’s, Source 
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BioScience facility. Sequence data of the respective gene was compared to the raw 
sequence from NCBI and looked for 100% identity with no variantions or base changes in 
the sequence. Sequencher 5.1 DNA sequencing software was used to analyse the 
sequencing data obtained from UCL. The below figures 35 – 39 are the forward and reverse 
sequences of the Heph, IRP1 and IRP2 cDNA’s confirming the PCR analysis. Sequencing 
analysis showed no single base change which confirmed no mutation/variation was 
introduced during the PCR. For the subsequent PPI work, Heph, IRP1 and IRP2 PCR 
amplicons were used as templates. 
 
 
Figure 35: Sequence confirmation of Heph obtained after PCR. Figure represents the 
forward sequence of Heph cDNA analysed using Sequencher v 5.1 sequencing software. 
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Figure 36: Sequence confirmation of IRP1 forward sequence obtained after PCR. 
Figure represents the forward sequence of IRP1 cDNA analysed using Sequencher v 5.1 
sequencing software. 
 
 
 
Figure 37: Sequence confirmation of IRP1 reverse sequence obtained after PCR. 
Figure represents the reverse sequence of IRP1 cDNA analysed using Sequencher v 5.1 
sequencing software. 
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Figure 38: Sequence confirmation of IRP2 forward sequence obtained after PCR. 
Figure represents a forward sequence of IRP2 cDNA analysed using Sequencher v 5.1 
sequencing software. 
 
 
 
Figure 39: Sequence confirmation of IRP2 reverse sequence obtained after PCR. 
Figure represents the reverse sequence of IRP2 cDNA analysed using Sequencher v 5.1 
sequencing software. 
 
119 
 
4.06 Construction and confirmation of Donor Vectors 
 
4.06.001 Donor Vector generation and restriction digestion analysis 
For the Donor Vector generation, the gene of interest (GOI) is extended at both ends with 
the combinatorial and StarCombinase sites by PCR. During the PCR the gene of interest 
(GOI) is cloned at both termini with combinatorial sites and the StarCombinase1™ 
recognition area which are necessary for the oriented insertion of the PCR fragment into 
pENTRY-IBA51, an entry vector. Recombination of the amplicon after PCR and the Entry 
Vector at the combinatorial sites leads to generation of the Donor Vector under loss of all 
StarCombinase1™ binding areas resulting in the recombination reaction unidirectional and 
thereby highly efficient. After the overnight incubation at 37°C of LB agar plates with 50 mg/L 
kanamycin and 50 mg/L X-gal DNA mini-preps were carried out by selecting the white 
colonies. Plasmid DNA extraction was then carried out using QIAGEN’s Plasmid mini-prep 
kit (UK). Extracted DNA was quantified using a Nano-drop and all the DNA extractions 
showed purity of 1.8 – 2.0. Restriction digestion analysis of the Donor Vector’s generated 
using the PCR product from the respective GOI was carried out using the HindIII restriction 
enzyme. Restriction analysis of Heph, IRP1 and IRP2 using Webcutter 2.0v revealed the 
information as shown in table 7A. 
Donor Vector No of times HindIII cuts  Fragment sizes 
Heph 2 38bp & 5362bp 
IRP1 1 Linearises the plasmid 
IRP2  4 2200bp, 1200bp, 705bp & 500bp 
Table 7A: Restriction analysis of Donor vectors. Above table shows the restriction 
fragment sizes after digestion with HindIII restriction enzyme. 
1µg of the pDNA was incubated overnight using 10Units of HindIII enzyme. 0.7% agarose 
gel electrophoresis was used to analyse the overnight restriction enzyme digestion of Heph, 
IPR1 and IRP2 Donor Vector pDNA. Figure 40 the 0.7% gel image of the digested fragments 
along with the undigested controls.  
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Figure 40: 0.7% gel electrophoresis picture of Heph, IRP1 and IRP2 restriction 
digestion. Figure shows the digested and undigested (controls) fragments of IRP1, IRP2 
and Heph with 1kb ladder on either side of the sample. 
Restriction digestion of the Donor Vector pDNA of IRP1, IRP2 and Heph with HindIII resulted 
in an expected linearised fragment of IRP1, three out of four fragments in IRP2 (the 500bp 
fragment ran off the gel during electrophoresis to get the clear picture of the bigger 
fragments) and an approximate 5.36kb fragment in Heph.  
4.06.002 Donor Vector sequence confirmation analysis 
pDNA extracted after Donor Vector generation was also confirmed for the correct clone 
using Sequence analysis. Sequencing of the Donor Vector pDNA was carried out using the 
Source BioScience facility at UCL. 100ng/ul pf pDNA and 3.2pmol/ul of primer was 
submitted to the Source BioScience facility at UCL for sequencing.  The sequence analysis 
(figures 41 – 46) with the highlighted ‘’AATG’’ and ‘’TCCTCCC’’ sequences flanking the GOI 
in all forward and reverse sequences of Heph, IRP1 and IRP2 is shown. DNA sequencing 
analyses was carried out using Sequencher 5.1v sequencing software. Sequencing analysis 
of Donor Vector extracted pDNA for the respective Heph, IRP1 and IRP2 cDNAs confirmed 
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the successful introduction of the required StarCombinase sites in the Donor Vector pDNA 
that are necessary to accept the One-Strep tag during Destination Vector Generation. 
 
 
Figure 41: Forward sequence confirmation of donor vector generated using Heph. 
Forward sequence of Donor Vector with GOI-Heph showing the highlighted region ‘’AATG’’ 
to the left of GOI which is necessary for further cloning analysis. 
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Figure 42: Reverse sequence confirmation of donor vector generated using Heph. 
Reverse sequence of Donor Vector with GOI-Heph showing the highlighted region 
‘’TCCTCCC’’ to the left of GOI which is necessary for further cloning analysis. 
 
 
Figure 43: Forward sequence confirmation of donor vector generated using IRP1. 
Forward sequence of Donor Vector with GOI-IRP1 showing the highlighted region ‘’AATG’’ 
to the left of GOI which is necessary for further cloning analysis. 
 
 
123 
 
 
Figure 44: Reverse sequence confirmation of donor vector generated using IRP1. 
Reverse sequence of Donor Vector with GOI-IRP1 showing the highlighted region 
‘’TCCTCCC’’ to the left of GOI which is necessary for further cloning analysis. 
 
 
Figure 45: Forward sequence confirmation of donor vector generated using IRP2. 
Forward sequence of Donor Vector with GOI-IRP2 showing the highlighted region ‘’AATG’’ 
to the left of GOI which is necessary for further cloning analysis. 
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Figure 46: Reverse sequence confirmation of donor vector generated using IRP2. 
Reverse sequence of Donor Vector with GOI-IRP2 showing the highlighted region 
‘’TCCTCCC’’ to the left of GOI which is necessary for further cloning analysis. 
4.07 Cloning and confirmation of Destination Vector 
 
4.07.001 Destination Vector generation and restriction digestion analyses 
During the destination vector generation, the GOI is transferred from the Donor Vector into 
an acceptor vector (pESG-IBA105 with N terminal Strep tag and pESG-IBA103 with Strep 
tag at the C-terminal end) which provided the desired genetic elements (i.e. tag, promoter, 
signal sequence etc.) by means of StarCombinase2. Since the signal peptide was present 
at the N terminal end of Heph, recombination was carried out such that the Strep tag is 
cloned at C terminal end of Heph by using the IBA-103 acceptor vector and in IRPs the 
signal peptide sequence was at C terminal and hence the tag was designed to be cloned at 
the N terminal end by using the IBA-105 acceptor vector. The resulting Destination Vector 
has the GOI under control of the selected promoter (CMV promoter) allowing GOI 
expression in the K562 cells. After the overnight incubation at 37°C of LB agar plates with 
100 mg/L ampicilin and 50 mg/L X-gal DNA mini-preps were carried out by selecting the 
white colonies. Plasmid DNA extraction was then carried out using QIAGEN’s Plasmid mini-
prep kit (Qiagen, UK). Extracted DNA was quantified using a Nano-drop and all the DNA 
extractions showed the purity value between 1.8 – 2.0 which is considered to be the pure 
extract. Destination Vectors generated using the Donor Vector pDNA from the respective 
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GOI (Heph, IRP1, IRP2) was analysed using the HindIII restriction enzyme. Analysis of 
Heph, IRP1 and IRP2 sequences carried in their respective destination vectors, using 
Webcutter 2.0v predicted the fragment sizes as shown in table 7B. 
Destination Vector Fragment sizes 
Heph 10.67kb, 0.1kb & 0.03kb 
IRP1 9.9kb, 0.1kb 
IRP2  7.7kb, 1.2kb, 0.7kb & 0.5kb 
Table 7B: Restriction analysis of Destination vectors. Above table shows the restriction 
fragment sizes after digestion with HindIII restriction enzyme. 
1µg of the pDNA was incubated overnight using 10 Units of HindIII enzyme. A 0.7% agarose 
gel was used to analyse the overnight restriction enzyme digestion of Heph, IPR1 and IRP2 
Destination Vector pDNA. Figure 50 shows the 0.7% gel image of the digested fragments 
along with the undigested controls. 
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Figure 47: 0.7% gel electrophoresis of donor vectors Heph and IRP1. Restriction 
analysis of the digested and undigested (controls) fragments of IRP1 and Heph with 1kb 
ladder. 
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Figure 48: 0.7% gel electrophoresis of donor vectors Heph and IRP2. Restriction 
analysis of the digested and undigested (controls) fragments of IRP2 with 1kb ladder. 
Restriction digestion of the Destination Vector pDNA of IRP2 with HindIII resulted in 
expected fragments of 7.7kb, 1.2kb, 0.7kb and 0.5kb. Since the gel was a concentration of 
0.7% the 0.5kb band could not be seen clearly. However, the Destination vector pDNA 
construction has also been confirmed by sequencing analyses. 
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4.07.002 Destination Vector sequence confirmation analysis 
pDNA extracted after Destination Vector generation was also confirmed for the correct clone 
using Sequence analysis. Sequencing of the Destination Vector pDNA was carried out using 
Source BioScience facility in UCL. 100ng/µl pDNA and 3.2pmol/µl of both forward and 
reverse primer was submitted to the Source BioScience facility in UCL for sequencing.  
Sequencing analysis of the destination vector DNA with One-Strep tag were analysed for 
any variations in the base sequence using Sequencher software. Figures 49 – 51 confirmed 
the fusion of One-Strep tag with no variations observed in full length clones. 
 
 
Figure 49: Forward sequence of Heph tagged with One-Strep tag destination vector. 
Forward sequence of Destination Vector with GOI-Heph showing the highlighted One-Strep 
tag at the C’ end of clone which is necessary for further expression analysis. 
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Figure 50: Forward sequence of IRP1 tagged with One-Strep tag destination vector. 
Forward sequence of Destination Vector with GOI-IRP1. 
 
 
Figure 51: Forward sequence of IRP2 tagged with One-Strep tag destination vector. 
Forward sequence of Destination Vector with GOI-IRP2. 
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To confirm the plasmid constructs of Heph, IRP1 and IRP2 tagged with One-Strep tag, 
western blotting and flow cytometry techniques were used. Two batches of K562 cells were 
respectively transfected using Lipofectamine-LTX plus and Magnetic-assisted transfection 
reagents. After 48 hrs and 72 hrs of incubations, transfected cells were used to prepare cell 
lysates. Cell lysates were then analysed by Western blotting to analyse the expression of 
the respective tagged protein. To further carry out pull-downs of the respective protein in 
K562 cells (to find and establish different interacting partners) detection of the protein on the 
western blot was necessary to establish the successful transfection and over-expression of 
the One-Strep tagged Heph, IRP1 and IRP2. Unsuccessful attempt was made to examine 
the expression of One-Strep tagged Heph, IRP1 and IRP2 expressed in K562 cells on 
western blots. Failure in detecting the tagged protein after western blotting left a question to 
answer whether the transfection was successful or not. In order to assess the transfection 
efficiency flow cytometry was used. 
4.08 Protein expression analyses of One-Strep tagged Heph, IRP1 and 
IRP2 using Flow Cytometry 
To examine expression efficiency of One-Strep tagged Heph, IRP1 and IRP2 K562 cells 
were transfected with the respective tagged pDNA by both Lipofectamine LTX-Plus and 
MATra approaches. 2 µg of pDNA was used during both MATra and Lipofectamine-LTX 
transfections, so as to keep the concentration of the pDNA consistent to compare the 
efficiency of transfection. Having the two transfection reagents gave an opportunity to further 
analyse which method may be more efficient and which is more viable and also to see if the 
magnetic nanoparticles used in MATra have any effect on iron metabolic gene expression. 
Viability and expression efficiency analyses were carried out after 48hrs of transfection using 
via count and intra cellular staining. From the figure 52 it can be seen that K562 cells treated 
by MATra are more viable compared with Lipofectamine-LTX after 48hrs with significant p 
value of 0.014. However, when the same K562 cells are transfected with One-Strep tagged 
Heph using both MATra and Lipofectamine LTX, more cells were dead in the MATra 
transfected batch of K562 cells. There is a very significant difference between the MATra 
untransfected and transfected K562 cells with p value of 0.0003. A significant p value of 
0.0197 was observed between Lipofectamine-LTX plus transfected and treated K562 cells. 
This concludes that MATra transfected cell viability is very low compared to Lipofectamine-
LTX plus transfected K562 cells after 48hrs. 
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Figure 52: Viability analysis of K562 cells transfected with Heph by Lipofectamine 
LTX-plus and MATra. Comparison of % of viability between MATra and Lipofectamine-LTX 
plus transfected K562 cells. M – MATra, LTX – Lipofectamine-LTX plus, H = Heph. 
Also, transfection efficiency and the hypothesised role of magnetic nanoparticles on IRP 
have also been examined by flow cytometry. Transfection of K562 cells was carried out 
using One-Strep tagged Heph and IRP2 by subjecting to MATra and Lipofectamine-LTX 
plus reagents. After 48 hrs of incubation, intracellular staining was carried out to analyse the 
transfection efficiency using a flow cytometer. From the Figure 56 it can be seen that 
Lipofectamine-LTX plus transfected K562 cells with One-Strep tagged Heph and IRP2 
showed higher efficiency than MATra transfected cells. K562 transfected with 
Lipofectamine-LTX plus and One-Strep tagged Heph had a significant difference compared 
with MATra transfected K562 cells with a p value of 0.0001. Likewise, Lipofectamine-LTX 
plus transfected K562 cells with One-Strep tagged IRP2 showed higher transfection 
efficiency compared with MATra-assisted transfection with a p value of 0.0085. K562 un-
transfected cells and K562 un-transfected cells but stained with antibody have been used 
as controls. To find if magnetic nanoparticles had any influence on the transfection efficiency 
of K562 cells, K562 cells transfected with One-Strep tagged Heph and One-Strep tagged 
IRP2 have been compared and analysed after 48 hrs. From the Figure 53 it can be 
concluded that there is no significant difference between the transfection efficiencies of 
MATra transfected K562 cells with One-Strep Heph and One-Strep IRP2 (K-M-H and K-M-
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P2). Hence it can be concluded that Lipofectamine-LTX plus reagent has more transfection 
efficiency compared to MATra and magnetic nanoparticles do not have any adverse or 
significant effect on IRPs during transfection. 
 
Figure 53: Percentage of K562 cells transfected by Lipofectamine-LTX plus and 
MATra reagents. Plot shows the %  of K562 transfected cells using One-Strep tagged Heph 
and One-Strep tagged IRP2 by both Lipofectamine-LTX plus and MATra transfections. K= 
K562 cells, M – MATra, L – Lipofectamine-LTX plus, H = Heph and P2 = IRP2. 
From the transfection efficiency studies in K562 cells it can be concluded that K562 cells 
have been transfected and it can be inferred that, number of transfected K562 cells with the 
respective One-Strep tagged protein may be significantly different to un-transfected cells but 
the significance achieved might not be enough to prepare a cell lysate for western blotting 
to identify the tagged protein on western blot. The percentage of detergent to lyse the cells 
may need to be optimised which might result in intact tagged protein complex during sample 
preparation for Western blotting. Along with the percentage of detergent, over-expression of 
tagged protein, that is higher transfection efficiency of K562 cells might give an opportunity 
to identify the protein of interest during Western blotting and also the interacting partners 
during the pull down studies. 
4.09 Discussion of Heph and IRPs Molecular cloning, expression and 
protein protein interaction studies 
Maintaining consistent levels of cellular protein requires a series of linked processes, 
spanning the transcription, processing and degradation of mRNAs to the translation, 
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localization, modification and of the proteins themselves. The abundance of the amount of 
protein reflects a balance among the cellular processes. It has long been a mystery of how 
this balance is achieved and to what extent each of these processes contributes to the 
regulation of cellular protein abundances. Approximately 40% of the variation in protein 
concentration can be explained by knowing mRNA abundances (de Sousa Abreu et al., 
2009; Maier et al., 2009) and the remaining 60% of the variations can be attributed to a 
combination of posttranscriptional regulation modifications. Real time PCR studies 
confirmed the gene expression of Heph, IRP1 and IRP2. Preincubation with 500 μM FAC 
did not result in any significant change of iron uptake by K562 cells and also did not show a 
significant effect on the mRNA level of Heph (Kovar et al., 2006). Caco-2 cells preincubated 
for 24hrs in 500 µM FAC showed statistically significant levels of Heph mRNA along with 
mRNA levels of Ireg1 (40-60%) (Balusikova et al., 2009). When K562 cells were subjected 
to the 500 µM FAC and incubated for 24 hrs, there was a 40% increase in Ireg1 m RNA 
levels, however mRNA levels of Heph though increased was not statistically significant 
(Balusikova et al., 2009). Since iron absorption is regulated by iron stores, before performing 
PPI studies, the analysis of gene expression of Heph and IRPs in K562 cells was carried 
out by treating K562 cells with 100 µM FAC. Real time PCR results confirmed a 2.8 fold 
increase of Heph and IRP1 expression in 100 µM FAC-treated K562 cells compared with 
normal K562 cells. Protein level expression was also carried out using K562 cells treated 
with 100 µM FAC and K562 cells treated with normal medium by western blotting.  As 
statistically significant increase of the mRNA levels of Heph in K562 cells treated with 100 
µM FAC, when compared with the control cells expression, correlated with an increased 
protein level in the case of Heph. Similar findings were reported by Balusikova et al in Caco-
2 cells, where they treated Caco-2 cells with 500 µM FAC (Balusikova et al., 2009). Iron 
release from non-intestinal cells was shown to require Cp ferroxidase activity (Vulpe et al., 
1999; Hellman and Gitlin, 2002). It is known that membrane-bound Heph is mainly involved 
in the transfer of iron from intestinal enterocytes into the circulation. However, there are a 
few conflicting reports about the expression of Heph in iron deficient conditions. Heph 
expression observed in rats duodenum which were iron deficient (Frazer et a l., 2001) 
showed a slight increase in mRNA levels. In patients with iron deficiency and 
haemochromatosis, a coordinated upregulation of the iron transporters DMT-1, Ireg1, Dyctb 
and Heph was observed (Zoller et al., 2003). Heph mRNA expression levels were not 
significantly different in, neither non-phlebotomized nor phlebotomized hereditary 
hemochromatosis (HH) patients with iron deficiency when compared with controls (Gleeson 
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et al., 2005). Likewise, gene expression of IPR1 and IPR2 was also carried out using K562 
cells. The importance of IRPs in vivo was demonstrated in mice where the double knockout 
of IRP1 and IRP2 is embryonic lethal (Smith et al. 2006). Additionally, the double knockout 
of these genes in the intestine resulted in the death of intestinal epithelial cells, presumably 
because of iron depletion (Galy et al. 2008). Functionality of the IRP-IRE system was best 
exemplified in the “mucosal block”, a phenomenon by which, shortly after exposure to a 
large dose of iron, enterocytes become refractory to absorbing more iron (Crosby 1966). In 
rat enterocytes, the ingestion of high iron-containing food causes increased cellular iron 
content and reduced mRNA levels of DMT1 and Dcytb (Frazer et al. 2003). Cellular iron 
loading reduces IRE-binding activity of IRPs, which results in the susceptibility of TfR1 
mRNA to degradation. It has been reported that hypertransfusional (>8 transfusions/year) 
iron in liver biopsies collected immediately after transfusions in beta-thalassemia and sickle 
cell disease correlated with increased expression (RNA) for iron regulatory proteins 1 and 2 
(Jenkins et al., 2007).  Gene expression analysis of IRP1 and IRP2 in K562 cells resulted in 
upregulation of IRP1 and IRP2 was down-regulated in K562 cells treated with 100 µM FAC 
compared with normal K562 cells. The idea in this study is only to establish if Heph and 
IRPs (IRP1 and IRP2) expresses in K562 or not, so as to decide whether K562 cells can be 
used to carry out protein-protein interaction studies. Since, expression of Heph and IRPs 
(IRP1 and IRP2) was detected; K562 cells were used to further carry out protein-protein 
interactions studies. Molecular cloning of Heph, IRP1 and IRP2 with One-Strep tag was 
achieved and it was also shown that Lipofectamine-LTX helps achieve higher transfection 
efficiency in K562 cells compared with MATra approach. Though the gene expression 
studies, molecular cloning and transfection resulted in the desired outcomes 
coimmunoprecipitation work of One-Strep tagged Heph and IRPs was unsuccessful in this 
study.  
Compared with other techniques to find interacting partners, fusion-based affinity protein 
purification is an excellent method to purify and identify multiprotein complexes as they aid 
in identifying multiple interactions. By expressing the POI directly in the cell this allows it to 
be directed to the right subcellular location which could help the baits interactions with its 
physiological targets to be restored. Since the tagged protein is expressed in-vivo, the 
protein can undergo post-translational modifications (PTMs). PTMs may have important 
implications during the purification of the protein complexes in the mammalian cells. In the 
case of regulatory proteins, its known that PTMs, such as phosphorylation, result in an 
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increase or decrease of the affinity towards the potential interacting partners. The affinity- 
based method used in finding Heph interactors may not be an optimal method in detecting 
the potential interacting partners, as it involved stringent rinsing procedures given its 
membrane-bound nature. Also, the failure to successfully carry out coimmunoprecipitation 
during this study can be attributed to lysis buffer concentrations. Since all interactions inside 
a cell occur in a concentrated mixture of molecules and the protein concentration in the 
cytosol may be as high as that of some proteins it is likely that the conditions were replicated 
in this study. The high protein concentration inside a cell influences the rate at which 
molecules diffuse. It can be said that the binding affinity of different proteins in a protein 
complex may be much higher in the crowded environment inside a cell compared to the 
protein complex in a buffer. Though, transient interactions with very short half lives could 
have existed in experiments carried out by affinity-based purification, concentration of the 
lysis buffer might have dissociated the interactions. In this study, the tagged Heph and IRPs 
were over-expressed, as compared to the expression level of endogenous counterparts to 
achieve transient interactions. However, over-expression of the bait might also caused 
disturbances in the physiological conditions. Over-expression of the bait proteins in this 
study might also lead to cytotoxicity that could explain non-detection of POI during western 
blotting. 
Since the bait protein in this study was fused with an exogenous tag, One-Strep tag, this 
could also have caused an introduction of an artificial protein into the cell. Tag fusion with 
POI might also have caused the tag to become buried inside the protein complex, upon 
which the complex may not have been retrieved during the pull-down on the affinity column. 
The tag could also have caused mislocalisation of the bait protein, in which case the bait 
would not have interacted with its natural interactors. In this study, microscopy analysis of 
the tagged protein was unsuccessful. Along with the salt concentrations in the buffers used 
for immunoprecipitation, stringent washes could also have reduced the binding of low-affinity 
targets. 
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Chapter 5 
 
After repeated failures to carry out successful pull-downs to identify the interacting partners 
of IRPs and Heph, Dr. Kenneth White suggested to continue the work initiated by Philip Goff 
under his supervision in identifying an extra band which appeared in the membrane fraction 
of K562 cells. 
 
5.01 Calreticulin (CALR) 
 
5.01.001 Introduction of CALR 
Calreticulin (also known as CRP55/Calregulin) was first identified as a Ca2+ binding protein 
of the muscle sarcoplasmic reticulum (Ostwald and MacLennan, 1974). Later it became 
clear that CALR is highly abundant in non-muscle tissues and that it is one of the major Ca2+ 
binding proteins of the endoplasmic reticulum (ER) (Michalak et al., 1992). CALR has been 
implicated in the regulation of a variety of cellular functions. Calreticulin is a highly conserved 
chaperone protein of the endoplasmic reticulum (ER) that has specificity towards 
glycoprotein substrates (Rutkevich and Williams, 2011). Calreticulin is important for the 
assembly and cell-surface expression of MHC class I molecules and hence for CD8 T cell 
recognition of antigens presented by MHC class I molecules (Gao et al., 2002). Calreticulin 
enhances the stabilities of components of the MHC class I assembly pathway (Del Cid et al., 
2010; Jeffery et al., 2011) and functions in the retrieval of MHC class I molecules from post-
ER compartments for their optimal assembly (Howe et al., 2009). Although calreticulin is 
best known for its ER chaperone functions, calreticulin also expresses on the cell surface. 
Induction of cell surface calreticulin in dying cells appears to be a feature of some apoptotic 
and preapoptotic cells (Gardai et al., 2005) and of cancer cells (Chao et al., 2010). Cell-
surface calreticulin contributes to the phagocytic uptake of cancer cells and dying cells 
(Gardai et al., 2005; Chao et al., 2010). Preapoptotic exposure of calreticulin has been linked 
to enhanced immunogenicity of dying tumor cells. The prophagocytic function of cell surface 
calreticulin is suggested to relate to the immunogenicity of extracellular calreticulin (Zitvogel 
et al., 2010; Kepp et al., 2011). In mammals, CALR is a 46-kDa multifunctional calcium 
binding protein of the endoplasmic reticulum (first characterised in rabbit by Ostwald and 
MacLennan, 1974) that has many critical functions in the eukaryotic cell including regulation 
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of intracellular calcium homeostasis, lectin binding and chaperoning and oxidative stress 
responses (Liu et al., 2011). 
5.01.002 Structure of CALR 
Calreticulin is a structural homolog of the ER chaperone calnexin. Both calreticulin and 
calnexin contain a globular domain arranged in a legume lectin fold (Figure 22) (Schrag et 
al., 2001; Kozlov et al., 2010). Each globular domain comprises a concave beta-sheet 
together with a convex sheet and a C-terminal alpha-helix in the globular domain. A single, 
conserved, high-affinity calcium-binding site in the globular domains of both calreticulin and 
calnexin confers structural stability to the domains (Kozlov et al., 2010; Chouquet et al., 
2011). Glycan-binding sites are present on the concave beta-sheets of calnexin and 
calreticulin (Schrag et al., 2001; Kozlov et al., 2010), both of which have specificities for 
monoglucosylated glycans. A few studies also suggested that calreticulin and calnexin can 
interact with polypeptide substrates in a glycan-independent manner (Duus et al., 2009; 
Pocanschi et al., 2011). The precise locations of the polypeptide-binding sites in calreticulin 
and calnexin remain elusive, although recent structural studies suggest that the periphery 
of the glycan-binding site of calreticulin could be involved in glycan-independent interactions 
(Chouquet et al., 2011). It is still unclear whether this putative binding site functions as a 
generic polypeptide recognition site or not. Both calreticulin and calnexin contain flexible 
arm-like, proline-rich, P domains that interrupt and extend from the globular domain (Schrag 
et al., 2011). Calreticulin contains a highly acidic C-terminal region (residues 351–359) that 
binds multiple calcium ions with low affinity (Baksh and Michalak, 1991; Wijeyesakere et al., 
2011). The counterpart of this region is absent in the lumenal domains of calnexin. The 
acidic C-terminus of calreticulin plays a significant role in the maintenance of cellular calcium 
homeostasis, and cells deficient in calreticulin have reduced calcium storage capacity in the 
ER (Nakamura et al., 2001). The acidic C- terminus is also important for the translocation of 
calreticulin from the ER to the cytosol (retrotranslocation) (Afshar et al., 2005). The total 
absence of CALR in the embryonic stage of mice is detrimental due to alterations in cellular 
calcium homeostasis (Mesaeli et al., 1999, Guo et al., 2002). The acidic region of calreticulin 
also plays a role in ER retention of the protein, because a calreticulin construct lacking this 
domain is secreted despite the presence of a C-terminal KDEL sequence (Sonnichsen et 
al., 1994). The presence of a KDEL motif specifies binding to the KDEL receptor, which 
functions in the retrieval of KDEL-containing proteins from ER–Golgi intermediate 
compartments and the Golgi back to the ER (Dancourt and Barlowe, 2010). 
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Figure 54: CALR structure. Figure shows the structural features of Calreticulin and 
Calnexin with their functional relevance. (a) The globular domain of Calreticulin is depicted 
in green and contains a glycan-binding site that interacts with monoglucosylated glycans of 
glycoproteins, including those present on major histocompatibility complex (MHC) class I 
heavy chains. The P domain of Calreticulin is depicted in yellow, the tip of which contains a 
co-chaperone binding site. The predicted structure of the C-terminal acidic region is shown 
in red. The acidic region contains multiple low-affinity calcium-binding sites that are 
important for the maintenance of endoplasmic reticulum (ER) calcium homeostasis. The 
model was built based on the crystal structure of the globular domain of Calreticulin 
(Pocanschi et al., 2011) and the NMR structure of the P domain (Ellgaard et al., 2001. The 
acidic domain is modeled de novo using the loopbuilding feature in I-TASSER (Roy et al., 
2010). (b) Overlay of the structures of the lumenal domain of calnexin (Schrag et al., 2001) 
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and the globular domain of calreticulin with a truncated P domain (Pocanschi et al., 2011) 
depicting the change in angle between the globular and P domains of Calreticulin compared 
to Calnexin. Figure taken from Raghavan et al., 2013. 
5.01.003 Role of CALR in and out of the ER 
Lately calreticulin is also found to have multiple functions in the cytoplasm, cell surface and 
extracellular matrix (Gold et al., 2010). For instance, the presence of calreticulin in the 
extracellular matrix is associated with the healing processes of cutaneous wounds (Nanney 
et al., 2008). Extracellular calreticulin addition significantly increases the rate of wound repair 
in pigs, wound tensile strength in rat models and moreover, in dermal cells undergoing 
wound repair, calreticulin expression is enhanced (Nanney et al., 2008). Specifically, the 
addition of calreticulin to wounds increases the expression of transforming growth factor β3, 
a crucial wound healing factor and increases cellular proliferation and migration of 
keratinocytes and fibroblasts, altogether enhancing repair of dermal and epidermal damage 
(Nanney et al., 2008). Therefore, extracellular calreticulin plays an important role in the 
process of tissue repair and remodeling as shown in figure 55. 
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Figure 55: Physiological and pathological roles of CALR. Figure shows the physiological 
and pathological roles of calreticulin. A summary of the functions of calreticulin and their 
effects on health and disease related systems when present outside and inside of ER. 
Figure taken from Wang et al., 2012. 
When calreticulin is present inside the endoplasmic reticulum (ER) it functions as a 
chaperone that regulates proper protein and glycoprotein conformation. Also it maintains the 
Ca2+ homeostasis, which can affect adipogenesis, cardiogenesis and cellular stress when 
present inside the ER. When calreticulin is present outside the ER it plays a role in immunity 
and enhances tissue repair and remodelling. calreticulin also plays a role in the cytoplasm, 
by regulating the cell adhesion, gene expression, translation and nuclear export.  
Translocation of Calreticulin to the cell surface can be induced by anthracyclines, irradiation 
and diminishing ER Ca2+ stores, which are all involved in the triggering of ER stress 
(Pekárikova et al., 2009; Peters and Raghavan, 2011; Tufi et al.,2008). Very little is known 
about the mechanisms by which calreticulin translocates to the cell surface. However, it was 
reported that the surface exposure of Calreticulin is the crucial component in activating the 
anti-tumor response needed in chemotherapy (Chaput et al., 2007). The addition of 
Calreticulin or induction of cell-surface Calreticulin expression causes cancer cells to 
undergo immunogenic cell death via phagocytosis by dendritic cells (Chaput et al., 2007; 
Obeid et al., 2007). As they open up a new potential treatment avenue, studies on cell-
surface exposure of Calreticulin makes them the potential candidates in cancer research. 
As of today, the molecular mechanisms of cell surface targeting of Calreticulin are still not 
well understood. 
5.01.004 CALR and Heph 
Owing to the ability to absorb dietrary iron despite reduced expression and mislocalisation 
Heph in sla-mice, it could be hypothesised that Heph on its own may not be essential for 
oxidising ferrous (Fe 2+) to ferric (Fe3+) iron. Iron is transported into mammalian cells via two 
different pathways. Most of the available iron is transported via transferrin. As there is no 
TfR in microvilli a second pathway is sought in small intestinal absorptive cells, (Parmley et 
al., 1985). Since microvilli do not have TfR, iron is absorbed as soluble iron chelates, such 
as ferric citrate with a cell-surface integrin (Conrad and Umbreit, 1993) and is subsequently 
transferred to a cytosolic protein named mobiliferrin (also known as Calreticulin or Calsperin) 
(Conrad et al., 1990). Previous studies have reported that there is an alternative pathway 
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for iron uptake in non-intestinal cells (Muir et al., 1984, Brissot et al., 1985 and Kaplan et al., 
1991). Experiments in K562 cells suggested there might be an interrelationship between the 
two pathways because some iron presented to the cells bound to transferrin was isolated 
from the cytosol complexed to mobiliferrin (Conrad et al., 1994). Mobiliferrin is found to be 
associated with transferrin-containing vesicles and labelled with iron released from 
transferrin in the vesicles and it also releases iron to be used for the synthesis of 
haemoglobin (Conrad et al., 1996). The non-transferrin ferric (Fe3+) iron pathway in 
reticulocytes was similar to the mobiliferrin-integrin pathway originally described in intestinal 
cells and is independent of the transferrin-transferrin receptor pathway (Umbreit et al., 1997).  
Confocal microscopy studies carried out by Simovich et al in 2002 established that 
mobiliferrin and hephaestin can be detected in the cytoplasmic region of cells thus 
suggesting intracellular roles for both CALR and Heph in addition to them serving to transit 
iron across the cell-surface membrane (Simovich et al., 2002  Intracellular iron accumulation 
leads to an oxygen radical formation (Toyokuni, 2002) and regulation of cellular iron levels 
is crucial in mediating an oxidative stress response (Braun, 1998). During bacterial infection, 
iron metabolism is particularly regulated as host and pathogen compete for control of iron 
stores (Ganz, 2003, Liu et al., 2010a). Iron-binding proteins and iron transport and regulatory 
proteins can play dual roles in both antioxidant and immunomodulatory (alteration of the 
immune response to a desired level) responses (Liu et al., 2011).  CALR gene was also 
reported to play a protective role in the iron-induced oxidative stress (Nunez et al., 2001). 
High levels of CALR gene expression was detected in spleen and liver and the lowest 
expression was found in muscle (Liu et al., 2011). Considering the role of the liver in iron 
metabolism and storage as a part of this study, I also carried out analysis of various 
cytosolic/soluble and membrane extracts from different cell lines like K562 (Human 
Caucasian chronic myelogenous leukaemia cells), MDA-MB-231 (Human Caucasian breast 
adenocarcinoma cells) and PNT2-C2 (Human prostate normal, immortalised with SV40 cells) 
to identify if CALR has any ferroxidase activity. 
M1 Results and discussion 
 
5.02 Identification of M1 band in K562 cells 
K562 cells express the ferroxidase hephaestin in significant amounts, compared with many 
other cell lines. This makes the cell line a convenient model for studying hephaestin activity.  
In the process of charactering the expression of hephaestin in K562 cells we used non-
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denaturing electrophoresis followed by staining for ferroxidase enzyme activity in the gel in 
situ. Membrane and cytosolic fractions were prepared using hypotonic lysis by freezing and 
thawing.  This strategy was chosen to avoid the use of detergents to make an extract of 
membranes and thereby avoid contamination of lysates with cytosolic proteins. Membrane 
and cytosolic extracts, together with 2.5 µg of pure Ceruloplasmin (Cp) from Calbiochem 
were subjected to non-denaturing gel electrophoresis, followed by staining for ferroxidases,. 
In addition to the expected ferroxidase band due to Heph an extra band appeared in the 
K562 membrane fraction. Even after repeated non-denaturing gel electrophoresis no bands 
were observed in K562 cytosolic fractions.  
5.02.001 Identification of M1 band as CALR in K562, MDA MB231 and 
PNT2-C2 cell fractions 
To check if the extra band was expressed exclusively in K562 cells, MDA-MB-231 (Human 
breast adenocarcinoma cells) cell fractions were also analysed. Both membrane and 
cytosolic fractions from MDA-MB-231 and membrane fraction of K562 cells were subjected 
to non-denaturing gel electrophoresis (Fig. 56). A band was observed only in the membrane 
fractions of both the cell lines and was named M1 (M = membrane fraction, 1 = first band to 
be observed). To rule out any non-specificity, gel electrophoresis was repeated thrice and 
the M1 band was observed each time. The presence of the M1 band in both K562 and MDA-
MB-231 cells confirmed its expression in cancerous cells. However, to establish whether or 
not the M1 band was also expressed in normal or non-cancerous cells, PNT2-C2 (Human 
prostate normal immortalised with SV40) cells were also fractionated and analysed (Fig. 58).  
The ferroxidase and coomassie stained non-denaturing gel confirmed the expression of the 
M1 band in K562, MDA-MB-231 and PNT2-C2 cell lines which established the ubiquitous 
nature of the M1 protein in both cancerous and primary cells.  
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Figure 56: 8% non-denaturing ferroxidase and coomassie stained gel. 8% non-
denaturing ferroxidase and coomassie stained gels shows the M1 band in both K562 and 
MDA-MB-231 membrane fractions but not in the MDA-MB-231 cytosolic fraction. 
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Figure 57: 8% SDS coomassie stained gel showing the M1 band in K562 and MDA-
MB-231 membrane fraction. Figure shows the presence of the M1 band in both K562 and 
MDA-MB-231 membrane fractions on a 8% SDS coomassie stained gel. 
 
 
 
 
 
 
  75 kD 
  50 kD 
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Figure 58: 8% SDS coomassie stained gel showing the M1 band in K562 and PNT2-C2 
membrane fraction. 8% non-denaturing ferroxidase and coomassie stained gels shows the 
M1 band in both K562 and PNT2-C2 membrane fractions but not in cytosolic fraction. 
Ceruloplasmin which is a ferroxidase (Frieden and Hsieh, 1976) was used as a positive 
control in all the electrophoretic runs, and gave a strong signal in both ferroxidase and 
protein staining (Fig. 56 and 58, lanes 1). One striking feature about M1 was that it ran as a 
single, separate protein band in the gel, and could be easily excised for further analysis. In 
all the non-denaturing gels, precision plud proteinTM standard marker from Bio-rad (UK) was 
used as a marker. The M1 band consistently appeared between the 75 kD and 50 kD bands 
as respresented in the protein marker lane. Since the sequence of the M1 band was not 
known we decided to carry out Mass spectrometry (MS-MS) to identify the M1 band. M1 
band was confirmed by MS-MS in association with our collaborator in Imperial College, UK. 
Figure 59 shows the 10% SDS-PAGE gel picture of the M1 band run by our colleagues in 
Imperial College to get the sample ready for proteomic analysis. Table 08 shows the p and 
Sf (Sf is a statistical indicative of the certainity of the id) values of the identified band by MS-
MS. MS-MS study confirmed the M1 band to be Calreticulin (CALR). It can be concluded 
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that CALR is only expressed only in the membrane fractions but not in cytosolic fractions of 
K562, MDA-MB-231 and PNT2-C2 cells.  
 
Figure 59: 10% SDS-PAGE gel used to run the excised M1 band for proteomic analysis. 
The M1 band in a 10% SDS-PAGE gel. Four slices at and around where the staining was 
observed in lanes PR1 and PR2 were excised and processed for proteomic analysis. 
 
Table 08: p and Sf vaues for CALR obtained after MS-MS. Table above represents the p 
and Sf value obtained for the M1/CALR identified after MS-MS. 
However, database analysis (Uniprot) suggests the sub-cellular localisation of CALR to be 
attributed to the endoplasmic reticulum, cytosol, extra cellular matrix and on the cell surface. 
This poses the question, why was CALR not shown in cytosolic fractions of K562, MDA-MB-
231 and PNT2-C2 cells used in the non-denaturing gel electrophoresis. To understand the 
absence of CALR in cytosolic fractions, the experimental set up was looked into and it was 
confirmed that membrane fractions were more concentrated than cytosolic fractions. 
Membrane fractions were prepared using 107 cells/ml and cytosolic fractions were prepared 
using 106 cells/ml. When non-denaturing gel electrophoresis was performed, the absence 
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of CALR band in the cytosolic fractions of the three cell lines thus can be attributed to the 
different concentrations of samples used. 
5.03 Bioinformatics analysis of CALR 
The identification of the M1 band as CALR by MS-MS raised further questions about any 
ferroxidase activity of CALR. The Protein Basic Local Alignment Search Tool (blastp) and 
Position-Specific Iterated Basic Local Alignment Search Tool (PSI-BLAST) analysis was 
carried out using the CALR protein sequence. Blastp was carried out using CALR, Heph 
and Cp (UniProt ids: P27797, P00450, Q9BQS7) and it was found that CALR and Cp have 
a 32% identity with a e-value of 3.4 and CALR-Heph showed sequence homology of 44% 
with a e-value of 2.3. The observed e-values 3.4 and 2.3 in figure 61 do not support the 
significant sequence homology between CALR, Cp and Heph. To find distant relatives and 
potential homologs, PSI-BLAST was performed using Cp, Heph and CALR protein 
sequences. While performing PSI-BLAST, reference protein database (refseq_protein) 
parameter was chosen to avoid duplicate or repeated results. In the blast algorithm 
parameters, the threshold was changed to a generally accepted value of 1e-4 from the 
default 5e-3 to carry out homology analysis and also rule out any false positives. Blast was 
carried out in organism specific (Homo sapiens) and against all organisms in the blast 
database, using the CALR protein sequence (UniProt id: P27797). Any blast result with e-
value less than 1e-4 has been considered to be homologous or related to the CALR protein. 
During PSI-BLAST analysis to find putative homologs which may have been missed during 
the first run, two iterations were carried out. Further protein sequence analysis of CALR, Cp 
and Heph showed metal-binding regions. In the case of CALR the metal bound was calcium 
and in Cp and Heph it is Cu-binding region. Both blastp and PSI-BLAST did not show any 
significant homology between CALR, Cp and Heph. Maybe structural analysis of CALR, Cp 
and Heph might reveal a specific ferroxidase signature in CALR. 
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Figure 60: Blast analysis of CALR, Cp and Heph protein sequence. Figure shows the 
blastp result of CALR, Cp and Heph protein sequence alignment. Red line in the above 
alignment is the CALR sequence, first black spaced line is of Cp and continuous bottom 
black line representing Heph. 
 
 
Figure 61: Blastp results of CALR, Cp and Heph showing the e-value. Above figure 
shows the blastp result of CALR, Cp and Heph protein sequence alignment with percentage 
of identity and e-value. 
5.04 Metal-binding nature of CALR 
Based on the CALR protein sequence analysis, the primary structure of CALR has been 
divided into four distinct domains with the signal peptide (residues1-17), the N-domain 
(residues 18-197), the P-domain (residues 191-255), and the C-domain (residues 309-408). 
The N-domain of CALR is highly conserved among CALR species (Michalak, 1996) and 
contains a low-affinity, high-capacity zinc-binding site with an apparent dissociation constant 
(apparent Kd) of 0.05 microM and 14 binding sites for Zn2+ with apparent Kd(Zn2+) of 310 
µM. (Khanna et al., 1986). It has been shown that the N-domain mediates interactions 
between CRT and the ER folding catalysts PDI and ERp57 (Corbett et al., 1999, Baksh et 
al., 1995). The central P-domain contains two proline-rich repeat sequences, type 1 and 
type 2 motifs, which have been shown from recent NMR studies (Ellgaard et al., 2001, 
Ellgaard et al., 2001) to be primarily structural motifs allowing the P-domain to adopt a 
unique hairpin-type fold in solution. It has been established that the P-domain is likely to 
contain a high-affinity calcium-binding site (Kd  of 0.05-10 µM and 1 mol of calcium/mol of 
CRT) (Khanna et al., 1986, Ostwald et al., 1974, Ostwald et al., 1974, Baksh et al., 1991, 
Khanna et al., 1987, Van Nguyen et al., 1989) and the domain has been implicated in the 
binding of isolated oligosaccharides as well as glycoprotein ligands in in vitro assays 
(Vassilakos et al., 1998, Peterson et al., 1999).The C-domain is characterized by a high 
content of acidic residues (Smith et al., 1989, Fliegel et al., 1989, Baksh et al., 1991, 
McCauliffe et al., 1990) which is consistent with the location of a low- affinity, high-capacity 
calcium binding site (Kd  1-2 mM and 25-50 mol of calcium/mol of CRT) (Ostwald et al., 
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1974, Baksh et al., 1991, Treves et al., 1990). The N-/C- domain of CRT, but not the P-
domain, responds to calcium and zinc ions through conformational rearrangements (Tan Y 
et al., 2006). The presence of CALR in different cellular compartments suggests CALR's 
role in many cellular processes both inside and outside the Endoplasmic reticulum (ER). 
Along with Calnexin and ERp57, CALR plays a critical role in the folding of glycoproteins 
and in quality control processes of the protein secretory pathway (Ellgaard and Helenius 
2003). In CALR-deficient fibroblasts, the Ca2+ storage capacity of the ER is reduced 
(Nakamura et al. 2001b), whereas in fibroblasts that over-express CALR, intracellular Ca2+ 
ion stores are increased (Arnaudeau et al. 2002).Its role in balancing the amount of Ca2+ is 
emphasized by the observation that its expression is sensitive to changes in ER Ca2+ 
concentration. For example, the emptying of ER Ca2+ stores results in enhanced expression 
of CALR (Waser et al. 1997) indicating that cells adapt to decreased ER Ca2+ concentrations 
by increasing the concentration of Ca2+ buffer proteins within the lumen of the ER. Changes 
in ER Ca2+ storage capacity and changes in Ca2+ binding to CALR impact the quality of ER 
protein folding because Ca2+ is required for formation of chaperone–substrate complexes 
(Lynch et al., 2006). An alteration in ER Ca2+ concentration disrupts normal ER dynamics, 
thereby impacting Ca2+ homeostasis and protein folding, such that these two functions are 
interdependent (Michalak et al., 2002). The basic CALR functions such as, regulation of 
Ca2+ homeostasis and molecular chaperoning in ER might be the key to explaining the multi-
process property of CALR (Michalak et al., 2009). 
5.05 CALR and diseases 
Though the Ensembl database shows 101 reported variations in the CARL gene none of the 
variation has been shown to be associated with any disease. However, Calreticulin 
deficiency is embryonically lethal in mice at E13.5, the lethality resulting from a lesion in 
cardiac development (Mesaeli et al. 1999). It appears that CALR-deficient cells have 
different metabolic properties which result from changes in intracellular Ca2+ levels. The 
CALR promoter is activated, and expression of the protein is high in the early stages of 
cardiogenesis, reaching a maximum at E14.5 (Mesaeli et al. 1999). CALR is highly 
expressed in the developing heart, but the expression is tightly regulated after birth, and the 
protein is only weakly expressed in the healthy mature heart. Close postnatal regulation of 
the CALR gene in the heart is vital because elevated expression of the protein in the heart 
after birth is fatal (Nakamura et al. 2001a). Mice that over-express CALR in cardiac cells 
develop bradyarrhythima and a complete heart block, and this is followed by sudden death 
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(Nakamura et al., 2001a). Sensitivity of the myocardium to oxidative stress and apoptosis 
may also be affected by levels of CALR (Ihara et al. 2005, Ihara et al. 2006, Kageyama et 
al. 2002, Nakamura et al., 2000). There is evidence to confirm that CALR acts as an auto 
antigen in patients with systemic lupus erythematosus (SLE) by playing a supportive role in 
the formation of the auto antigen complex-Ro/SS-A (Eggleton et al., 1997). Synthetic linear 
CALR peptide analogues prepared against the N-terminal region of CALR were 
immunoreactive to sera from patients not only with SLE or Sjogrens syndrome (SS), but also 
in rheumatoid arthritis (RA) (Routsias et al., 1993). Anti-calreticulin auto antibodies are not 
restricted to patients with SLE, for example they have been found in patients with rheumatoid 
arthritis (RA) (Verreck et al., 1995, Jacob et al., 1997). CALR is targeted by auto antibodies 
following its release into the extracellular environment, possibly as a result of cell death, or 
its presence at the cell surface in response to insults such as viral infection or ultraviolet 
irradiation (Eggleton and Llewellyn, 1999). 
5.06 Significance in identifying iron binding sites of CALR for its 
ferroxidase activity 
Uptake of non-transferrin-bound iron into enterocytes occurs either through the Integrin-
Mobilferrin pathway (IMP) or the Di-valent Metal Transporter-1 pathway (DMT-1, Nramp 2). 
The IMP pathway is thought to transport only ferric iron (Conrad et al., 2000). Mobilferrin is 
a homologue of Calreticulin (Bothwell et al., 1979). It is possible that the two proteins are 
identical (Umbreit et al., 2002) which was reported to be identical to calreticulin for the first 
20 NH2-terminal amino acids, and antibodies  to both the NH2-terminal and COOH-terminal 
sequences of calreticulin react with mobilferrin except that mobilferrin lacks the carboxy 
terminal sequence of KDEL. Mobilferrin, in association with β3 integrin, forms a 
macromolecule known as paraferritin, which has been assigned to have ferrireductase 
activity (Umbreit et al., 1996) resulting in the conversion of the absorbed Fe3+ to Fe2+. Up-
regulation of mobilferrin could be responsible for the increased absorption of iron and iron 
overload (Baber et al., 2000). However, the role of calreticulin as a proposed component of 
paraferritin still remains unanswered (Srai et al., 2007). Owing to high expression levels of 
CALR in liver (Khanna and Waismann, 1986) and its role as a multi-functional protein, 
studies on selective glycosylation sites by site-directed mutageneis in CALR isolated from 
human liver cells may shed some light on CALR as a ferroxidase. Further enzymatic 
characterisation of the CALR obtained from the membrane fraction of K562, MDA-MB-231 
and PNT2-C2 will confirm its ferroxidase properties. In Cp, the predicted high-affinity Fe(II) 
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binding sites are located beneath large protein loops (Lindley et al., 1997; Brown et al., 2002; 
Quintanar et al., 2004). The overall structure of the molecule as well as the charge 
distribution in Cp was predicted to be conserved in Heph (Syed et al., 2002). On the basis 
of the results of crystal soaking experiments (Lindley et al., 1997), Cp contains two ferrous 
binding sites in domains 4 and 6. Crystal soaking experiments did not reveal ferrous iron 
binding in domain 2 of ceruloplasmin, which contains E236, E633, N323, and Y241 in the 
corresponding positions (Syed et al., 2002).  
Domain Putative iron ligands 
Ceruloplasmin Hephaestin 
 
2 E236,Y241,N323,E633 E264,H269,S351,E652 
4 E597,H602,D684,E971 D616,H621,S703,D996 
6 E935,H940,D1025,E272 E960,H965,D1050,E300 
Table 09: Putative iron ligands in Cp and Heph. Table shows the putative ligands in 
Ceruloplamin and Hepaestin. Putative iron ligand information is from Lindley et al., 1997 for 
Ceruloplasmin and Syed et al., 2002 for Hephaestin. 
Compared with Cp, hephaestin contains conserved ligands in the Fe(II) binding site of 
domain 6 (E960, H965, D1050, E300), whereas in domains 2 and 4, the equivalent residues 
are E264, H269, S351, and E652 and D616, H621, S703, and D996, respectively. 
Recombinant human hephaestin (rhHp) with putative Fe(II) binding residues were 
constructed by site-directed mutagenesis to examine the functional role of individual amino 
acid residues in iron oxidation by human Heph (Vashchenko and MacGillivray, 2012).  
Kinetic analysis of ferroxidation rates of wild-type rhHp and mutants demonstrated the 
important roles of hephaestin residues E960 and H965 in the observed ferroxidase activity 
(Vashchenko and MacGillivray, 2012). The amino acid sequence homology between CALR, 
Cp and Heph may predict similar biochemical properties. However, any specific enzymatic 
function of CALR probably results from its structural differences from Heph and Cp and 
hence needs to be examined by identifying the iron binding sites in CALR. 
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CONCLUSIONS  
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CHAPTER 6 
 
This study attempted to identify and establish the potential genetic markers and interacting 
partners of different iron metabolic genes Mfrn, IRPs and Heph. 
Owing to the practical infeasibility of genotyping all single nucleotide polymorphisms, 
selecting a subset of SNPs, (that is sufficiently informative to conduct disease-gene 
association which information is enough to reduce the genotyping and data analysis) a 
process known as tag SNP selection, is a key step toward effective association studies. In 
the regions of low haplotype diversity, tags SNPs are sufficient to account for the majority of 
the haplotype diversity of the human genome. 18 tagSNPs of the Mfrn gene were analysed 
in an Asian-Caucasian cohort to examine the correlation between the Mfrn tagSNPs, 
haemoglobin levels and birth weight. Ideally serum ferritin and transferrin information 
(percentage saturation and total iron binding concentration or TIBC), would have been used. 
However due to lack of information in the data set, Hb levels were used as a proxy for body 
iron levels. Of the 18 tagSNPs genotyped only four tagSNPs were in Hardy-Weinberg 
equilibrium. The four tagSNPs (rs6986233, rs11781222, rs7089331 and rs17089358) were 
analysed for correlation by two-way ANCOVA using SPSS (v.20) analysis software. It can 
be concluded that neither of the four SNPs showed any significance correlation between the 
genotype, Hb levels and birth weight. This rules the Mfrn tagSNPs out as tagSNP candidates. 
However, investigating other solute carrier family genes could show a potential correlation 
between Hb levels, birth weight and the genotype. 
Protein-protein interaction studies of IRPs and Heph were unsuccessful even after 
successful molecular cloning and expression of IRPs and Heph with One-Strep tag. Failure 
to carry out immunoprecipitations/pull-downs can be partly attributed to the percentage of 
detergent used in the lysis buffer and part to the number of transfected cells after 
Lipofectamine-LTX plus transfection of the K562 cells using IRPs and Heph tagged with 
One-Strep tag. A G418 selection process was used to isolate only transfected cells with no 
success. However, a couple of conclusions that came out of the protein-protein interaction 
study were, lipid mediated transfection by Lipofectamine-LTX plus reagent of K562 cells 
using IRPs and Heph tagged with One-Strep tag showed higher transfection efficiency and 
viability compared with magnetic assisted transfection method. By using magnetic 
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nanoparticles for transfection of K562 cells with IRPs tagged with One-Strep tag, it can be 
concluded that magnetic nanoparticles do not have any effect on iron regulator proteins. 
This work identified and concluded that the M1 band appeared in the membrane fractions 
of K562, MDA-MB-231 and PNT2-C2 cells when analysed on an 8% non-denaturing gel. 
The band was identified and concluded as Calreticulin in collaboration with Prof. Rob, 
Imperial College by mass spectrometry. This study only found the CALR in membrane 
fractions of K562, MDA-MB-231 and PTN2C2 cells. However, the work carried out later by 
Dr. Kenneth White and Suam confirmed the presence of CALR in both membrane and 
cytosolic fractions of K562 cells. This study also proposes further kinetic analysis of CALR 
to establish CALR as a ferroxidase. 
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CHAPTER 7 
 
• Owing to the interaction of Mfrn with ABCB10, either ABCB10 or other iron metabolic 
genes could become the candidate gene for tagSNP analysis 
• Cell line other than K562 which could achieve higher transfection efficiency could well 
yiled potential protein complexes after the pull down 
• May be the choice of detergent used while performing the washing steps during the 
pull down needs to have a through look 
• Comparing GOI cloned with One-Strep-tag and GFP tagged clones could tell whether 
using One-Strep-tag is efficient 
• Identifying any potential iron binding sites in CALR will help confirm its ferroxidase 
nature along with kinetic studies. 
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